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SUMMARY 
The tumour suppressor protein p53, is a transcription factor responsible for regulating the cell 
cycle and/or apoptosis in proliferating cells subjected to a variety of stressful events, 
including DNA damage. Mutations of p53 occur in >50% of human tumours, the most 
frequently altered gene in cancers. This thesis looks at the responses of the p53 interactome in 
B-lymphoid cancers after fludarabine (2-FaraA) induced DNA damage. The overall purpose 
was to contribute to our understanding of B-lymphoid cancers by 1) looking at the response 
of p53 and family proteins p63 and p73, after 2-FaraA induced DNA-damage, 2) compare the 
p53 interactome following DNA damage in cells with and without mutations in p53, 3) study 
the DNA-damage phosphorylation cascades in the p53 interactome and 4) analyse the effects 
of p53 knock-down on fludarabine responsive cells.  
Analysis using 1D and 2D Western blotting and quantitative PCR has demonstrated that in 
the 2-FaraA-sensitive cell lines, Raji and IM9, p53 accumulates in nuclei, mitochondria and 
cytosol. Raji cells accumulate p53 in mitochondria earlier than in the nucleus suggesting that 
initiation of apoptosis in these cells is dependent on the roles of p53 at mitochondria, prior to 
effects on gene expression in the nucleus. In Raji, accumulation of p53 is likely to result from 
increased mRNA levels, and from inhibition of p53 degradation due to phosphorylation. 2-
FaraA also induces phosphorylation and accumulation of lower molecular weight derivatives 
of p53, p63 and p73 in the nuclei of Raji cells that may have roles in inducing apoptosis.  
Qualitative analysis of the p53 interactome in Raji, IM9 and MEC1 cell lines using mass 
spectrometry indicated that MEC1 may have a gain of function p53 mutation that may 
contribute to 2-FaraA resistance. In 2-FaraA responsive cells, treatment dissociates HSP90 
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from the p53 interactome. This suggests that HSP90 binding to p53 may play a role in 
regulating p53 activity and sensitivity to 2-FaraA treatment. 
Quantitative phospho-proteomics of the p53 interactome showed that in response to 2-FaraA, 
HSP90 is phosphorylated at serine 254 by casein kinase, that may be associated with its 
dissociation from p53. 2-FaraA may also dysregulate ribosome biogenesis, essential for cell 
survival. p53 knockdown in Raji and IM9 with siRNA induced up-regulation of transcription 
the factor YY1, and the surface antigen ICAM1, that may have roles in altering the 
biochemistry of the cells and allow them to become resistant to 2-FaraA-induced apoptosis in 
p53 knock-down cells  
Taken together the novel findings of this thesis provide greater insight into the p53-centric 
mechanism of 2-FaraA against B-lymphoid cancers and suggest new treatment strategies for 
drug resistant chronic lymphocytic leukaemia and lymphoma.  
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CHAPTER ONE 
General Introduction 
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1.1 B-LYMPHOID CANCERS 
The biological process of haematopoiesis describes the formation of leukocytes in the bone 
marrow and their differentiation into the different white blood cells from the original stem 
cells. The common lymphoid progenitors eventually differentiate into T- or B-lymphocytes 
(Figure 1.1) and the cancers of these cells are referred to as T- or B-lymphoid cancers. The 
latter  arise when B-cell differentiation and activation are disrupted, resulting in lymphomas 
and leukaemias [1]. This thesis uses 4 immortalised cell lines that represent different B-
lymphoid cancers.  
The Raji cell line was derived from  Burkitt ’s lymphoma (non-Hodgkin's lymphoma), an 
aggressive B-cell lymphoma of children and young adults that is associated with 
translocations of the gene encoding the transcription factor c-MYC to immunoglobulin loci 
[2]. Burkitt’s lymphomas can also accumulate somatic mutations of c-MYC that might alter 
its function as a transcription factor [3, 4]. These mutations of c-MYC could promote tumour-
cell proliferation [5].The endemic form of Burkitt’s lymphoma involves Epstein–Barr virus 
(EBV) infection of B-lymphoid cells, whereas the sporadic form is EBV independent. These 
lymphomas can be cured in more than 80% of cases [1]. 
The human IM9 and U266 cell lines are derived from myeloma, an incurable malignancy of 
plasma cells with a median survival of three years. Multiple myeloma constitutes ~10% of all 
haematological malignancies, with a median age at diagnosis of ~65. Neoplastic cells are 
located in the bone marrow, and osteolytic bone lesions are characteristic [6]. Reciprocal 
chromosomal translocations between one of the immunoglobulin loci and various other 
genes, including those that encode cyclin D1, cyclin D3, c-MAF, MMSET (multiple 
myeloma SET-domain protein) or fibroblast growth factor receptor 3 (FGFR3), are 
considered to be primary oncogenic events [7]. 
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The MEC1 cell line was derived from chronic lymphocytic leukemia (CLL); the most 
common leukaemia, with a median age of onset of 65. CLL is molecularly and clinically 
related to a nodal lymphoma known as small lymphocytic lymphoma. Current therapies can 
remove CLL cells from the blood , but is not curative and does not prolong survival [1]. 
  
Figure 1.1 Hematopoiesis of B-lymphocytes from which Raji, IM9, MEC1 and U266 cell lines are derived.  
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1.1.1 Raji cell line (non-Hodgkin's lymphoma) 
The Raji cell line (ACC319) was established from the left maxilla of a 12-year-old African 
boy with Burkitt’s lymphoma in 1963 and is the first continuous human hematopoietic cell 
line.  In suspension, Raji are round cells that partly grow in clusters and double in 24-36 h. 
The immunophenotype is positive for CD10, CD19, CD20, HLA-DR, CD37, CD79a, CD80 
and IgM; and negative for CD3, CD13, CD34, and CD138 [8]. Raji cells have a p53 point 
mutation Arg(213)-Gln, but it retains the functional properties of wild-type p53 [9]. 
 
1.1.2 IM9 cell line (EBV-transformed B-lymphoblastoid)  
The IM9 cell line (ACC117) was isolated from the bone marrow of a woman with multiple 
myeloma in 1967. Cells synthesize IgG, have receptors for insulin and calcitonin, and express 
BCL2 mRNA. IM9 are Epstein Barr Virus positive and B-lymphoblastoid derived cells. In 
suspension, IM9 are lymphoblastoid shaped, as single cells or clusters. The cells are positive 
for CD19, CD20, cyCD79a, CD80, CD138, and HLA-DR and negative for CD3, CD10, 
CD13, CD34, and CD37 [10, 11]. IM9 cells are p53 wild-type [12].  
 
1.1.3 MEC1 cell line (chronic lymphocytic leukemia)  
The MEC1 cell line (ACC497) was established in 1993 from the peripheral blood of a 61- 
year-old Caucasian man with chronic B-cell leukemia (B-CLL in prolymphocytoid 
transformation to B-PLL); a serial sister cell line MEC-2 (DSM ACC 500) was also isolated. 
In suspension, they appear as round to polymorphic cells growing singly or in clusters, a few 
cells are slightly adherent. The cells are positive for CD19, CD20, CD37, CD79a, CD80 and 
HLA-DR. They are negative for CD3, CD10, CD13, CD34 and CD138 [13]. For MEC1 and 
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MEC2, p53 is mutated with a deletion of 40 amino acids at the N-terminus of the protein 
[14].  
1.1.4 U266 cell line (myeloma) 
The U266 cell line (ACC9) was established from the peripheral blood of a 53-year-old man 
with IgE-secreting myeloma (refractory, terminal) in 1968. In suspension, they are round to 
polygonal, and grow singly or as clusters, some are loosely adherent. They are positive for 
CD33, CD38, CD79a, CD138 and HLA-DR. They are negative for CD3, CD4, CD5, CD10, 
CD13, CD14, CD15, CD19, CD20, CD21, CD22, CD34, CD37 and CD80. The U266 cell 
line has a single mutant p53 allele [15] in codon 161 [16]. 
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1.2 FLUDARABINE (2-FaraA) 
The anticancer drug fludarabine, was synthesized in 1969 by Montgomery and Hewson [17]. 
The chemical name for fludarabine is 9-β-D-arabinofuranosyl-2-fluoroadenine 5’-
monophosphate, FdAMP (2-FaraAMP). It consists of an adenine base linked to a deoxyribose 
through a glycosidic bond, with a fluorine atom attached at carbon 2 of the purine ring and a 
phosphate group attached at carbon 5 of the deoxyribose group (Figure 1.2). The phosphate 
group aids in drug solubility. 
 
Figure 1.2 Chemical structure of 2-FaraAMP 
 
1.2.1 Uptake and metabolism  
Administered as a 2-FaraAMP, fludarabine is de-phosphorylated by the plasma membrane 
phosphatase CD73 to 2-FaraA [18]. 2-FaraA enters the cell through both (human) equilibrative 
nucleoside-specific membrane transporters (hENT1 and hENT2) and (human) concentrative 
nucleoside-specific membrane transporter (hCNT3) [18-20]. After 2-FaraA uptake, it is 
converted to the triphosphate form by deoxycytidine kinase (dCK), adenylate kinase (AK) and 
nucleoside diphosphate kinase (NDK) to produce 2-FaraATP [21]. In proliferating and 
resting cells 2-FaraATP accumulation is dependent on a high ratio of dCK/CD73 activity 
[22]. 
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Figure 1.3 Schematic of Fludarabine uptake and metabolism by B-lymphocytes. The boxes represent the 
phosphatase CD73, deoxycytidine kinase (dCK), adenylate kinase (AK) and nucleoside diphosphate kinase 
(NDK). The circle in the plasma membrane represents nucleoside-specific membrane transporters. 
 
1.2.2 Mechanisms of action  
The principal mechanism of action of 2-FaraATP is inhibition of DNA synthesis [23, 24]. 
Specifically, the 2-FaraATP inhibits DNA polymerase by acting as an alternative substrate to 
deoxyadenosine 5’-triphosphate (dATP) and inhibits DNA primase by perturbing 
ribonucleoside triphosphates levels [25, 26]. 2-FaraATP also inhibits ribonucleotide 
reductase which results in lowering of cellular deoxynucloetide pools [27, 28]. 2-FaraAMP 
can also incorporate into the DNA and cause strand breaks due to the inability of DNA ligase 
I to join it to the adjacent DNA strand [29, 30]. 
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2-FaraATP also inhibits RNA polymerase II and 2-FaraAMP is incorporated into mRNA 
resulting in premature termination of RNA transcripts resulting in inhibition of RNA and 
protein synthesis [31]. 2-FaraATP can induce cell death in quiescent cells without 
incorporation into DNA by activation of the intrinsic pathway from mitochondria, by the 
apoptotic cascade [32] Combinations of these effects lead to complete inactivation of DNA 
synthesis followed by initiation of apoptosis of cells [33, 34]. 
1.2.3 Therapy  
Fludarabine was first established for treatment of relapsed or refractory CLL [35] and is now 
standard treatment for patients with CLL and indolent NHL [36]. Fludarabine is a first line 
therapy for CLL. A study published by Keating et al. involved the long term follow-up of a 
group of 174 patients with progressive or advanced CLL, treated with fludarabine [37]. 
Results from the study showed that fludarabine induced a complete response rate of 38% in 
these patients. Similarly, Hagenbeek et al. showed that patients with newly diagnosed low 
grade NHL who received fludarabine, achieved higher overall response and complete 
response compared with patients treated with the conventional CVP (cyclophosphamide, 
vincristine, and prednisone) therapy. They concluded that fludarabine is a highly active single 
agent agonist low grade NHL [38]. Other diseases that use fludarabine as mono-therapy 
include mantle cell lymphoma (MCL), Walddenström’s macroglobulinemia (WM), hairy cell 
leukemia (HCL), MALT lymphoma and cutaneous T-cell lymphoma [39-41]. Fludarabine is 
also used in combination therapy most commonly with cyclophosphamide and rituximab 
(FCR) for relapsed CLL patients [42] and indolent NHL [43]. 
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1.3 CELLULAR TUMOUR ANTIGEN P53 
The tumour suppressor protein p53 is one of the most studied proteins in cancer research. As 
a transcription factor, p53 plays an essential role as the “guardian of the genome” [44] by 
regulating the expression of at least 361 genes [45] involved in cell cycle arrest, apoptosis 
and other functions in response to cellular stress signals. Loss of p53 function, through 
mutations or perturbations in the signalling pathways for p53, is a common feature of most 
human cancers [46]. 
 
1.3.1 History, structure and isoforms  
p53 was inadvertently discovered in 1979, when studies of SV40-transformed cells showed 
that a 55-kDa protein co-precipitated with the large-T antigen. Mice inoculated with murine 
cells transformed by SV40 showed a strong immune reaction and produced antibodies against 
a nuclear protein known as Large T antigen. Immuno-precipitation of this large T antigen co-
precipitated an associated protein of molecular weight 53 – 54 kDa [47-50]. This associated 
protein of cellular rather than viral origin was later called p53. The p53 gene was initially 
thought to be an oncogene and later proven to play the opposite role as a tumour suppressor; 
p53 has been the focus of thousands of research studies of cancer. 
p53 is composed of 393 amino acids and has five major domains (Figure1.4) The N-terminal 
domain (amino acids 1-100) is required for the transcriptional activity of p53, it consists of 
two transactivation domains (TADs) and a proline-rich domain. At least one of the two TADs 
is necessary for transcriptional activity, and the first TAD is dispensable for apoptosis 
induction [51, 52]. It is also the binding site for the p53 inhibitor mdm2. The transactivation 
domains have 10 known phosphorylation sites that are S6, S9, S15, T18, S20, S33, S37, S46, 
T55 and T81. [53]. Amino acids 61 - 94 constitute the proline rich domain, that binds prolyl 
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isomerase PIN1 decreasing the affinity of p53 for the inhibitor MDM2 [54]. The proline rich 
domain has also been implicated in transcription-independent p53 functions [55]. The core 
DNA binding domain comprising amino acids 101-300 specifically binds to DNA consensus 
recognition elements in the promoters of target genes. It is in this domain that most p53 
mutations are found in human tumours and most mutations in the DNA binding domain 
dramatically affected the transactivation efficiency of p53 in yeast assays. There are 4 known 
phosphorylated residues in the domain, S149, T150, T155 and S215. The C-terminal 
oligomerisation domain (OD) forms homo-tetramers. It contains a β-strand and α-helix, 
which associate with another p53 subunit across an interface containing anti-parallel β-sheet 
and an anti-parallel helix-helix, forming a dimer. The two dimers are held together by the 
large hydrophobic surface of each helix pair [56]. The native tetramer of p53 activates 
transcription whereas the monomer is transcriptionally inactive [57]. The last domain of p53, 
from amino acids 360 to 393, is the C-terminal regulatory domain  that binds DNA non-
specifically and may regulate specific DNA binding by the DBD [58, 59]. Residues 
phosphorylated in these domains include S313, S314, S315, S366, S371, T377, S378, T387 
and S392. 
 
Figure 1.4 The major domains and sites of phosphorylation of p53. The transactivation domains (TAD1 and 
TAD2) are blue squares, the proline rich section is a clear square with dotted lines. The DNA binding, 
oligomerisation (OD) and the C-terminal regulatory domains are in green, orange and red squares, respectively.  
 
10 | P a g e  
 
In humans p53 is found in chromosome 17. There are nine natural isoforms of p53 generated 
by alternative transcription sites and splicing (Figure 1.5). Wild-type p53, p53β and p53γ are 
transcribed from promoter 1 and alternative splicing of intron 9 generates the p53β and p53γ 
isoforms. ∆40p53, ∆40p53β and ∆40p53γ transcribed from codon 40 and are alternatively 
spliced at intron 9, similar to the full length protein, to form the β and γ isoforms. Lastly, 
∆133p53 ∆133p53β and ∆133p53γ are transcribed from codon 133 and undergo alternative 
splicing at intron 9 to generate the β and γ isoforms.  
 
Figure 1.5 p53 protein isoforms generated from alternative splicing (α, β, γ) and alternative promoters [60] 
 
1.3.2 Mechanism of action  
In unstressed cells, p53 levels are minimal. Cellular stress stabilises p53 and allows it to 
accumulate resulting in events such as apoptosis, growth arrest and/or senescence [61, 62]. 
For example, DNA damage triggers the accumulation of signal mediators such as ATM and 
ATR kinases, and p14ARF (Figure 1.6). These mediators collectively lead to accumulation of 
p53 following phosphorylation, and p14ARF inhibits MDM2 that induces ubiquitination of 
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p53. The activated p53 tetramer can undergo further modifications such as acetylation [63, 
64] and methylation [65]. p53 binds to the p53RE and triggers transcription of target genes. 
These genes vary according to the cell’s requirement. For apoptosis, genes like Puma, Noxa, 
Bax and Fas are transcribed, whereas for cell cycle arrest p21, Waf1 and Snf proteins are 
required [66, 67]. 
 
 
Figure 1.6 DNA damage induces apoptosis and cell cycle arrest following phosphorylation and accumulation of 
p53 
 
1.3.3 Other p53 family proteins (p63 and p73) 
The p63 gene was discovered in 1997 as the last member of the p53 family [68]. The p63 
gene has a high degree of sequence homology to p53 (Figure 1.7); however there are some 
differences between the two genes and their respective proteins. Human p63 has three 
alternatively spliced C-terminal isoforms (α, β, γ) and is transcribed from two different 
promoters. The promoter that is found upstream of exon 1 transcribes the transactivating 
isoforms (TAp63) and the promoter found in intron 3 transcribes the N-terminal truncated 
isoforms (ΔNp63). Taken with the C-terminal alternative splicing, p63 has the potential to 
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express 6 different mRNAs encoding 6 p63 isoforms. The functional motifs of p63 are 
similar to p53 with one exception, the α-isoforms (both TAp63α and ΔNp63α) have an 
additional sterile alpha motif (SAM) implicated in protein-protein interactions associated 
with early developmental processes, a biological function unique to p63 [69]. The TAp63 
isoforms are ‘p53-like,’ they can bind to DNA through p53 responsive elements (p53RE) and 
activate target genes to induce cell cycle arrest and apoptosis. They can also bind to the 
p63RE, similar to p53RE but only binds p63. The ΔNp63 isoforms can also bind to the 
p53RE but cannot induce transcription, thus exerting a dominant negative effect on 
transactivating p53 and p63. Therefore ΔNp63 isoforms hinder tumour suppressive functions 
and are thought to have oncogenic properties [68]. ΔNp63 isoforms also activate specific 
gene targets not induced by TAp63 isoforms and are abundantly expressed in progenitor cells 
of skin, breast and prostate where levels of TAp63 are barely detectable, indicating that 
ΔNp63 plays particular roles in differentiation [70]. 
Unlike p53, p63 mutations are not directly linked to cancer [71]. The role of p63 in cancer is 
difficult to define due to its contradictory activities as a tumour suppressor or an oncogene 
[72]. Mouse models have shown that some p63+/- mice develop cancer while others are not 
cancer prone, but may be subject to premature aging leading to senescence [73, 74]. 
Squamous cell carcinoma has ΔNp63 as the main isoform expressed, contradictory to most 
malignant lymphomas where TAp63 isoforms are expressed and ΔNp63 isoforms are not. In 
humans, the p63 gene is frequently amplified in squamous, lung and cervical cancers [75].  
 
The p73 gene was accidentally in 1997 discovered during a search for novel interleukins by 
Caput et al. [76] and found to have sequence homology with p53. The p73 gene is located at 
human chromosome 1p36 and is frequently deleted in some human cancers, specifically 
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neuroblastomas, melanomas and breast cancers. Human p73 have 15 exons, and similar to 
p63, the p73 gene can be transcribed from an alternative promoter in intron 3 generating the 
transactivating (TAp73) and amino terminal truncated (ΔNp73) isoforms. p73 can also be 
alternatively spliced at the C-terminus to form 7 different isoforms (α, β, γ, δ, ε, ζ and η). 
Taken together, the p73 gene expresses 35 mRNA variants, however only 14 have been 
described [77]. Structurally p73 is very similar to p63 (Figure 1.7) with homologous domains, 
in particular the DBD (~85% homology). 
 
p73 does not have its own responsive element but can bind to p53RE to transcribe genes [78]. 
It induces p53-like responses (TAp73) in the cell as well as dominant negative responses 
(ΔNp73). In the developing mouse brain, the principal form of p73 is ΔNp73. The amino-
truncated isoforms are required to counter p53-mediated neuronal death during sculpting of 
the developing mouse neuronal system [79-81]. TAp73 may also play important roles in the 
terminal differentiation program during nephron development in kidneys [82]. Studies using 
mouse models show that p73 null mice have striking defects such as hippocampal dysgenesis, 
hydrocephalus and suffer chronic infections and inflammation, with abnormalities in the 
pheromone sensory pathways [83]. 
 
The role of p73 in cancer is ambiguous. The p73 gene is seldom found mutated in cancer but 
there is evidence of differential expression in different tumours. The functions of ΔNp73 are 
important for tumour survival as it inhibits the apoptotic effects of p53 [84]. Studies by 
Beitzinger et al. (2008) show that in pre-malignant stages, expression of TAp73 is triggered 
which helps increase sensitivity to chemotherapeutic agents and prevents anchorage-
independent tumour growth, a hallmark of melanoma and ovarian cancers [85]. Studies in B-
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CLL show expression of p73 gene variants was much higher in leukemic cells compared to 
controls [86]. 
 
Figure 1.7 Homology between p53, p63 and p73. Functional domains include the transactivation domain (TA), 
proline-rich domain (PR), DNA binding domain (DBD), oligomerization domain (OD) and sterile alpha motif 
(SAM) [87].  
 
Studies of cell biology over the years have curated an extensive knowledge of protein 
function, structure, localisation and modifications of multiple organisms in databases [88]. 
However a protein rarely acts individually. For a biological event to occur, a network of 
proteins collaborates to induce signalling cascades. Mapping the protein-to-protein 
interactions can provide a clearer picture of the molecular mechanisms involved with 
biological events. The complete map of a protein’s interactions that can occur in a living 
organism is called the interactome [89]. For a protein like p53, the interactome can be 
complex as it is able to bind to DNA, RNA, and proteins (Figure 1.8) and is regulated by 
many macromolecules. Study of the p53 interactome will indicate the number of molecular 
and biological processes it’s involved in. 
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Figure 1.8 Components of the p53 interactome. (A) p53 binds to the p53RE of target genes and any other 
proteins binding to or near the p53RE may be detected in the interactome. (B) RNA may bind to p53 which aids 
in oligomerization [90], thus, other RNA binding proteins may form part of the interactome. (C) Proteins and 
protein complexes that directly bind to p53 as well as proteins that bind to p53 binding proteins (indirect) are a 
part of the interactome.  
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1.4 PRINCIPLES OF PROTEOMIC TECHNIQUES  
The term ‘proteomics’ was coined in 1995 by Wilkins and co-workers in Australia [91]. 
Proteomics involves the identification, modification, quantification and localisation of a 
complete set of proteins in an organism or system. Factors that influence the success of a 
proteomics experiment include sample preparation, separation methods, data acquisition and 
analysis. There are more than 100,000 unique proteins within a typical human cell. Thus, 
enrichment techniques such as sub-cellular fractionation and as adsorption to TiO2 for 
phosphorylation should be considered when designing studies. The two main approaches to 
proteomic analysis are ‘bottom-up’ and ‘top-down’ methods. Bottom-up (shotgun) analysis 
typically involves digestion of proteins using a specific protease (trypsin), and the resulting 
peptides are separated using liquid chromatography. The separated peptides are ionized and 
directly injected into a mass spectrometer, where the mass-to-charge (m/z) ratios of the 
molecular ions are determined. Peptide (precursor) ions are chosen on the basis of an 
abundance-guided heuristic and subjected to fragmentation. The mass of each precursor and 
fragment ions are then assigned by a database search tool to the best-matching peptide 
sequence in a database. Changes in protein abundance between samples can be quantified by 
directly comparing the ion abundance between subsequent mass spectrometric analyses 
(label-free quantification) or with stable isotope labelling. With all its advantage, there are 
also several drawbacks to the shotgun approach. The variability of the precursor selection 
means poor reproducibility between runs. Validation techniques such as western blot or flow 
cytometry are limited by availability of antibodies which limit hypothesis generation [92]. 
Recent advances with techniques such as selected reaction monitoring are being developed to 
combat this problem.  
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The top-down mass spectrometry involves the introduction of intact protein molecular ions 
generated by electrospray ionisation into the mass analyser and are subjected to gas-phase 
fragmentation. The two major advantages of the top-down strategy are the potential access to 
the complete protein sequence and the ability to locate and characterize post translational 
modifications. In addition, the time-consuming protein digestion required for bottom-up 
methods is eliminated. Top-down proteomics is a relatively young field compared to bottom-
up proteomics, and has several limitations such as low sensitivity, as the technique does not 
favour intact proteins larger than ~50 kDa and underdeveloped bioinformatics.  
 
1.4.1 Mass spectrometry  
Mass spectrometry is an analytical technique that can provide both qualitative (structure) and 
quantitative (molecular mass or concentration) information on analyte molecules after their 
conversion to ions. The molecules of interest are introduced into the ionisation source of the 
mass spectrometer, where they are ionised to acquire positive or negative charges. The ions 
then travel through the mass analyser and arrive at different parts of the detector according to 
their mass/charge (m/z) ratio. After the ions make contact with the detector, useable signals 
are generated and recorded by a computer system. The computer displays the signals 
graphically as a mass spectrum showing the relative abundance of the signals according to 
their mass to charge (m/z) ratio [93]. Tandem mass spectrometry (MS/MS) enables 
identification of proteins by sequencing of their peptides. Peptides are individually selected 
from the mixture in the first mass analyser and dissociated by collision with an inert gas, such 
as argon or nitrogen. The resulting fragments are then separated in the second mass analyser, 
producing the tandem MS/MS spectrum [94]. Peptide sequences can be obtained by manual 
annotation of the MS/MS spectra and the parent protein identified by database searching. 
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1.4.1.1  Liquid chromatography  
In proteomics, the use of liquid chromatography provides a high-speed, high-resolution and 
high-sensitivity separation of macromolecules. In addition, the unique features of 
chromatography enable the detection of low-abundance species and post-translational 
modified proteins [95]. In shotgun studies, liquid chromatography is used to fractionate 
peptides prior to mass spectrometry to achieve a greater depth of proteome coverage. This 
involves the separation of molecules in solution, based on their interactions with stationary 
and mobile phases [96, 97]. The 3 types of liquid chromatography used in this thesis are 
reverse phase (RP-LC), two dimensional (2D-LC) and gel based (GeLC).  
Reverse phase liquid chromatography (RP-LC) separates proteins by their hydrophobicity. 
Polypeptides adsorb to the hydrophobic surface of the column matrix in a polar mobile phase. 
Decreasing the mobile phase polarity by adding more organic solvent reduces the 
hydrophobic interaction between the solute and the solid support resulting in desorption. The 
more hydrophobic the molecule the more time it will spend on the solid support and the 
higher the concentration of organic solvent that is required to promote desorption. Commonly 
used matrices in RP consist of small, spherical, porous silica beads with a hydrophobic surface 
such as C4, C8 or C18. The most popular mobile phase is the organic solvent, acetonitrile (ACN). 
Two-dimensional (2D) separations involve fractionation of the sample based upon different 
properties [98], enabling resolution of complex samples such as cellular peptide digests. A 
typical 2D-LC separation couples strong cation exchange (SCX) with RP separation. The 
SCX separates the peptides by charge where a negatively-charged resin (stationary phase) 
binds positively charged analytes. All the peptides are positively charged by adjusting the pH 
to be lower than most peptide isoelectric points (pH 2-4). Increasing the salt concentration in 
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the mobile phase displaces peptides according to their charge due to competition for binding 
on the stationary phase. Buffers such as ammonium acetate and ammonium formate are 
generally used as competitive salts. 
Gel based liquid chromatography (GeLC, slice and dice) is another form of 2D-LC. Here 
molecules are separated based on their molecular weight then fractionated by RP. Protein samples 
are first separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE).  The detergent 
SDS linearizes proteins and coats them with negative charge. Proteins are separated by their 
ability to migrate through the polyacrylamide gel. Equal portions of the acrylamide gel are 
sliced and then the peptides are generated by in-gel tryptic digestion. Each section is then 
further separated by RP. 
 
1.4.1.2 Ionisation 
Peptides must be ionised to proceed with mass spectrometry analysis. The two forms of 
ionisation are electrospray ionisation (ESI) and Matrix-Assisted Laser Desorption Ionisation 
(MALDI). ESI is primarily used with bottom-up approaches and is the method used in this 
thesis. For ESI, a micro-capillary is used under a high potential energy. As the liquid analyte 
emerges from the needle-tip of the capillary, a strong electric field causes charge separation 
between the ions, that is offset by surface tension resulting in formation of a Taylor cone and 
a jet of charged positive droplets at the capillary tip (Figure 1.9) [94]. Evaporation of these 
droplets brings the charges closer together, then increasing coulombic repulsion destabilises 
the droplets so they disperse into smaller droplets until gas-phase ions form [99]. 
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Figure 1.9 Mechanism of electrospray ionisation [100]. 
 
1.4.1.3 Fragmentation  
The next step in the MS/MS process is the fragmentation of the precursor (parent) ions to 
form product (daughter) ions. Figure 1.10 depicts the various ion series a & x, b & y and c & 
z, that can be achieved through fragmentation. Fragments will only be detected if they carry 
at least one charge. If this charge is retained on the N terminal fragment, the ion is classed as 
either a, b or c. If the charge is retained on the C terminal, the ion type is either x, y or z. A 
subscript indicates the number of residues in the fragment. The most commonly used 
fragmentation is collision induced dissociation (CID). In this method, the parent ions are 
accelerated by an electric field to high kinetic energy and then allowed to collide with a 
neutral gas (helium, nitrogen or argon). This causes the fragmentation of the peptide 
backbone. CID largely generates a, b and y ions. In this thesis, trypsin was used to cleave C-
terminal arginyl or lysyl residues of proteins [101]. Thus the predominant ion series observed 
is the y-ions. Fragmentation methodology can often vary depending on the type of mass 
analyser used. While CID can be used in most MS/MS experiments, it is useful to consider 
other methods when using ion trap instruments. For example, compared to traditional ion-
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trap-based CID, a more recent type of fragmentation called higher-energy C-trap dissociation 
(HCD) provides detection of fragment ions at high resolution in the orbitrap mass analyser 
[102]. In HCD the ions pass through a C-trap and into the HCD cell, an added octopole 
collision cell, where dissociation takes place. The ions are then returned to the C-trap before 
injection into the orbitrap for mass analysis [103]. This form of analysis yields better data for 
post translational modification studies. 
 
 
Figure 1.10 Peptide fragmentation and formation of two ion series [104]. 
 
 
 
1.4.1.4 TOF and TRAP mass analysers 
Mass analysers store ions and separate them based on m/z ratios, which can be done in two ways, 
ion trap (TRAP) or time-of-flight (TOF). Ion trap mass analysers such as the orbitrap or ion 
cyclotron resonance (ICR), separate peptides based on m/z resonance, i.e., speed and distance of 
the cycling ion. Quadrupole TRAP setups measure m/z stability. In comparison, TOF instruments 
use the flight time required for the ion to reach the detector [105]. 
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1.4.2 Phosphopeptide enrichment  
Phosphopeptide enrichment uses the principle that phosphate groups in phosphorylated 
peptides have very low pKa values compared with other functional moieties in amino acids, 
so a negative charge is maintained even in an acidic environment. For efficient and selective 
capture of phosphorylated peptides, solid matrices with positive charges under acidic 
conditions are required, such as titanium dioxide (TiO2) particles (Figure 1.11). However, the 
binding of non-phosphorylated peptides with multiple acidic residues, such as glutamic acid 
or aspartic acid, hinders the efficiency of enrichment and number of phosphopeptides 
identified via MS/MS [106]. Thus, TiO2-based enrichments are improved by the use of ‘non-
phospho excluders’ such as 2,5-dihydroxybenzoic acid, phthalic acid, and glycolic acid [107] 
although the physico-chemical mechanism is unclear. The adsorption of phosphate ions to 
TiO2 forms a strong bidentate complex and is highly sensitive to the pH of the solution [108]. 
Minimal binding is seen at pH 11 where phosphopeptides are eluted from TiO2. Lower pH 
values generate a gradient of binding strength enabling multiple fractionations of peptides 
from TiO2 [109].  
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Figure 1.11 Binding of phosphorylated peptide to titanium dioxide (TiO2). Adapted from Rogers et al. 2009 
[110]. 
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1.5 PRINCIPLES OF MOLECULAR TECHNIQUES 
While the proteomics techniques discussed above are useful for discovery studies, molecular 
techniques are more useful for validation and targeted studies. Here a protein, gene or 
pathway of interest is selected, before experimental design. For example, when validating 
changes in surface antigens, flow cytometry is more useful compared to validating changes in 
intercellular molecular pathways, where RNA knockdown or q-PCR more suitable. Using 
molecular techniques to validate proteomic studies allows orthogonal analysis and greater 
confidence in data. 
 
1.5.1 Immunoprecipitation and Western blotting  
Both of these techniques use the affinity of antibodies (monoclonal or polyclonal) for their 
target proteins (antigens). Immunoprecipitation (IP) is a procedure in which an antigen is 
isolated by binding to a specific antibody attached to a sedimentable matrix. The source of 
antigen for immuno-precipitation can be unlabelled cells or tissues, radio-labelled cells, or in 
vitro-translated proteins [111]. Several type of immuno-precipitation can be achieved.  
Normal IP involves using an antibody to isolate a particular protein out of a solution 
containing many proteins. Co-IP is immunoprecipitation of intact protein complexes using an 
antibody that targets a known protein (e.g., p53) that may be part of a complex of proteins. 
Targeting a known member of a complex may lead to the identification of new members. 
Chromatin immunoprecipitation (ChIP) is used to determine the location of DNA binding 
sites on the genome for a particular protein. DNA-binding proteins in cells can be cross-
linked to the DNA which is then precipitated with the protein. ChIP is followed by DNA 
sequencing and PCR. This strategy can also be applied to RNA and RNA-binding proteins. 
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One of the major drawbacks of IP is non-specific binding of proteins to the antibody. It is 
important to use positive and negative controls in IP experiments with unrelated antibodies, 
or cell lines that that is null for target protein. Alternatively tagging the N or C terminal of the 
target protein and then pulling down the tag may be used to improve specificity; an example 
of this is the Strep-tagging of proteins described by Schmidt et al [112].  
Western blots detect the relative abundance and isoforms of a protein. A complex protein 
mixture is separated by using 1D or 2D gel electrophoresis with transfer to polyvinylidene 
difluoride (PVDF) or nitrocellulose membrane, and incubation of the membrane with the 
antibody for the target protein. The protein is visualised and quantified using a secondary 
antibody coupled to an enzyme (e.g. horseradish peroxidase) that binds to the primary 
antibody followed by chemiluminescence using x-ray films or a scanner.  
 
1.5.2 Quantitative PCR 
qPCR or real-time PCR can measure the increase or decrease of a particular messenger RNA 
(mRNA) in a cell. This technique can be used to determine if an observed increase in protein 
is due to transcription or post- translational events. A typical analysis starts with the 
extraction and purification of cellular RNA. Reverse transcriptase PCR converts the RNA 
into single-stranded complementary DNA (cDNA). In qPCR, the amount of PCR product is 
measured at each heat cycle. Monitoring the reaction during exponential phase (Figure 1.12) 
enables determination of the initial amount of mRNA. The amount of DNA is measured after 
each PCR cycle using fluorescent markers (SYBER) incorporated into the PCR product. The 
threshold cycle (Ct) which is the cycle number at which the fluorescent signal of the reaction 
crosses the set threshold for change in fluorescent signal (Δ Rn) is used to calculate the initial 
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DNA copy number. The Ct value is inversely related to the amount of starting template 
(mRNA) thus the higher the Ct, the less of the target gene is transcribed. No template controls 
(no DNA) are used in PCR experiments to control for arbitrary products or fluorescent 
signals generated by the primers (Figure 1.12).  
 
Figure 1.12 qPCR plot showing derivation of Ct and sample comparison to no template control. Δ Rn is an 
increment of fluorescent signal at each time point. 
 
1.5.3 siRNA knock-down 
Small interfering RNA (siRNA) knock-down uses the method of RNA Interference (RNAi), 
also a cell’s natural mechanism of controlling gene expression. In RNAi response (e.g. after 
viral infection), siRNAs (21-23 nucleotides long) are snipped from longer dsRNA chains by 
an enzyme called Dicer. The anti-sense strand of the siRNA is used by an RNA-induced 
27 | P a g e  
 
silencing complex (RISC) to guide mRNA cleavage, so promoting mRNA degradation [113]. 
In RNAi-based knock-down, a double-stranded siRNA molecule is engineered to precisely 
match the protein-encoding nucleotide sequence of the target mRNA to be silenced. This 
engineered siRNA is then transfected into the cells by lipid based (Lipofectamine) fusion 
with the cell membrane, or by electroporation, forming pores in the cell membrane. After 
entering the cell, the siRNA uses this RNAi pathway. It associates with RISC and directs it to 
the target mRNA. The siRNA-associated RISC binds to the target mRNA through a base-
pairing interaction and degrades it. Suppression of gene expression by RNAi is generally 
transient [114].  
 
1.5.4 Flow cytometry 
Flow cytometry uses the principles of light scattering, and excitation and emission of 
fluorochromes to measure the abundance of a particular cellular protein. Fluorescently 
labelled cells are hydro-dynamically focused in a sheath of fluid before excitation by a light 
source (laser). The emitted fluorescent light is detected at a longer wavelength and recorded. 
Flow cytometry is able to measure each cell individually. Detectors are aimed at the point 
where the narrow stream of cells passes through the light beam; the forward scatter (FSC) is 
in line with the light beam. The perpendicular detectors quantify side scatter (SSC), and 
fluorescence (Figure 1.13). FSC correlates with the cell size and SSC with granularity or 
internal complexity of the cell. Each cell passing through the beam scatters the light, and 
fluorescent antibodies attached to the cells may be excited to emit light at a longer 
wavelength. A fluorescent dye, conjugated to a monoclonal antibody, is used to determine the 
expression levels of surface CD antigens on each cell.  
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Figure 1.13 Schematic setup and components of a typical flow cytometer. A single cell suspension is hydro-
dynamically focused with sheath fluid to intersect an argon-ion laser. Signals are collected by a forward angle 
light scatter detector, a side-scatter detector (1), and multiple fluorescence emission detectors (2–4). The signals 
are amplified and digitised  for analysis and display on a computer [115]. 
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1.6 AIMS 
I. Elucidate the roles of the p53, p63 and p73 in the response of B-lymphoid cells to 2-FaraA. 
Using 1D and 2D Western blot analyses, look at changes in protein abundance and sub-
cellular distribution in the human B-lymphoid cell lines Raji, IM9, MEC1 and U266 
following treatment with the 2-FaraA. q-PCR will be used to measure mRNA levels for p53, 
p63 and p73 in all four cell lines. Similar experiments will be performed with clinical 
samples of CLL, to see if there is translation from the results with cell lines. 
II. Qualitative study of p53 binding partners (interactome) using immuno-precipitation and 
mass spectrometry. This aim is in two parts (1) the study of the p53 interactome in the cell 
lines (Raji, IM9 and MEC1) with varying p53 mutational status. (2) the effects of 2-FaraA on 
the p53 interactome in the responsive (Raji and IM9) cell lines. 
III. Quantitative study of protein phosphorylation in the p53 interactome using immuno-
precipitation, isotopic labelling and mass spectrometry. p53 phosphorylation is a key event in 
the induction of apoptosis in B-lymphoid cancers. Phospho-proteomics will be utilised to 
assign increases or decreases in protein phosphorylation to identify phosphorylation cascades 
essential for the p53 network in response to 2-FaraA. 
IV. Quantitative study of the effects of p53 siRNA knock-down on 2-FaraA treatment in Raji 
and IM9 cell lines, using isobaric labelling and mass spectrometry. Cancers that have mutant 
or null p53 are often resistant to DNA-damaging agents. Elucidation of the cellular response 
to 2-FaraA in Raji and IM9 cells with and without p53 may reveal p53-independent apoptotic 
pathways and/or mechanisms of chemo-resistance in B-lymphoid cancers. 
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CHAPTER TWO 
Materials and Methods
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2.1 CELL CULTURE SYSTEMS AND ASSAYS 
2.1.1 Materials   
The B-lymphoid cell lines Raji, IM9, MEC1 and U266 were obtained from the Deutsche 
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, 
Germany, and the American Type Culture Collection (ATCC), Manassas, VA, USA.  
All other materials and reagents for this Chapter are listed in Appendix I. 
 
2.1.2 Reconstitution, culture and storage of cell lines  
Frozen cells were thawed rapidly in a 37°C water bath and resuspended in 10 mL of pre-
warmed (37°C) RPMI growth medium. To remove DMSO, the cells were centrifuged (300 x 
g, 5 min, room temperature, Eppendorf 5810R). The cell pellet was resuspended in fresh 
RPMI growth medium to a final density of 3 x 105 cells/ mL. 
 
The human cell lines were cultured in RPMI 1640 medium (HEPES modification) 
supplemented with 10% foetal calf serum and 50 μg/mL gentamicin in 25 cm2, 75 cm2, 175 
cm2 culture flasks or 24-well plate format, at 37°C in a non-humidified incubator (Heraeus, 
Hanau, Germany). All cell culture work was performed under sterile conditions using aseptic 
technique in a Class II biological safety cabinet (Westinghouse Pty. Ltd., Sydney, Australia). 
Cultures were passaged every 2-3 days to maintain cells in the exponential growth phase 
(105–106 cells/mL). Fresh cells were brought up from storage in liquid nitrogen at regular 
intervals (every 2-3 months) to replace older cultures. 
 
To provide a stock of a certain cell line, cells were harvested (300 x g, 5 min, room 
temperature, Eppendorf 5810R) and resuspended in RPMI growth medium to a final 
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concentration of 107 cells/ mL. An equal volume of RPMI growth medium with 20% (v/v) 
DMSO was added drop-wise while swirling the cell suspension, resulting in a final cell 
density of 5 x 106 cells/mL and DMSO concentration of 10%. Cryovial aliquots of 1 mL were 
stored in a -80°C freezer overnight and then transferred into a liquid nitrogen Dewar 
container for long-term storage. 
 
2.1.3 Isolation and primary culture of mononuclear cells from CLL patients  
Blood was drawn from leukaemia patients (Symbion Pathology, North Ryde, Australia) with 
informed consent and approval of the Human Ethics Committee of the University of Sydney 
(reference number 99/07/07). Peripheral blood leukocytes were isolated from blood samples 
by density-gradient centrifugation using Ficoll-Histopaque (Sigma-Aldrich, 800 x g, 15 min, 
4 ˚C). The layer of mononuclear cells was collected and washed with PBS. The leukocyte 
pellet was incubated in 155 mM NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA for 5 min at 4˚C 
to lyse residual red blood cells. Purified leukocytes were washed in PBS, resuspended in 
RPMI medium supplemented with 50 μg/mL gentamycin and 10% (w/v) BSA to a final 
concentration of 2 x 105 cells/ml.  
 
2.1.4 Cell density and viability 
Cell density and viability were determined using the Trypan blue exclusion method. The cell 
sample (50 μL) was mixed with an equal volume of 0.4% Trypan blue solution in a 
microcentrifuge tube and then pipetted into the chamber of a Neubauer haemocytometer. 
Trypan blue stains DNA, but is not able to permeate the membrane of live cells, only dead 
cells are stained blue within a minute of exposure to the dye [315]. The number of viable and 
33 | P a g e  
 
dead cells within five squares was counted using a Nikon TMS microscope (Nikon, 
Kanagawa, Japan).  
The following equations were used to calculate density and viability: 
Density (cells/mL) = (total cells counted/number of squares) x dilution factor x 104 
Cell viability (%) = (Viable cell density/ Total cells (viable + non-viable)) x 100 
Alternatively the Countess TM automated cell counter system was used to determine cell 
viability and density using the manufacturer’s protocol. 
 
2.1.5 Treatment of cells with 2-FaraA and various inhibitors 
Cells were grown to a density of 5 x 105 cells/ml and 2-FaraA (3 µM, Sigma, St. Louis, MO, 
USA) was added for the indicated times. Caspase activity was blocked using the pan-caspase 
inhibitor Z-VAD-FMK at 100 µM as previously described [116].  
 
2.1.6 Sulforhodamine B (SRB) assay  
Cell viability was determined for drug dose-response analyses using the Sulforhodamine B 
(SRB) assay that measures the total biomass by staining cellular proteins with 
Sulforhodamine B. The increase or decrease in the number of cells (total biomass) results in a 
concomitant change in the amount of dye incorporated by the cells in the culture. Briefly, 
3x104 cells were seeded per well of a 96-well plate in a final volume of 100 µl of RPMI-1640 
medium with the indicated concentrations of 2-FaraA (3 µM) and/or all trans-retinoic acid (1 
µM) at 37oC for the indicated times. Cells were fixed by incubating (1 h, 4oC) in 10% (w/v) 
trichloroacetic acid. The supernatant was removed and cells were stained for 30 min with 
0.4% sulforhodamine B dye. Wells were washed with 1% acetic acid to remove excess dye 
and the incorporated dye was solubilised with 10 mM Tris (base). Absorbance was measured 
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at 565 nm. Results are expressed relative to a vehicle-treated control well and are the means 
(+/- standard deviation) of three independent experiments. 
 
2.1.7 Apoptosis kit (Annexin V and 7-AAD)  
The proportion of apoptosis induced by drugs was determined using the Annexin V-PE 
Apoptosis Detection Kit I (BD Biosciences, San Diego, CA, USA). In cells undergoing 
apoptosis, phosphatidylserine (PS) is translocated from the inner to outer leaflet of the plasma 
membrane, exposing PS to the extracellular environment. Annexin V, a Ca
2+
-dependent 
phospholipid-binding protein, binds with high affinity to the PS exposed on apoptotic cells. 
The Annexin V is conjugated to the fluorochrome phycoerythrin (PE). 
Externalization of PS on cells during early apoptosis was quantified by Annexin V-PE 
binding, while the loss of cell membrane integrity on dead cells was detected by binding of 7-
amino-actinomycin D (7-AAD) to DNA. The combination of Annexin V-PE and 7-AAD 
staining allows the detection of three states within a cell population:  
 viable, non-apoptotic cells (7-AAD- and Annexin V-PE-negative);  
 apoptotic cells (7-AAD-negative, Annexin V-PE positive);  
 dead cells (7-AAD- and Annexin V-PE-positive).  
 
The percentages of viable cells, apoptotic cells and dead cells were determined using the 
following protocol provided with the Annexin V-PE Apoptosis Detection Kit I. Cells were 
collected by centrifugation (450 x g, 5 min, room temperature, Sorvall® RT 6000D) washed 
twice with PBS and resuspended at a density of 10
6 
cells/mL in binding buffer (10 mM 
HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). An aliquot of the suspension (50 μL; 0.5 x 
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10
5 
cells) was transferred to a FACS tube and incubated with 2.5 μL of Annexin V-PE and 
2.5 μL of 7-AAD for 15 min at room temperature in the dark. Cells were then resuspended in 
450 μL of binding buffer and analysed with a FACScan flow cytometer (BD FACSCalibur, 
BD Biosciences, San Diego, CA, USA) using CellQuest™ Pro software, Version 5.2 (BD 
Biosciences, San Diego, CA, USA). The instrument detected 10,000 cells (events) per 
sample. Forward scatter (FSC) and side scatter (SSC) were detected using linear 
amplification. Annexin V-PE and 7-AAD fluorescence detection used logarithmic 
amplification (FL2 = 585/42 nm and FL3 = 650 nm long pass, respectively). Percentages of 
viable, apoptotic and dead cells were defined by their distribution in a fluorescence 
Annexin/7-AAD dot plot. Unstained cells, cells stained only with Annexin V-PE and cells 
stained only with 7-AAD were used as controls to set up laser compensation and fluorescence 
for the Annexin/7-AAD dot plot. 
 
2.1.8 MTT Assay 
Cell viability was determined for drug dose-response analyses using the 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay, where viable cells convert the 
yellow MTT reagent into blue formazan crystals.  
Manufacturer’s instructions were followed, briefly, 1x105 cells were seeded per well of a 96-
well plate in a final volume of 200 µl of RPMI-1640 medium with the indicated 
concentration of 2-FaraA at 37oC for 48 h. For the final 4 h, 0.5 mg/ml MTT reagent was 
added. Cells were then spun down in the plate, the supernatant removed and the blue 
formazan crystals solubilised with 100 µl of dimethyl sulfoxide (DMSO). Absorbance was 
measured at 540 nm. Results are expressed relative to a vehicle-treated control well and are 
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the means (+/- standard deviation) of three independent experiments. IC50 calculations were 
performed using the BioDataFit software (http://www.changbioscience.com/stat/ec50.html). 
 
2.1.9 Cell cycle analysis 
 
Control and drug-treated cells were fixed and permeabilised in ice-cold 70% ethanol for 2 h 
at 20 °C. Cells were then pelleted (300 × g, 5 min, 4 °C) and stained in a solution containing 
50 μg/mL propidium iodide, 0.1 mg/mL RNase A and 0.1% Triton-X-100 for 30 min at room 
temperature. The DNA content of the cells was analysed by flow cytometry (FACSCalibur, 
Becton Dickinson, Franklin Lakes, NJ) and the proportion of cells in each phase of the cell 
cycle was calculated using ModFit software (Verity Software House, Topsham, ME). 
 
2.1.10 Intercellular staining for flow cytometry 
Following treatment, cells were fixed in 1% paraformaldehyde for 30 min at 4C, centrifuged 
at 1400 rpm, washed in a PBS buffer containing 0.5% BSA, 0.1% saponin and 0.05% triton-
X100 before being resuspended overnight in 100% methanol. Prior to staining, the cells were 
washed in the PBS/BSA buffer and incubated for 1 hour at room temperature with antibodies 
to either p21 or p27 (R&D Systems) at a concentration of 0.5 µg / 10^6 cells. The cells were 
then washed in PBS and incubated with a 1/100 dilution of a goat anti-mouse FITC-
conjugated antibody for 15 minutes at room temperature. Cells were further washed in PBS 
and the expression of p21 and p27 was assessed using a FACS Calibur (Becton Dickinson) 
instrument and CellQuest Pro software. 
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2.2 ISOLATION OF SUB-CELLULAR FRACTIONS  
2.2.1 Differential centrifugation 
Cells (5 × 108, n = 3) were collected by centrifugation (450 g, 5 min, room temperature), 
washed twice in PBS, resuspended in 5 mL of lysis buffer (10 mM HEPES, pH 7.4, 10 mM 
KCl, 1.5 mM MgCl2, 0.5 mM PMSF, 10 mM NaF, 1 mM Na3VO4, 0.2% (v/v) okadaic acid, 
0.05% (v/v) NP-40), incubated on ice for 5 min and lysed with 10 gentle strokes using a 
Dounce glass homogenizer.  
The cell suspension was vortexed for 30 s and centrifuged (800× g, 5 min, 4 °C) to remove 
crude nuclei and cellular debris. The supernatant was centrifuged (15,000× g, 30 min, 4 °C) 
to isolate crude mitochondria, followed by centrifugation (100,000× g, 60 min, 4 °C) to 
isolate the cytosolic proteome as the supernatant depleted of the microsomal fraction. Crude 
mitochondria were further purified by centrifugation on a two-step sucrose gradient. 
Mitochondria were resuspended in 5 mL isotonic buffer (10 mM Tris-HCl, pH 7.4, 0.25 M 
sucrose, 1 mM EDTA) and layered onto a 1.0/1.5 M sucrose step gradient (14 mL of 10 mM 
Tris-HCl, pH 7.4, 1.0 M sucrose, 1 mM EDTA over 20 mL of 10 mM Tris-HCl, pH 7.4, 1.5 
M sucrose, 1 mM EDTA) and centrifuged with the brake off (87,000× g, 2 h, 4 °C).  
The mitochondrial fraction sedimented at the 1.0/1.5 M sucrose interface and was carefully 
collected, diluted 2-fold in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5 mM 
PMSF and centrifuged (15 000× g, 20 min, 4 °C) to pellet mitochondria. The crude nuclear 
pellet was resuspended in 0.25 M sucrose, 10 mM MgCl2, 20 mM Tris−HCl pH 7.4 and 1 
mM DTT. To further purify the nuclei, the suspension was layered onto a two-step sucrose 
gradient (1.3 M sucrose, 6.25 mM MgCl2, 20 mM Tris−HCl pH 7.4, 0.5 mM DTT above 2.3 
M sucrose in 2.5 mM MgCl2 and 20 mM Tris−HCl, pH 7.4), then centrifuged (5000× g, 45 
min, 4 °C). The purified nuclear pellet was carefully resuspended in 10 mM HEPES pH 7.9, 
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10 mM KCl, 1.5 mM MgCl2, 1 mM DTT and 0.5 mM PMSF and centrifuged again (1000× g, 
5 min, 4 °C). 
 
2.2.2 Protein solubilisation  
The nuclear and mitochondrial pellets was solubilised in a 2DE compatible buffer (5 M urea, 
2 M thiourea, 2% (w/v) CHAPS, 40 mM Tris–base, 65 mM DTT, 2% (w/v) sulfobetaine 3–
10, 1% (v/v) Bio-Lyte 3–10 carrier ampholytes and 0.002% (w/v) bromophenol blue). To 
remove DNA from extracts of whole nuclei, Benzonase (200 U/mL) was added, the extract 
incubated at RT for 25 min and then centrifuged (20,000×g, 10 min, 25 °C) to remove 
insoluble material. 
 
2.2.3 Protein quantification using 2D-Quant Kit (GE Healthcare) 
Nuclear, cytosolic and mitochondrial proteins were purified using the ReadyPrep 2-D 
Cleanup Kit (Bio-Rad, Hercules, and CA). Samples for a standard curve were generated 
using the 2 mg/mL BSA standard solution provided with the kit (protein quantity range 0–50 
μg). Tubes containing the samples (5 μL) were prepared in duplicate, and 500 μL of 
precipitant was added to both BSA standards and the samples. All tubes were then vortexed 
and incubated at RT for 2 min. After adding 500 μL of co-precipitant, the tubes were 
vortexed briefly again, and the precipitated protein pelleted by centrifugation (14,000 rpm, 10 
min, RT). Supernatants were quickly decanted, and the tubes briefly centrifuged again to 
bring all remaining liquid to the bottom of the tube for removal. The precipitated protein was 
then resuspended in 100 μL copper solution and 400 μL MQ-water, before 1 mL of a 100: 1 
solution of colour reagent A: B was added to all tubes. Samples, and standards, were 
incubated at RT for 15 min, before the absorbance at 480 nm was read on an UVVisible 
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spectrophotometer (SmartSpecTM 3000, Bio-Rad Pty. Ltd. Hercules, CA, USA). MQ-water 
was used to zero the spectrophotometer. Protein concentrations of the unknown samples were 
then calculated from the equation obtained by linear regression to the BSA standard curve. 
 
2.3 GEL ELECTROPHORESIS  
2.3.1 1D electrophoresis 
Proteins were separated with a Bio-Rad Mini- Protean III gel electrophoresis cell using a 5% 
polyacrylamide stacking gel (5% (w/v) acrylamide/bis, 125 mM Tris-HCl (pH 6.8), 0.1% 
(w/v) SDS, 0.05% (w/v) ammonium persulfate and 0.1% (v/v) TEMED) and a 12% 
polyacrylamide separating gel (12% (w/v) acrylamide/bis, 375 mM Tris-HCl (pH 8.8), 0.1% 
(w/v) SDS, 0.05% (w/v) APS and 0.1% (v/v) TEMED). Protein samples were resuspended in 
SDS-PAGE loading buffer (62.5 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 5% (v/v) 2-
mercaptoethanol, 2% (w/v) SDS and 0.02% (w/v) Bromophenol blue), heated at 95°C for 15 
min and cooled on ice for 2 min prior to loading onto gels. Pre-stained molecular weight 
markers were loaded onto the first track. Electrophoresis was carried out at 120 V for 
approximately 90 min in running buffer (192 mM glycine, 0.1% (w/v) SDS, 24.8 mM Tris-
HCl (pH 8.3)), until the dye front had run off the gel. Following electrophoresis, the gels 
were fixed for 1 h, stained in CCB-G250 (17% (w/v) ammonium sulphate, 3% (v/v) 
phosphoric acid, 0.1% (w/v) Coomassie G-250 and 34% (v/v) methanol) and de-stained 
overnight, or Western blotted. 
 
2.3.2 2D electrophoresis 
Samples were transferred onto 11 cm pH 4-7 pH linear gradient IPG gel strips for overnight 
passive in gel-rehydration. Isoelectric focusing was carried out in an IEF focussing cell (Bio- 
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Rad Pty. Ltd. Hercules, CA, USA) using a five-step program (2 h at 200 V, 2 h at 1000 V, 2 h 
at 3000 V, 42 KVh at 5000 V and 24 h at 100 V/hold ) for a total of ~ 44 KVh. After 
focusing, the IPG strips were treated for 10 min in equilibration solution (6 M urea, 2% (w/v) 
SDS, 20% (v/v) glycerol, 5 mM TBP, 2.5% (v/v) 40% acrylamide, made up in 1 X Tris/HCl 
Gel Buffer for 2D SDS-PAGE, pH 8.8), then transferred onto an 11 cm second dimension 
Criterion XT Bis-Tris Gel, 4–12% acrylamide, sealed with 0.5% (w/v) agarose in 1 X MES 
buffer with a trace of Bromophenol blue. Second-dimension electrophoresis was run at 180 V 
until the Bromophenol blue dye front ran off the gel (~ 53 min) in a Criterion cell. The gels 
were fixed with 10% (v/v) methanol and 7% (v/v) acetic acid for 1 h, stained with Sypro 
Ruby overnight and washed in 10% (v/v) methanol and 7% (v/v) acetic acid for 2 h before 
visualisation using a Molecular Imager®FX (Bio-Rad Pty. Ltd. Hercules, CA, USA) or 
blotted directly onto Immobilon-P PVDF membranes. 
 
2.3.3 Western blotting  
The proteins from the gel were transferred onto the Immobilon-P PVDF membrane using the 
CriterionTM Blotter (Bio-Rad Pty. Ltd. Hercules, CA, USA) for 45 min at 400 mA, at 
4oC.They were then washed 2 times with 0.1% TSBT (25 mM Tris-HCl (pH 7.5), 150 mM 
sodium chloride and 0.1% (v/v) Tween-20) for 10 min. The membranes were blocked with 
skim milk (Skim milk powder 5% (w/v) made up in 0.1% TBST) for 1 hour at RT or 
overnight at 4oC on a rocker. The membranes were washed again with 0.1% TSBT for 10 min 
and then incubated at RT with primary antibody for 1 h (overnight for phospho-specific 
antibodies at 4 oC) on a rocker. The wash with 0.1% TSBT was repeated and the membrane 
was incubated with secondary antibody for 1 h at RT. The wash with 0.1% TSBT was 
repeated and the membrane was placed in PBS. The membranes were visualised with 
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AttoPhos® (Figure 2.1) and scanned using a Molecular Imager® FX Pro Plus (Bio-Rad Pty. 
Ltd. Hercules, CA, USA). When required, the membranes were stripped with 1% HCl. Three 
biological replicates were done for each antibody at each time point. 
 
2.3.4 Estimation of protein phosphorylation from pI values 
Western blot images were analysed using Adobe Photoshop CS3 vr 10.0.1 (Adobe Systems 
Inc, San Jose, CA, USA). A grid was placed over the gel image indicating 0.1 changes in pH. 
The pI values for isoforms of the protein were read from the grid starting with the most basic 
spot. A search was conducted on the PhosphoSitePlus website (www.phosphosite.org) and 
the ‘Predict pI for various phosphorylation states’ option was used to estimate the degree of 
phosphorylation of a protein from the pI value of the spot. 
 
2.3.5 Protein dephosphorylation  
Protein de-phosphorylation was conducted using calf intestinal alkaline phosphatase (CIP) 
according to the manufacturer’s protocol. Briefly, solubilised proteins were precipitated from 
samples and reconstituted at 0.1 µg protein /µl in NEBuffer. CIP was added (5 U/µg of 
protein) to each sample, followed by incubation at 37 oC for 60 min.  
 
2.4 QUANTITATIVE PCR 
2.4.1 RNA extraction and quantification 
Cell pellets were lysed in 1 mL TRITM Reagent Solution and centrifuged (20,000 x g, 20 min, 
4 oC). The supernant was collected and incubated at room temperature for 5 min (dissociation 
of the nucleoprotein complex). Chloroform (200 μl) was added, the sample vortexed for 30 s 
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and allowed to stand at room temperature for 2 min and centrifuged (20,000 x g, 20 min, 4 
oC). After separation of the sample into three distinct visible phases (RNA, DNA and 
protein), the top aqueous phase containing the RNA was retained and 500 μl of isopropanol 
was added and the sample was mixed by inversion and incubated at room temperature for 5 
min. The sample was centrifuged (20,000 x g, 20 min, 4 oC) to precipitate the RNA. The 
supernatant was removed and the RNA pellet resuspended in 80% ethanol (1 ml), vortexed 
briefly and centrifuged (20,000 x g for 15 min, 4 oC). The supernatant was removed and the 
pellet resuspended in 20 μl TE buffer (pH 7.0). Quality of RNA was assessed by 
formaldehyde gel electrophoresis. Quantity of RNA was measured by the Nanodrop (ND-
1000; NanoDrop Technologies Inc., Wilmington, DE, USA) at280 nm.  
 
2.4.2 RNA quality assessment using formaldehyde gels 
The RNA quantity and quality in the extracts were determined by spectrophotometry 
(Nanodrop) and with formaldehyde–agarose gels. Gels were prepared using 1.5% agarose, 40 
mM MOPS and 6.6% v/v formaldehyde. RNA samples (1 μl) were mixed with the loading 
buffer (40 mM MOPS buffer pH 7.0, 2.2 M formaldehyde, 15.9 M formamide, 50% glycerol, 
1 mM EDTA, 0.01% bromophenol blue, and 0.5% v/v Ethidium Bromide), heated at 65oC for 
5 min and immediately cooled on ice. Samples were then loaded onto formaldehyde–agarose 
gels, and run at 80 V for 40 min. Gels were visualised using Gel doc XR software (BioRad 
Laboratories, Hercules, CA, USA).  
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2.4.3 Reverse transcription  
RNA was converted into cDNA using the SuperScript® VILO™ cDNA Synthesis Kit, 
(Invitrogen Life Technologies, Victoria, Australia) according to the manufacturer’s protocol. 
Briefly, a reaction mixture of 200 ng RNA, 5x VILOTM Reaction Mix (4 μl), 10 x 
SuperScript® Enzyme Mix (2 μl) was made up to 20 μl with DEPC–treated water and 
incubated at 25 oC for 10 min. The reaction mixture was further incubated for 60 min at 25 oC 
and terminated at 85 oC for 5 min. The resultant cDNA was diluted 1:1 and 1:8. 
 
2.4.4 Real time PCR using SYBER green 
Quantitative PCR (qPCR) was carried out in a final volume of 20 µl per reaction, containing 
1 µl of cDNA, 10 µl of Fast SYBER Green Master Mix, 6 µl of H2O and 1.5 µl of forward 
and 1.5 µl of reverse primers. A negative control (-PCR) was prepared with H2O substituted 
for the cDNA. The PCR amplification was performed in a StepOne 7500 Fast Real-time PCR 
system (Applied Biosystems, Mulgrave, VIC, Australia). Amplification was carried out by 
heating the sample to 95°C for 30 s followed by repeating cycles of 95°C for 3 s, then 60°C 
for 30 s for a total of 40 cycles. The comparative Cycle Threshold (Ct) method was used for 
relative quantification of target gene expression normalized using a housekeeping gene 
encoding the 18S ribosomal RNA. Data were analysed using Microsoft Office Excel 2007. 
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2.5 DOTSCAN ANTIBODY MICROARRAY  
2.5.1 Immunophenotyping of Raji and U266 cell lines and primary CLL cells 
Purified mononuclear leukocytes or B-lymphocyte cell lines were washed and resuspended at 
a density of 1 x 107cells/mL in PBS. Optimally, 300 μL of the resuspended cells was used for 
each assay. The DotScan microarray was moistened with PBS and any excess liquid around 
the nitrocellulose film was carefully wiped off with Kimwipes tissues. Cell suspensions (300 
μL) were incubated on the microarray in a humidified chamber at room temperature (20oC). 
After 15 min, unbound cells were poured off and the microarray was gently washed with PBS 
(2 x10 s), and placed into the Array Fixative Solution (3.7% (w/v) formaldehyde in PBS) for at 
least 1 h, preferably overnight, to fix the cells to the antibodies of the microarray. The 
Fixative Solution was washed off with PBS and the microarray was scanned using a Medsaic 
DotReaderTM (Medsaic Pty. Ltd.). Dot intensities were quantified using DotScan software 
(Medsaic Pty. Ltd.) using 8-bit pixel greyness scale from 1-256. The arrays have alignment 
dots around the border consisting of a 1:1 mixture of CD44 and CD29 antibodies performing 
as positive controls for cell binding as well as immunoglobulin (IgG1, IgG2a, IgG2b, IgM 
and sIg) antibodies were used as isotype controls. Cell binding should not occur in non-
antibody-dotted regions. 
 
2.5.2 Statistical analysis  
Numerical value of binding intensity (after intra-array normalisation) for each antibody was 
obtained from a csv file generated by the DotScanTM software (Medsaic Pty. Ltd.). The values 
were normalised using mean-centered normalisation. The Log of the normalised values was 
used to conduct student 2-tailed, equal variance t-tests in Microsoft Excel (Microsoft Corp, 
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Redmond, WA USA). A p-value of <0.05 was required for significant differentially 
abundance. 
 
2.6 IMMUNO-PRECIPITATION  
2.6.1 Antigen pulldown  
Cell lysates in RIPA buffer (10 mM Na3HPO4, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 
1% Triton X, 1% Halt Phosphatase Inhibitor Cocktail, 1% protease inhibitor cocktail) were 
pre-cleared with 50 μL of Dynabeads. Dynabeads (50 μL) and 15 μg anti-p53 (DO1) were 
incubated in PBS-Tween (0.1 M PBS, 0.5% Tween 20, pH 7.3) 4oC for 1 h with shaking. The 
tubes were placed on the magnet, the supernatant removed. 5 mM BS3 was added to cross-
link the antibody–Dynabead complex for 30 min at room temperature, with shaking. The 
reaction was quenched by addition of 1 M Tris–HCl, pH 7.5 at room temperature for 15 min, 
shaking. The tubes were placed on a magnet and the antibody–Dynabead complex was 
washed three times using 1 ml of PBS-Tween. Protein lysate (300 μg) in 1,000 μL RIPA 
buffer was added to the antibody–Dynabead complex. The solution was incubated O/N at 4 
OC with shaking. The tubes were placed on a magnet and the Dynabead complex was washed 
3 X using 1 ml PBS-Tween. 
 
 
 
 
46 | P a g e  
 
2.6.2 Elution of antigen from Dynabeads  
2.6.2.1 GeLC-MS based analysis  
SDS-PAGE loading buffer (50 µl; 62.5 mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 5% (v/v) 
2-mercaptoethanol, 2% (w/v) SDS and 0.02% (w/v) Bromophenol blue) was added to the 
beads with the antibody-antigen complex and heated at 95°C for 5 min. The samples were 
cooled on ice for 2 min before collecting the supernatant for subsequent analysis by SDS-
PAGE. 
2.6.2.2 Shotgun-MS analysis  
The Dynabeads with the antibody-antigen complex were washed once with 400 μL of ice-
cold 0.1 M TEAB. The beads were resuspended in 40 μL of Reduction Buffer (0.5M TEAB, 
0.05% SDS, 0.0025M TCEP) and incubated at 85 oC for 5 min and 60 oC for 30 min 
respectively.  Cysteine blocking reagent MMTS (5mM) was added, mixed and incubated at 
room temperature for 10 min. Trypsin (2 µg) was added and the samples were incubated 
overnight at 37 oC. Supernatant was collected and lyophilised.  
 
2.7  GELC-MS  
2.7.1 Trypsin in gel digestion  
Lanes to be analysed were excised from SDS-PAGE gels using a razor blade and divided into 
10 ~ 1 cm slices. Each slice was then further divided into ~ 1 mm3 pieces. Each section was 
washed in water and completely destained using 100 mM ammonium bicarbonate in 50% 
acetonitrile. A reduction step was performed by addition of 100 μl 50 mM ammonium 
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bicarbonate pH 8.9 and 10 μl of 10 μM TCEP at 37 °C for 30 min. The proteins were 
alkylated by adding 100 μl 50 mM iodoacetamide and allowed to react in the dark at 20° C 
for 40 min. Gel sections were first washed in water, then acetonitrile, and finally dried by 
SpeedVac for 30 min. Digestion was carried out using 20 μg/ml sequencing grade modified 
trypsin in 50 mM ammonium bicarbonate. Sufficient trypsin solution was added to swell the 
gel pieces, which were kept at 4° C for 45 min and then incubated at 37° C overnight. 
Peptides were extracted from the gel pieces by vortexing 1 min and collecting the 
supernatant. Samples were lyophilised and resuspended in 0.1% formic acid prior to analysis 
on the mass spectrometer.  
 
 
2.7.2 LC-MS/MS analysis with QSTAR Elite 
Samples were analysed using  an Agilent 1100 HPLC system interfaced with a QSTAR Elite 
mass spectrometer (AB SCIEX, 181 Foster City, CA, USA). The peptides were loaded onto 
the C18 trap column (ZORBAX 300SB-182 C18, 300 μm × 5 mm, 5 μm, Aligent) at 10 
μL/min and washed for 7 min before switching the trap column in line with the C18 
separation nano-column (ZORBAX 300SB C18, 3.5 μm, 150 x 0.1 mm, Agilent). The 
peptides were eluted directly into the ionization source of the mass spectrometer at 0.6 
μL/min with the following gradient: 0 min, 5% solvent B (0.1% (v/v) formic acid in ACN); 8 
min, 5% B; 10 min, 15% B; 90 min, 30% B; 105 min, 60% B; min, 5% B; 120 min, 5% B. 
Solvent A (0.1% (v/v) formic acid in water). The nano-LC-ESI-MS/MS system was set for 
data acquisition in the positive ion mode, with a selected range of 350–1750 m/z. Peptides 
with +2 to +4 charge states were selected for tandem mass spectrometry, and the time of 
summation of MS/MS events was 2 s. The three most abundantly charged peptides above a 
count threshold >30 were selected for MS/MS and dynamically excluded for 30 s with (50 
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ppm mass tolerance). The instrument was run in information dependent acquisition (IDA) 
mode using Analyst QS 2.0 software (AB SCIEX Inc., Foster City, CA, USA). Automatic 
collision energy and MS/MS accumulation modes were used in the advanced IDA settings.  
 
2.7.3 Data analysis using ProteinPilot 
GeLC-MS data were analysed using ProteinPilot 3.0 software (AB SCIEX), which uses the 
Paragonalgorithm to perform protein identification. All MS/MS spectra were searched 
against a combined Swiss-Prot protein database, version uni_sprot_20070123. Parameters set 
in ProteinPilot 3.0 included (i) sample type, Identification, (ii) cysteine alkylation, 
Acryalmide, (iii) digestion, trypsin allowing two missed cleavages, (iv) species, Homo 
sapiens, (v) instrument, QSTAR Elite and (vi) special factors, Gel-based ID. The following 
processing options were used: bias correction, background correction, biological 
modifications and thorough identification search. A concatenated target-decoy database 
search strategy was also employed to estimate the rate of false positives. Only proteins 
identified with at least 95% confidence and unused ProtScore of >1.3 were reported. 
Microsoft Excelwas used to combine data sets and select protein ID’s that appear in all 
replicates and have more than two unique peptides. 
 
2.8 PHOSPHO- PEPTIDE ENRICHMENT  
2.8.1 Dimethyl labelling (reductive amination) 
Peptides of the p53 interactome (Section 2.6.2.2) were dissolved in 40 µL TEAB (125 mM) 5 
µL formaldehyde (1% v/v) was added, and then mixed with an Eppendorf Thermomixer 
(Eppendorf, Hamburg, Germany) for 5 min. NaBH3CN (light; 5 µL, 100 mM) or 100 mM 
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NaBD3CN (heavy) was added and the tubes were mixed for 15 min. To consume the excess 
formaldehyde, 1 µL of NH4OH (25% v/v) was added and the tubes were vortexed, followed 
by addition of 1 µL formic acid (100% v/v). The digests were lyophilised and the samples 
were redissolved in TiO2 loading buffer, and light and heavy were combined prior, to 
phospho-peptide enrichment. Figure 2.1 shows a schematic of how the mass shift in peptides 
is achieved for quantification.  
 
Figure 2.1 Labelling scheme of light and heavy stable isotope dimethyl labelling. Adapted from Boersema et al, 
2008 [117].  
 
2.8.2 TiO2 purification 
Peptides were redissolved in TiO2 loading buffer (80% ACN, 5% TFA, 1 M glycolic acid). 
The optimal ratio of TiO2 beads (0.6 mg/100 μg) were added to the peptide mixture. The 
tubes were placed in an Eppendorf Thermomixer at 1400 rpm at room temperature for 10 
min. After incubation, the sample was centrifuged briefly to pellet the beads. The solvent was 
removed carefully without disturbing the beads. A total of 100 μL of TiO2 loading buffer was 
added to the beads, that were mixed and the contents transferred to a microcentrifuge tube. 
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This was centrifuged (1000 x g, 30 s, RT) to pellet the beads, and the solvent removed.  The 
beads were washed first with 100 μL of washing buffer 1 (80% ACN, 1% TFA), mixed for 
15 s, centrifuged (1000 x g, 30 s, RT) to pellet the beads, and the solvent was discarded. The 
beads were washed with 100 μL of washing buffer 2 (20% ACN, 0.1% TFA), mixed for 15 s, 
then centrifuged to pellet the beads, and the solvent was finally discarded. This final step was 
performed to remove peptides that bind to TiO2 due to hydrophilic interactions. The TiO2 
beads were dried for 5 - 10 min in the vacuum centrifuge to remove all solvent. The TiO2 
beads were subsequently incubated with 100 μL of 1% NH4OH, pH 11.3 for 10 min on a 
shaker. After incubation, the beads were pelleted and the supernatant was collected and 
acidified (0.1% formic acid) and subsequently desalted using Poros Oligo R3 RP 
microcolumns prior to LC–MS/MS.  
 
2.8.3 LC-MS/MS analysis with VELOS Orbitrap 
All of the titanium dioxide eluate or 5% of the titanium dioxide “flow through” was analysed 
by LC-MS/MS using a Dionex Ultimate 3000 HPLC and a Thermo Fisher Scientific Velos 
Orbitrap mass spectrometer. The sample was loaded onto a 300 μm inside diameter 5 mm 
long trap column packed with Acclaim PepMap100 C18, 5 μm, 100Å material (Dionex) at 5 
ml/min and eluted through a 75 μm inside diameter 16 cm long C18 column (ReproSil-Pur 
120 C18-AQ, 3 μm beads, Dr Maisch, Germany). The main part of the gradient was from 0% 
eluent B (90% acetonitrile, 0.1% formic acid and 9.9% water) to 40% eluent B in 105 min, to 
65% eluent B in 10 min and to 100% eluent B in 3 min and held at 100% eluent B for 5 
minutes. The outlet of the column was connected to a 10 μm i.d. uncoated SilicaTip (New 
Objective, USA) to electrospray the eluent into the mass spectrometer with 2.2 kV applied. 
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Other parameters were as follows: capillary temperature was 275 °C, the S-Lens 
radiofrequency level was 69%, peptide detection was between m/z 350-2000 at 60,000 
resolution in the orbitrap, the top 8 peptides above 5,000 counts were selected for 
fragmentation, fragment ion detection was at 7,500 resolution in the orbitrap, predict ion 
injection time was enabled, charge state rejection was enabled (+1 rejected, >+4 not rejected), 
chromatography mode was enabled (expected FWHM = 14 s), dynamic exclusion was 
enabled (exclusion duration was 40 seconds), the FT first mass value was m/z 110, the 
isolation width was 2, the activations time was 0.1 ms and the normalized collision energy 
was set to 45. 
 
2.8.4 Data analysis using Max Quant 
The LC–MS/MS data were analysed using MaxQuant software (version 1.3.0.5, Max Planck 
Institute for Biochemistry, Martinsried, Germany). The algorithms used to assign protein 
identification, quantification and feature detection are described by Cox and Mann (2008) 
[118]. Analysis was conducted as described by the software user guide. Briefly, the RAW 
files generated by Thermo mass spectrometer were uploaded into MaxQuant. The following 
parameters were set (i) variable modifications: Oxidation (M), Acetyl (Protein N-term) and 
Phospho (STY) (ii) Type: Standard (iii) Labels: Light (DimethLys0, DimethNter0) and 
Heavy (DimethLys8, DimethNter8) (iv) Enzyme: Trypsin/P allowing two missed cleavages 
(v) fixed modifications: Carbamidomethyl (C). A reversed sequence database was used for 
false discovery rate analysis and the spectra were also scanned against a contaminants 
database. For quantification Oxidation (M) and Phospho (STY) modifications were included 
and only razor and unique peptides were used. For site quantification normalised ratio mode 
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was used. All MS/MS spectra were searched against a Uniprot database (human.fasta.gz) 
downloaded from: 
 ftp://ftp.uniprot.org/pub/databases/uniprot/current_release/knowledgebase/proteomes/. 
 
2.9 SIRNA KNOCKDOWN WITH LIPOFECTAMINE  
2.9.1 Knockdown with Lipofectamine RNAi MAX 
Three siRNA duplexes for p53 were obtained from Invitrogen. Cells were transfected with 
siRNA duplexes at concentrations of 200 nM using 0.18% (v/v) Lipofectamine RNAiMAX 
(Invitrogen, Paisley, UK), according to the manufacturer's instructions. Briefly, using the 24-
well plate format the siRNA and Lipofectamine complexes were incubated in 100 μL of 
serum-free OptiMEM media for 15 min. 1ml of 1 x 10^4 cells grown 24 h in complete RPMI 
media with 10% foetal calf serum minus antibiotics were added to wells. Plates were placed 
on an orbital shaker and gently mixed for 10 min at room temperature. Plates were incubated 
at 37 °C for 24 h, prior to western blotting for knockdown.  
 
 
2.9.2 ITRAQ labelling and MS analysis  
Figure 2.2 shows a flowchart of the iTRAQ labelling and analysis process. Protein samples 
were prepared from control and 2-FaraA-treated p53 wild-type and knock-down Raji and 
IM9 cells. Protein digestion and peptide labelling was performed according to manufacturer’s 
protocol (AB Sciex, Foster City, CA, USA). Briefly, 20 µg proteins from each sample were 
resuspended in 0.5 M TEAB pH 8.5 and 0.1 % (w/v) SDS were reduced with 50 mM tris-(2-
carboxyethyl) phosphine (TCEP) for 1 h at 60OC. To block cysteine residues, samples were 
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incubated at room temperature for 10 min in 200 mM methyl methanethiosulfonate (MMTS). 
Protein digestion was performed by adding trypsin at a ratio of 1:100 (trypsin: protein) and 
the samples were incubated (37 OC, 16 h). Samples were dried in a vacuum centrifuge 
Concentrator 5301 (Eppendorf, Hamburg, Germany) and then resuspended in 7 μL 1M 
TEAB pH 8.5. The peptide samples labelled with iTRAQ tags according to Table 2.1. 
Briefly, the iTRAQ reagents were solubilised with 50 μL isopropanol and 20 μL of the 
resulting iTRAQ mix as added to the peptide samples ensuring a final organic concentration 
of at least 65% (v/v). The labelling reaction was incubated at room temperature for 2 h. 
Labelled samples with a set of iTRAQ tags (112-119, 121) were pooled together as one 
sample. 
Table 2.1: iTRAQ labelling plan for samples  
Sample iTRAQ label 
Raji control RNA control 113 
Raji control RNA 2-FaraA 114 
Raji knock-down Control 115 
Raji knock-down 2-FaraA 116 
IM9 control RNA Control 117 
IM9 control RNA 2-FaraA 118 
IM9 knock-down Control 119 
IM9 knock-down 2-FaraA 121 
 
Peptide samples were purified by strong cation-exchange (SCX) chromatography using the 
cartridge system (ICAT Accessories). All procedures were performed according to the 
manufacturer’s instructions. Briefly, the peptide sample (40μg) was diluted to1 mL in cation 
exchange buffer-load solution 1 (10 mM KH2PO4 in 25% (v/v) acetonitrile (ACN), pH 3.0), 
ensuring the sample was between pH 2.5-3.3. The cartridge was washed first with 1 mL of 
cation exchange buffer-load solution 2 (10 mM KH2PO4 in 25% (v/v) ACN/1 M KCl at 
pH3.0), and 2 mL cation exchange buffer-load solution 1 to remove TCEP, SDS and excess 
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iTRAQ reagents. The peptides were eluted with 500 μL of cation exchanged buffer-eluate (10 
mM KH2PO4in 25% (v/v) ACN/350 mM KCl, pH 3.0). 
 
Eluted peptides were desalted and concentrated by hydrophilic-lipophilic-balanced (HLB) 
cartridges as per instructions. Briefly, the cartridge was conditioned with 1 mL 100% (v/v) 
methanol, followed by 100% (v/v) ACN and then 5% (v/v) ACN with 0.1% (v/v) formic acid. 
Before the sample load, the sample was diluted 5 times with 0.1% formic acid in water, then 
loaded and washed twice with 2 mL 5% (v/v) ACN with 0.1% (v/v) formic acid. The sample 
was eluted with 0.5 mL 50% ACN with 0.1% (v/v) formic acid, followed by 0.3 mL of 100% 
(v/v) ACN with 0.1% (v/v) formic acid.  
 
The MS/MS analysis was carried out as described in section 2.7.2. In addition, a modified 
Enhance All mode Q2 transition setting was used, favouring low mass ions, therefore the 
iTRAQ reporter ions (113-119, 121) intensities were enhanced for quantification. Data 
analysis was conducted using ProteinPilot 3.0 software as described in section 2.7.3. 
Alternative parameters for iTRAQ analysis include (i) sample type: iTRAQ 8-Plex, (ii) 
cysteine alkylation, MMTS, (iii) digestion: trypsin, (iv) instrument: QSTAR ESI, (v) special 
factors: urea denaturation and (vi) species: Homo sapiens. The processing options were as 
following: quantitative, bias correction, background correction, biological modifications and 
thorough identification search. Relative peptide abundances were determined using the 
MS/MS scans of iTRAQ labelled peptides, where the ratios of peak areas of the iTRAQ 
reported ions reflect the relative abundances of peptides and hence the up-or down-regulation 
of the proteins associated with these peptides in different samples. 
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Figure 2.2 Flow-chart of iTRAQ labelling (8-plex) and LC-MS/MS analysis. Proteins were extracted from 8 
samples and digested. Peptides were labelled with iTRAQ reagents and combined. The peptides were 
fractionated by SCX chromatography and analysed by RP-LC-MS. The fragmentation spectrum identifies the 
peptides and the spectrum inset shows the low-mass iTRAQ marker ions for peptide quantification 
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CHAPTER THREE 
Fludarabine induced effects on p53 family proteins in B-
lymphoid Raji, IM9, MEC1 and U266 cell lines 
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3.1 INTRODUCTION 
DNA damage induced by 2-FaraA activates several protein kinases, including ATM, that 
which in turn trigger an accumulation of phosphorylated p53 and a p53-mediated gene 
expression response [119, 120] leading to cell cycle arrest and apoptosis. Wild-type p53 
protein is short-lived and found at low levels in resting cells. In addition to its role as a 
transcription factor in the nucleus, p53 may also have an important pro-apoptotic role in 
mitochondria [121]. It is becoming increasingly apparent that p53 has multiple roles, targets 
and cellular locations.  
The p53 family includes two other members, p63 and p73, with DNA binding domains 
homologous to p53. Both p63 and p73 have 2 major types of isoforms called TA and ΔN. 
The TAp63 and TAp73 isoforms have been described as ‘p53-like’, binding to DNA through 
p53, p63 and p73-responsive elements (RE) and activating target genes inducing  cell cycle 
arrest and apoptosis [122]. The ΔNp63 and ΔNp73 isoforms also bind to p53RE but cannot 
induce transcription,  thereby exerting a dominant negative effect on the activities of p53 and 
the TAp63 and TAp73 isoforms [123]. Despite the similarities in structure and function 
between p53, p63 and p73, mutations or deficiencies in p63 and p73 have not been linked 
with the development of spontaneous human cancers [71].  
The Christopherson laboratory has previously reported that Raji cells treated with 2-FaraA (3 
µM) accumulate multiple forms of nuclear, cytosolic and mitochondrial p53 with molecular 
weights of ~47, 43 and 40 kDa (Figure 3.1) and that the pattern of nuclear expression of p63 
and p73 following treatment was similar to that of p53 [124-126].  
To further elucidate the roles of the  p53, p63 and p73 in the response of cells to 2-FaraA, we 
explored changes in their expression and sub-cellular distribution in the human B-lymphoid 
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cell lines Raji (Burkitt’s lymphoma), IM9, MEC1 (chronic lymphocytic 
leukemia/prolymphocytic leukemia) and U266 (myeloma cells) following treatment with the 
purine analogue. This chapter aims to look at p63 and p73 isoforms in the cytosol and 
mitochondria of Raji cells and at the effects on mRNA levels of p53, p63 and p73 in all four 
cell lines. The observations with cell lines will be translated to clinical CLL samples.  
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Figure 3.1 2D Western blots for p53 in sub-cellular fractions from Raji cells treated with 2-FaraA (3 µM, 24 h or 48 h). (A) nuclei, (B) mitochondria, (C) cytosol. Extracts 
(100 μg protein) were focused on an 11 cm pH 3-10 IPG strip and separated in the second dimension using 4-12% SDS-PAGE. Proteins were then transferred onto a PVDF 
membrane and Western blots were performed with the p53 antibody DO1.  
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3.2 METHODS  
Raji, IM9, MEC1 and U266 cells were treated with 2-FaraA (3 µM for 24 h or 48 h). Cell 
viability was determined by MTT assay and apoptosis by flow cytometry. Nuclear, cytosolic 
and mitochondrial fractions were isolated as described in chapter 2. The resulting sub-cellular 
fractions were analysed by 1D SDS-PAGE or 2D gel electrophoresis followed by Western 
blotting using p53, p63, ∆Np63 and p73 specific monoclonal antibodies and actin and SDHA 
antibodies as loading controls. Western blots were quantified by Quantity One software. 
mRNA levels were quantified by reverse transcription PCR followed by Real-time 
quantitative PCR. 
 
Blood samples from patients with B-CLL were collected with informed consent and under 
local ethical approval. All patients were diagnosed by criteria described by the international 
workshop on CLL (IWCLL). Peripheral blood mononuclear cells (PBMC) were isolated by 
Ficoll density centrifugation and stored in a viable state in FCS containing 10% DMSO in 
liquid nitrogen until required. All treatments were conducted in RPMI 1640 medium (HEPES 
modification) supplemented with 10% bovine serum albumin (BSA) and 50 μg/mL 
gentamicin in 24-well culture plates. Patient samples were selected based on ATM and p53 
functionality, determined using the assay described by Best et al. [127]. Briefly, 
cryopreserved mononuclear cells from each case were thawed and exposed to 50 µM 
etoposide alone, or 50 µM etoposide plus 5 µM nutlin-3a and the expression of TP53 and p21 
was detected using cell cycle analysis (section 2.1.9) and flowcytometry (section 2.1.10).  
Percentage increases in TP53 and p21 expression below 30 and 15% respectively defined 
dysfunctional cases. Those cases in which function was restored with the combination of 
61 | P a g e  
 
etoposide and nutlin-3a were classified as category 2 dysfunction, while failure to restore 
function was classified as category 1. 
Previous studies have shown that categorisation of patient samples using this assay correlates 
well with the presence of mutations in the ATM or TP53 genes and with the in vitro 
sensitivity of samples to 2-FaraA. Due to the limited availability of cells from each patient, 
sub-cellular fractionation was not possible and all experiments on patient cells were 
conducted on whole cell lysates.  
 
In a pilot experiment, we also explored the effects of 2-FaraA on a CLL patient sample 
cultured in an in vitro model of the CLL tumour microenvironment. This was achieved by co-
culture of the CLL cells with a feeder layer of mouse fibroblasts expressing the ligand to 
CD40 (referred to as CD40L cells). Viability of the CLL cells following treatment was 
determined by trypan blue exclusion on the Countess cell counter (Invitrogen). Changes in 
the immunophenotype of the CLL cells were evaluated by antibody microarray, while 
changes in protein expression were measured by 2D gel-based analysis. 
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3.3 RESULTS 
3.3.1 Drug dose-responses and IC50 values for 2-FaraA 
Figure 3.2 shows dose-response curves to 2-FaraA for the 4 human B-lymphoid cell lines, 
generated using the MTT assay. Results are expressed relative to vehicle-treated control 
cultures. As expected, the p53-wild type Raji and IM9 lines showed the greatest sensitivity to 
2-FaraA following incubation for 48 h (Figure 3.2 A). Significant decreases in the number of 
viable Raji and IM9 cells were evident even at 1 µM 2-FaraA after 48 h. 2-FaraA (50 µM, 48 
h) reduced the viability of Raji and IM9 cell cultures to <10%. In contrast, the p53-mutated 
MEC1 and U266 cell lines were relatively resistant to 2-FaraA; even following exposure to 
200 µM 2-FaraA for 48 h, >50% of cells remained viable relative to controls. The IC50 values 
for 2-FaraA were as follows, Raji (2.6 µM), IM9 (11.7 µM), MEC1 (161 µM) and U266 (100 
µM), calculated using the online tool BioDataFit 
(http://www.changbioscience.com/stat/ec50.html). Subsequent experiments exploring the 
effects of 2-FaraA on the expression of p53, p63 and p73 were conducted at 3 µM, as reports 
suggest that this represents the clinically achievable steady-state plasma level of 2-FaraA.  
Treatment with 2-FaraA (3 µM for 24 h) significantly decreased the viability of Raji and IM9 
cells by 35 ±1.4 % and 8 ±1.4 % respectively  In contrast, 3 µM 2-FaraA had no effect on the 
viability of either MEC1 or U266 cells (Figure 3.2B). 
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Figure 3.2 Effects of 2-FaraA on the viability of the 4 B-lymphoid cell lines. (A) Dose-response curves 
following 48 h with 2-FaraA, and (B) viability  after 24 h or 48 h with 3 µM 2-FaraA. Viability was determined 
using the MTT assay, error bars indicate standard deviations (n=3). 
 
3.3.2 p53, p63 and p73 sub-cellular distribution before and after 2-FaraA  
Next, we examined the effect of 3 µM 2-FaraA on the expression and sub-cellular 
distribution of p53 (Fig 3.3.1), p63 (Fig 3.3.2) and p73 (Fig 3.3.3) in nuclear (A), 
mitochondrial (B) and cytosolic (C) extracts from the Raji, IM9, U266 and MEC1 cells. All 
results are expressed relative to expression of -actin as a loading control.p53 protein was 
expressed at 53 kDa in Raji, IM9 and U266 cells and at ~47 kDa in MEC1 (Figure 3.3.1). 
Basal levels of p53 are higher in the Raji nucleus compared to the other cell lines and higher 
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in U266 and MEC1 mitochondria and cytosol. 2-FaraA induced a significant (p < 0.05) 
accumulation of p53 in the nuclear fraction of IM9 cells after 24 h, and in Raji and U266 by 
48 h. In contrast, no p53 was evident in the nuclei of MEC1 cells before or after treatment 
(Figure 3.3.1A). In the mitochondrial fraction of Raji and IM9 cells, p53 expression was 
significantly (p <0.05) increased after 24 h 2-FaraA treatment (Figure 3.3.1B). However, no 
effect of 2-FaraA was apparent on the expression of p53 in the mitochondria of MEC1 or 
U266. Elevated levels of p53 in response to 2-FaraA in the cytosolic fraction were only 
observed in Raji and IM9 (Figure 3.3.1C).  
 
p63 was detected in all 3 sub-cellular fractions of all 4 cell lines (Figure 3.3.2). In the nuclei 
(Fig 3.3.2 A), p63 was detected predominantly at ~120 kDa with an additional band of ~240 
kDa in Raji cells. In the mitochondrial fractions, p63 was detected at 120 kDa in Raji and 
IM9 and at 63 kDa in MEC1 and U266. In the cytosol, p63 was found at 70 kDa in all 4 cell 
lines. Expression of p63 in the nuclei of Raji and IM9 cells increased significantly (p < 0.05) 
after 24 h 2-FaraA (3 µM), whereas in MEC1 and U266 cells, nuclear p63 was unchanged by 
the treatment (Fig 3.3.2A).  
2-FaraA reduced p63 in the mitochondria of IM9 and MEC1 by 24 h. p63 levels in 
mitochondria were further decreased by 48 h in IM9, but returned to basal levels in MEC1. 2-
FaraA had no effect on mitochondrial p63 in Raji or U266 cells. 2-FaraA reduced cytosolic 
p63 in IM9, but increased it in MEC1 and U266 cells. Raji cells showed no significant 
change in cytosolic p63 following 2-FaraA (Figure 3.3.2C). p73 was detected only in the 
nuclear fractions of the 4 cell lines (Figure 3.3.3 A). 2-FaraA induced an increase in nuclear 
p73 in all 4 lines, with the greatest increases observed in Raji and IM9. These observations 
are summarized in Table 3.1 below. 
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Table 3.1: Summary of the changes in p53 family after 2-FaraA treatment in the nuclei, 
mitochondria and Cytosol  
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Figure 3.3  Figure 3.4
Figure 3.5
Figure 3.3-3.5 1D Western blots for p53 (3.3), p63 (3.4) and p73 
(3.5). Panels (A) nuclear, (B) mitochondrial and (C) cytosolic 
fractions showing control, 2-FaraA 24 h treatment and 2-FaraA 48 
h of B-lymphoid cell lines. Extracts (20 µg protein) were analysed 
by 1D SDS-PAGE in 12% gels and Western blots were performed 
for p53 (clones DO1 and Pab240). The PVDF membrane was 
then stripped and blotted with antibodies against actin (8 μg/mL, 
sc-8432 clone C-2) or succinate dehydrogenase complex subunit 
A (SDHA, 1 μg/mL, sc-59687 clone 2E3) as internal controls.  
Graphs of relative amounts of p53 in each fraction are shown. 
Significant changes (p <0.05) are indicated by (*) relative to the 
control (n=3). 
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3.3.3 mRNA changes of p53, p63 and p73  
To determine whether 2-FaraA regulates p53, p63 and p73 at the transcriptional level, we 
evaluated changes in the mRNA levels of the 3 proteins in the 4 cell lines following 
treatment. Figure 3.6 shows changes in mRNA levels for p53, p63 and p73 after 2-FaraA (3 
µM, 24 h). p53 mRNA levels only increased in Raji cells (3.5-fold). In MEC1 and U266, p53 
mRNA decreased 1.2-fold and 1.4-fold, respectively. No significant changes in p63 mRNA 
were observed for any of the cell lines. p73 mRNA increased in Raji and IM9 cells (3.8-fold 
and 2.5-fold, respectively), but no significant change were observed in MEC1 or U266 cells. 
Western blots for p53, p63 and p73 in whole cell lysates are provided in the APPENDIX II 
(Supplementary Figure SF3.1) for comparison of levels of mRNAs with proteins.  
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Figure 3.6 Fold-changes in mRNA levels in the 4 B-lymphoid cell lines after treatment with 2-FaraA (3 µM, 24 
h). (A) p53, (B) p63, (C) p73, results are the means of two technical and three biological replicates. Significant 
changes (>2-fold) are indicated by (*). 
 
3.3.4 Analysis of p63 isoforms and proteolytic derivatives in mitochondria and cytosol 
In the Raji nuclear fraction, p63 and p73 have already been characterised [126], thus this 
chapter will only look at p63 in mitochondria and cytosol of Raji cells. Three isoforms of p63 
at ~50 kDa were identified (pI 6.3 - 6.6) in mitochondria, (Figure 3.7B). 2-FaraA did not 
*
*
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affect the expression of these isoforms. In the cytosol, 3 isoforms of p63 at a higher 
molecular weight (~70 kDa, pI 6.2 - 6.4) were identified, and were again unaffected by  2-
FaraA treatment (Figure 3.7C).  
 
Figure 3.7 2D Western blots for p63 in sub-cellular fractions from Raji cells before and after treatment with 2-
FaraA (3 µM, 24 h or 48 h). (A) nuclei (B) mitochondria (C) cytosol. Western blots were performed with the 
p63 antibody 4A4.  
 
3.3.5 Translation of analysis to clinical CLL samples  
Next, the levels of p53, p63 and p73 following 2-FaraA treatment was evaluated in CLL 
patient samples. Samples were selected on the basis of p53 functionality; 5 patients (1 to 5) 
were deemed to have functional p53 and 4 patients (6 to 9) to have dysfunctional p53, either 
as a consequence of inactivation of ATM or p53. Consistent with the functional 
categorisation, we observed an increase in p53 after 24 h of 2-FaraA (3 µM) in the p53 
functional samples, and no change in p53 expression in the 4 p53 dysfunctional samples 
(Figure 3.8). In contrast, there was no distinct pattern of response for p63 and p73 that 
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correlated with the p53 functionality of the samples). Actin was used as internal control 
(Figures 3.8). 
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Figure 3.8 1D Western blots of p53, p63, p73 and actin of PBMC isolated from 9 CLL patient samples. Patients 1 to5 have functional p53, while 6 to 9 have dysfunctional 
p53. Actin is used as internal control. 
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3.3.6 Differential proteins that may contribute to resistance to 2-FaraA in CLL cells 
grown on fibroblast layer 
The lymph nodes, and to a lesser extent the bone marrow, form important niche environments 
that support the survival and proliferation of CLL cells in vivo. A growing body of data 
highlights the importance of considering the contributions of these microenvironments in 
drug-effect studies. Several models of the CLL tumour microenvironment have been tested, 
including the method employed in this pilot study, that which involves the co-culture of CLL 
cells with a mouse fibroblast cell line expressing the ligand to CD40[128]  
One patient CLL sample (Pt 10) was grown either in media or on a confluent layer of CD40L 
cells and treated with 3 µM 2-FaraA for 24 h (Table 3.2). Viability assays using trypan blue 
demonstrated that this dose of 2-FaraA had no effect on the growth or survival of the feeder 
layer. This patient deemed to be slowly progressive disease, ZAP70 and CD38+, but had 
responded well to treatment with fludarabine/cyclophosphamide/rituximab (FCR). These 
clinical and biological characteristics predict nodal and/or bone marrow involvement, making 
these cell forms appropriate for in vitro studies modelling the tumour microenvironment.   
Table 3.2 details the viability of the patient cells following culture in media or on the feeder 
layer, with or without 2-FaraA. Following culture in media alone, 72% cells remained viable. 
2-FaraA treatment of cells in media reduced the cell viability to 41% after 24 h. CLL cells 
cultured with the feeder layer were 95% viable in the control and 92% viable following 2-
FaraA.  
To investigate the effects of CD40L co-culture with the feeder layer and 2-FaraA treatment 
on the intracellular proteome, we used 2D gel electrophoresis and gel analysis using the PD 
Quest program. Four proteins were identified as up-regulated after co-culture with the feeder 
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layer and two were down-regulated. Due to low protein yield, it was only possible to identify 
the up-regulated proteins.  The up-regulated proteins were Endoplasmin, Heat shock cognate 
71 kDa protein, Lymphocyte-specific protein 1 and Protein SET (Figure 3.9 and Table 3.3).  
 
Table 3.2: Cell viability of  patient 10 by trypan blue staining followed by analysis with the 
Countess® Automated Cell Counter (Life Technologies) 
Conditions 
Viability 
after 24 h 
(%) 
Control media 72 
Test media 41 
Control feeder 95 
Test feeder 92 
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Figure 3.9 2D gel analysis of proteins up-regulated by co-culture with feeder CD40L cells. 
 
Table 3.3: Identification of intracellular proteins up-regulated by CD40L co-culture in 
patient 10 by ESI-MS/MS 
 
 
 
 
 
 
 
 
 
 
Spot 
number  
Accession 
number Protein Gene 
Mowse 
score 
Unique 
peptide 
1 P14625 Endoplasmin HSP90B1 601 22 
2 P11142 
Heat shock 
cognate 71 kDa 
protein 
HSPA8 270 7 
3 P33241 Lymphocyte-specific protein 1 LSP1 169 7 
4 Q01105 Protein SET SET 124 4 
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3.3.7 Differential abundant surface antigens on primary CLL cell grown in medium 
and on a feeder layer treated with 2-FaraA 
Results from section 3.3.6 established that growth on a feeder layer of fibroblasts alters the 
biochemistry of patient cells. We further investigated the effects of the feeder layer on CLL 
cells by profiling surface antigens using DotScan antibody microarrays in 4 patients (10, 11, 
12 and 13). To determine statistical significance, the logarithm of the normalised raw vale 
was used for t-tests, tails (2, 2). A p-value of <0.05 and raw intensity values > 10 were 
considered differential. Table 3.4 summarises the antigens regulated under the various growth 
and treatment conditions. Comparing growth of cells in normal medium with growth on 
feeder layer, the antigens up-regulated with the feeder layer were CD23, CD54, CD80, 
CD262, CD264 and CD319. Antigens down-regulated were CD6, CD27, CD43, CD45, 
CD47, CD50, CD53 and CD185. 
The surface profiles of cells growing in media compared with a feeder layer were treated with 
3 µM 2-FaraA (24 h). In media 2-FaraA up-regulates CD24, CD262 and CD264, while CD39 
was down-regulated. Treatment of cells on a feeder layer resulted in up-regulation of CD45 
and CD222. 
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Table 3.4: Differentially abundant CD antigens on CLL cells from patients 10, 11, 12 and 13 
levels on cell in growth media were compared with those on a feeder layer before and after 2-
FaraA.  
Antigen B-cell Marker Ratio P-value Function  
Ratio in feeder layer compared to medium 
CD6 Yes 0.37 1.91E-03 
Regulation of 
apoptosis in 
lymphocytes  
CD23 Yes 2.53 3.39E-03 
Roles in inflammation 
by release of TNF, IL-
1, IL-6  
CD27PH No 0.27 4.23E-04 
Activates NF-κB, 
SAPK, JNK kinases  
CD43 No 0.21 1.61E-05 
Promotes T-cell 
activation, 
proliferation, inducing 
IL-2  
CD45 No 0.32 5.09E-04 
Intrinsic cytoplasmic 
protein tyrosine 
phosphatase activity  
CD47 No 0.55 2.03E-02 
Mediate caspase 
independent cell death 
CD50 Yes 0.50 1.63E-02 
Primary immune 
response  
CD53 No 0.39 6.92E-05 
Decreased expression 
is found in activated 
and migrating 
leukocytes  
CD54 No 4.18 7.33E-05 
Inflammatory 
signalling  
CD80 No 4.68 2.82E-03 
Binding to CD28 on T 
cells for activation, or 
CD152 for T cell 
inhibition 
CD185 No 0.51 8.96E-03 
Migration & 
localisation of B-cells 
to primary and 
secondary follicles in 
lymphoid tissue   
CD262 No 6.07 9.47E-06 
Induced by p53, role in 
Caspase-8 related cell 
death  
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CD264 No 4.99 3.60E-02 
Decoy receptor by 
competing for binding 
with other TRAIL 
receptors and 
inhibiting TRAIL 
induce apoptosis 
CD319 Yes 8.01 7.50E-07 
Expressed by activated 
b-cells, NK cell-
mediated cytotoxity   
Ratio for cells in  medium after and before 2-FaraA 
CD24 No 2.78 4.19E-02 
B-cell differentiation, 
adhesion and 
metastatic tumours 
CD39 No 0.70 4.55E-02 
Hydrolyses ATP and 
ADP which inhibits 
inflammatory response 
CD262 No 2.52 3.25E-03 
Induced by p53, role in 
Caspase-8 related cell 
death 
CD264 No 1.80 8.67E-03 
Decoy receptor by 
competing for binding 
with other TRAIL 
receptors and 
inhibiting TRAIL 
induce apoptosis 
Ratio for cells on feeder layer after and before 2-FaraA 
CD45 Additional 1.81 2.61E-02 
Intrinsic cytoplasmic 
protein tyrosine 
phosphatase activity 
CD222 Other 2.87 4.54E-02 
Internalizes a variety  
of extracellular ligands 
and directs them to 
lysosyme and sorts 
M6P-containing 
lysosomal enzymes 
 
.
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3.4 DISCUSSION 
3.4.1 The p53 family response to 2-FaraA  
Henrich and Christopherson (2008) showed that p53 accumulates in the nuclei of Raji cells 
treated with 2-FaraA (3 µM, 24 h) and that this accumulation preceded the onset of apoptosis.  
In the present study, we have extended these observations to the effects on cytosolic and 
mitochondrial p53 levels and to other members of the p53 family, namely p63 and p73, in 4 
human B-lymphoid cell lines selected to represent cells with both wild-type and mutant p53, 
and sensitive or resistant to 2-FaraA. In response to a clinically relevant dose of 2-FaraA (3 
µM), p53 accumulates in the mitochondria and nuclei of Raji and IM9 cells before apoptosis  
is apparent. In Raji cells, p53 accumulates in mitochondria earlier (24 h) than in nuclei (48 h), 
suggesting that prior to effects on transcription in nuclei, p53 may initiate apoptosis at 
mitochondria. p53 is known to induce apoptosis at mitochondria in response to stress signals 
including DNA damage and hypoxia [129, 130]. Accumulation of p53 at mitochondria occurs 
during p53-dependent apoptosis, but not during p53-independent apoptosis or p53-mediated 
cell cycle arrest [129]. Chipuk et al. demonstrated that p53 induces expression of Puma, that 
in turn frees cytoplasmic p53 from inhibitory interactions with the anti-apoptotic protein Bcl-
xL. The  ‘free’ p53  then induces homo-oligomerisation of Bax to form a pore in the 
mitochondrial outer membrane,  resulting in apoptosis [131].  
 
Our study suggests that translocation of p53 to nuclei may depend on the type of p53 
mutation. In MEC1 cells, the mutation has been reported to result in a protein with a 
truncated N-terminus [132], consistent with our observations of a lower molecular weight 
protein of ~47 kDa (Figure 3.3). The p53 gene in U266 cells is reported to harbour a point 
mutation that does not affect its translocation to nuclei, but may prevent induction of genes 
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required for apoptosis. Our data suggest that p53 in nuclei and mitochondria are involved in 
2-FaraA-induced apoptosis. Accumulation of p53 in Raji cells induced by 2-FaraA (3 µM, 48 
h) may result from an increase in p53 mRNA levels (Figure 3.6A), and likely inhibition of 
p53 degradation. In contrast, the increase in p53 in IM9 cells in the absence of an increase in 
transcript levels (Figure 3.6A, Supplementary Figure SF3.1) suggests that accumulation of 
p53 in this line is likely due to reduced p53 protein degradation [133].  
 
The transcription factors, p63 and p73, have significant sequence homology to p53 and 
overlapping functions, but are rarely mutated in cancers [122]. Recent studies indicate that 
the functions of these p53 family members depend on the status of all 3 proteins. For 
example, Flores et al. demonstrated that loss of p63 and p73 results in the failure of mouse 
E1A embryonic fibroblasts  with functional p53 to undergo apoptosis in response to DNA 
damage [134]. In the present study, nuclear p63 was detected at higher than expected 
molecular weights of ~120 and 240 kDa (Figure 3.4A). Similarly in the mitochondrial 
fractions of Raji and IM9 cells, p63 was detected at ~120 kDa. This may be explained by the 
formation of dimers and tetramers of p63 complexed with DNA in the nuclear and 
mitochondrial fractions, but not in the cytosol. This hypothesis is further supported by the 2D 
western blot analysis of p63 in Raji cells. The 2DE compatible buffer (Section 2.2.2) contains 
benzonase which is breaks down DNA and RNA in the sample, and the higher molecular 
weight p63 can no longer be detected. Previous studies with nuclear extracts of HeLa cells 
have shown strong binding of homodimers of the thyroid hormone receptor alpha (TRα) to 
DNA in Western blots [135]. The high molecular weight forms of p63 were only found at the 
mitochondria of the 2-FaraA-responsive Raji and IM9 cells, and not the resistant MEC1 or 
U266 lines. These p63 complexes could contribute to the mechanisms of the cytotoxicity of 
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2-FaraA. 2-FaraA-induced apoptosis in Raji and IM9 cells with accumulation of 
transcription-activating TAp63 in nuclei (Figure 3.4) is consistent with previous studies with 
lymphoma and hepatocellular carcinoma cells where TAp63 was up-regulated by 
chemotherapeutic agent bleomycin [136]. It is important to note that the accumulation of p63 
observed here is not due to increased gene expression since we observed no increase in 
mRNA levels (Figure 3.6B), but may be due to decreased degradation following p63 
phosphorylation.  
p63 is self-inhibitory, due to a transactivation inhibitory domain (TI) at the C-terminus of the 
Tap63α isoform that binds the transactivation domain within the N-terminus of an adjacent 
p63 molecule [137]. The p63 2D western blot analysis was only extended to Raji cells as it 
responds best to 2-FaraA treatment (Figure 3.2) and the changes observed in Raji p63 are 
more likely due to post-translational modifications, than changes in protein transcription 
(Figures 3.4 and 3.6)..Figure 3.7 shows that 2-FaraA treatment of Raji cells primarily affects 
p63 in nuclei; the smaller derivatives of p63 (~47 and 45 kDa, pI 6.5 - 6.8) found in untreated 
cells are the same size as the N-terminal truncated p63 (ΔNp63γ) isoform (~47–53 kDa) 
reported by Petitjean et al. (2008) [69]. However, Western blots with an antibody specific for 
ΔNp63 showed that these smaller p63 derivatives were not ΔNp63 isoforms, which 
eliminates the possibility of mRNA splice variants. The biological significance of the ~47 
and ~45 kDa derivatives of p63 at 48 h (Figure 3.7A) is not clear, but it is possible that these 
derivatives are the result of proteolytic cleavage of TAp63α at the C-terminus, that removes 
the self-inhibitory element in the TAp63 molecule resulting in  a TAp63 protein with 
enhanced transcriptional activity [137]. The acidic nature and lower molecular weights of 
these isoforms are consistent with loss of basic amino acid residues from the C-terminus. The 
low molecular weight derivatives of p63 (Figure 3.7A) could have a role in increasing the 
81 | P a g e  
 
sensitivity of cells to apoptosis. Sayan et al. found that p63 fragments localize in nuclei [137], 
a finding which is consistent with our data (Figure 3.4). There are limited reports describing 
the expression and role of p63 in mitochondria; Gressner et al. described the ability of 
TAp63α to induce expression of the CD95/FAS and BAX genes [138]. However, we 
observed no significant change in p63 in mitochondria after 2-FaraA treatment (Figure 3.7B). 
 
The p63 isoforms observed in the cytoplasmic and mitochondrial fractions of Raji and IM9 
cells (Figures 3.7B and C) have different molecular weights to those identified in nuclei. 
Cytosolic p63 of ~70 kDa may correspond with the 68 kDa splice variant TAp63β reported 
by Petitjean et al. The isoforms of ~50 kDa that accumulated in mitochondria are similar to 
the ∆Np63γ isoforms of 47–53 kDa described by Petitjean et al. It is interesting to note that 
the dimers and tetramers of p63 seen in 1D Western blots (Figure 3.4) are not seen in 2D 
Western blots (Figure 3.7), suggesting that the additional isoelectric focusing step in  2D gel 
analysis may dissociate such complexes.  
The transcription factor, p73, accumulates in nuclei of Raji and IM9 cells after 2-FaraA 
(Figure 3.5). However, unlike p63, this accumulation may be due to increases in the levels of 
mRNA for p73 in Raji (4.0-fold) and IM9 (2.5-fold, Figure 3.6C). Zhu et al. showed that 
MCF7 breast cancer cells treated with camptothecin express the inactive p73α isoform [139]. 
The molecular weight of p73 here of ~70 kDa (Figure 3.5) is consistent with p73β that is 
transcriptionally active and pro-apoptotic [77, 122, 140]. Levrero et al. found that p73 
accumulates in response to cisplatin and taxol in human colon cancer cells [122]. The present 
study is the first to report changes in p73 mRNA in response to 2-FaraA.  
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In 9 patient CLL samples, the pattern of response to 2-FaraA was less clear. The expression 
of p53 correlated well with our observations in the cell lines, however the same was not true 
for p63 and p73 (Figure 3.8). There may be several reasons for this, the most obvious being 
that p63 and p73 are dispensable, unlike p53, and do not play a role in 2-FaraA-induced 
apoptosis in CLL cells. However, we must consider that in vitro culture of CLL cells in 
media alone does not accurately mimic the in vivo conditions experienced by CLL cells. CLL 
cells undergo spontaneous apoptosis when cultured in media in the absence of any supportive 
factors such as cytokines or contact with stromal cells [141]. Under these conditions the roles 
of p63 and p73 may be masked by spontaneous apoptotic processes.  
 
3.4.2 2-FaraA resistance of CLL cells grown in CD40L feeder layer  
Our pilot study (Table 3.2) and those of others [142] suggest these effects can be overcome 
by modelling the CLL tumour microenvironment in vitro. Co-culture of the CLL patient cells 
with the CD40L feeder layer increased the viability of the CLL cells by 23%, that isolation of 
CLL cells from the tumour microenvironment causes the cells to undergo spontaneous 
apoptosis and/or necrosis. While reproducing the tumour microenvironment effectively 
increased cell viability to 95%, this also conferred resistance to 2-FaraA. Only a 3% loss in 
cell viability was observed following 2-FaraA treatment on the feeder layer compared with 
31% in media alone (Table 3.2). This is an interesting observation, as records indicate that the 
patient had responded well to chemotherapy. Thus in the original microenvironment, 
chemotherapy had induced apoptosis in these CLL cells. So the resistance to treatment may 
be an artefact of the artificial culture microenvironment. Proteomic analysis of CLL patient 
cells yielded some interesting results (Figure 3.9 and Table 3.2). Endoplasmin (HSP90 beta) 
and HSP70 are molecular chaperones that are up-regulated in aggressive cancers and are 
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associated with metastasis [143]. Given the wide array of proteins that are stabilised by these 
molecular chaperones, their up-regulation may play a role in the survival of CLL cells on the 
feeder layer. The Lymphocyte-specific protein 1 (LSP1) is a human leukocyte marker, with 
no known role in cancer [144]. Nodal involvement in CLL is a clinical indication of 
aggressive/progressive disease and LSP1 may promote CLL cell survival and proliferation in 
the tumour microenvironment.  
SET is an oncoprotein that inhibits the tumour suppressor protein phosphatase 2A (PP2A). 
Previous studies have linked increased levels of SET with CLL stage and disease progression. 
Accumulation of SET increases levels of phosphorylated Akt and PTEN and this pathway 
can contribute to cell survival [145]. However, our data suggest a role for SET in the survival 
of CLL cells in an in vitro model of the tumour microenvironment.  
It should be noted that this pilot study only used one patient. This is due to the limitations of 
using clinical samples. Only patient ten yielded enough mononuclear cells to undergo the 
microenvironment studies with antibody microarray and 2DE. Unfortunately there was not 
sufficient protein extracts left to validate candidate proteins using western blotting or other 
orthogonal techniques. If possible future studies should focus on repeating the 2DE analysis 
with more patients.  
Surface profiling [146] of 4 CLL samples with DotScan microarrays showed differences in 
the immunophenotype when cultured in media alone or on a feeder layer (Table 3.4 & 
Supplementary Figure SF3.2). CLL is a disease of accumulation; however recent evidence 
indicates that proliferation occurs in lymphocytes. CLL cells respond to stimuli provided by 
interactions with stromal cells and T-cells within specific micro- environmental niches. These 
interactions promote proliferation, up-regulate apoptosis-regulatory proteins and modulate 
the expression of chemokines and surface molecules. Regulation of CLL cell growth in 
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micro-environments is linked to antigen stimulation through the B-cell (antigen) receptor 
(BCR) on the surface of CLL cells. Inflammation is involved in the initiation and progression 
of several chronic lymphoid malignancies [147]. The observations in this pilot study correlate 
well with the biology of CLL. Comparison of cells in medium alone with growth on a 
fibroblast layer shows that the artificial stroma prevents cells from undergoing 
apoptosis/necrosis (Table 3.2).  
CD23 and CD54 are up-regulated on CLL cells on the feeder layer and have reported roles in 
inflammation [148], known to aid CLL progression. Activation of T-cells and induction of an 
immune response may limit CLL survival. We have observed down-regulation of CD43, 
CD45, CD50 and CD53 involved with the immune response, and up-regulation of CD80 that 
may result in T-cell activation (binding to CD28) or inhibition (binding to CD152), the latter 
may aid cell survival.  
There is also differential abundance of surface antigens involved in apoptosis. Down-
regulation of CD6, CD27, and CD47 may prevent the cells from undergoing programmed cell 
death up-regulation of CD264 would inhibits TRAIL-induced apoptosis. A combination of 
these factors may determine cell survival on the feeder layer. Several pro-apoptotic factors 
such as CD262, CD319 are up-regulated which suggests an inclination for death; however 
these signals may be overridden by the multiple pro-survival signals. 
A comparison of the effects of 2-FaraA on cellsin medium alone showed up-regulation of 
CD24 that enhance DNA-damage induced apoptosis by inducing NF-κB signalling in breast 
cancer [149]. There is also an increase in CD262 that induces p53-dependent apoptosis in 
response to DNA-damage [150]. Only two differentially abundant antigens were found after 
treatment on a feeder layer. CD45 was up-regulated, in contrast to its down-regulation for 
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untreated cells grown on a feeder layer compared to medium. CD222 is also up-regulated; 
CD45 and CD222 do not have known roles in apoptosis. 
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3.5 CONCLUSIONS 
The data presented in this chapter demonstrate that the 2-FaraA-sensitive cell lines, Raji and 
IM9, accumulate p53 in their nuclei, mitochondria and cytosol. Raji cells accumulate p53 in 
mitochondria earlier than in the nucleus suggesting that initiation of apoptosis in these cells is 
dependent on the roles of p53 at mitochondria, prior to effects on gene expression in the 
nucleus. In Raji, accumulation of p53 is likely a result of increased p53 protein given the 
increased mRNA levels, and from inhibition of p53 degradation. 2-FaraA also induces 
phosphorylation and accumulation of lower molecular weight derivatives of p53, p63 and p73 
in the nuclei of Raji cells that may have roles in inducing apoptosis. Several molecular weight 
and phosphorylated forms of p63 exist in the nuclear, mitochondrial and cytosolic fractions of 
Raji following 2-FaraA. 1D Western blots showed that mitochondrial p63 in the 2-FaraA-
sensitive cell lines, Raji and IM9, exists as dimers and tetramers, while in the cell lines 
resistant to 2-FaraA (MEC1 and U266), p63 is found as a monomer. The data presented here 
provide further insight into the effects and mechanisms of action of 2-FaraA, and define 
patterns of response of the p53 family members in sub-cellular compartments of B-lymphoid 
cells. In addition, several surface antigens were differentially expressed in CLL cells grown 
on feeder layer that manipulate cellular apoptosis, inflammation and T-cell activation with 
parallel with increases in novel intracellular targets Protein SET and Lymphocyte-specific 
protein 1 that may contribute to CLL cell survival in the tumour microenvironment and to 
resistance of CLL cells to 2-FaraA based treatments.  
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CHAPTER FOUR 
Qualitative analysis of p53 interactome in response to 2-
FaraA and the effect of p53 mutational status 
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4.1 INTRODUCTION 
As discussed in the preceding chapter, the treatment of Raji and IM9 cells with 2-FaraA 
induces apoptosis through a p53-dependent mechanism. Particularly, the treatment causes the 
appearance of phosphorylated isoforms and proteolytic derivatives of p53. Thus, an 
understanding of the interactions of the p53 protein with potential binding partners is very 
important in defining the mechanisms of sensitivity and resistance to 2-FaraA. In addition, it 
may provide insights into the candidates responsible for the generation of the p53 isoforms 
and derivatives seen in chapter 3.   
The interactions of the p53 protein have been studied extensively, yet the versatility of p53 
means that new interactions and functions are still being elucidated. Thus far, there are 
several p53 binding partners that are well known in the prevention and or induction of 
apoptosis. In resting cells, p53 is short-lived and found at low levels. This is largely due to 
the interaction of p53 with MDM2 which induces ubiquitination and subsequent proteosomal 
degradation of p53. Cellular stresses can result in DNA damage and accumulation of active 
forms of signal mediators such as ATM and ATR kinases at the sites of DNA damage. The 
activity of these kinases results in the accumulation of p53 through phosphorylation and 
p14ARF inhibition of MDM2 binding to p53. This chapter (1) describes the results of a 
qualitative study of the p53 interaction partners (interactome) in 3 cell lines with varying p53 
mutational status and (2) investigates the p53 interacting proteins in Raji and IM9 cell lines 
after 2-FaraA treatment to better understand the mechanisms that regulate p53 expression and 
activity following drug treatment.  
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4.2 METHODS 
Cell lines were cultured and treated with 2-FaraA (3 µM, 24 h) as described earlier (Chapter 
2). Cells (5 x 108) were harvested, washed in phosphate buffered saline (PBS) and lysed with 
RIPA buffer (Chapter 2). p53 was precipitated from cell lysates using monoclonal antibody 
(clone DO1) coupled to Dynabead protein G. Western blotting was used to confirm 
successful p53 precipitation. There were 3 biological replicates for each cell line and 
treatment condition. Non-specific binding was detected by using a rabbit polyclonal antibody 
against CD3 and subjected to shotgun mass spectrometry analysis.  
The samples were separated by SDS-PAGE followed by GeLC-MS analysis using the 
QSTAR Elite mass spectrometer. ProteinPilot 3.0 software (ParagonTMalgorithm) was used 
to search and assign protein ID followed by further analysis using Microsoft Excel®. Figure 
4.1 shows a schematic of the procedure. Down-stream analysis was conducted using a 
combination of online software STRING (http://string-db.org/), BioMyn 
(http://www.biomyn.de/) and the Human Protein Reference Database 
(http://www.hprd.org/index_html).  
p53 functionality was tested by measuring the expression of p21 and p27 using 
flowcytometry, as these two proteins are downstream targets of p53 modulated cell cycle 
arrest.  
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Figure 4.1 Schematic of the p53 pull-down workflow 
91 | P a g e  
 
4.3 RESULTS 
4.3.1 Comparison of p53 interactome between cell lines with various p53 mutational 
status 
In Raji, IM9 and MEC1 cells the number of interaction partners detected in all replicates with 
≥2 unique peptides were 52, 80 and 73 respectively. In Raji and IM9 (functional p53), 27 
common proteins were identified (Figure 4.2). The p53 precipitates from Raji and MEC1 
shared only 5 proteins in common while IM9 and MEC1 shared only 2. There were no p53 
interacting proteins common between all 3 cell lines. The Human Protein Reference Database 
(HPRD) assigned primary cellular localisation of p53 binding proteins (Figure 4.3A). In Raji 
cells, 62% of the p53 interaction proteins were primarily cytosolic. (including ribosome and 
endoplasmic recticulum), 21% were from the nucleus and 11% from the mitochondria. A 
similar pattern was observed in IM9 cells; 55% of the proteins identified were cytosolic , 
35% nuclear and 7% mitochondrial. However, in MEC1 cells the pattern differed, with 81% 
of the proteins identified as cytosolic, 12% nuclear and 6% mitochondrial. 
HPRD assigned biological processes for these p53 interactomes (Figure 4.3B)  with some 
interesting trends. Firstly in the Raji and IM9 cell lines, 15% and 10% respectively of the p53 
binding proteins identified are known regulators of cell growth/maintenance. However in 
MEC1, this percentage was higher at 32%. Secondly, in Raji and IM9 cell lines the 
percentage of the p53 interactome involved in energy production was 12% and 18%, 
respectively, while in MEC1 cells these proteins only represented 1% of the proteins 
precipitated. Proteins involved in nucleic acid metabolism are also higher in Raji (21%) and 
IM9 (28%) than in MEC1 (15%). All other functional groupings were represented equally 
between the 3 cell lines.  
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Figure 4.2 Venn diagram showing the numbers of p53 interaction partners that are common or distinct between 
the Raji, IM9 and MEC1 B-lymphoid cell lines. 
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Figure 4.3 Pie charts of the p53 interactome in Raji, IM9 and MEC1 cells categorised by (A) cellular 
localisation and (B) biological function based on the Human Protein Reference Database.  
94 | P a g e  
 
4.3.2 p53 binding partners in Raji and IM9 cell lines after 2-FaraA treatment  
4.3.2.1 2-FaraA-induced p53 binding proteins common to both Raji and IM9 
Figure 4.4 shows a Venn diagram of the p53 interacting proteins found in control and 2-
FaraA-treated Raji and IM9 cells. In control samples, there were 2 major cytosolic forms of 
the HSP90 protein, HSP90AA1, an inducible form, and HSP90AB1, a constitutive form. The 
other interaction partners of p53 identified under control conditions, all of which have been 
previously reported, are the ribosomal proteins L13, L13A, L23A, L14 and L26L1, DDX21, 
ATP5B, CLTC, LRPPRC, ERPS, PKM2, TAGLN2 and HNRNPA1L. Among the unreported 
partners are NUP210, NOL5 and CAD.  
In the 2-FaraA-treated cells, DDX39, MCM5, HNRNPH1, HNRNPK, HNRNPM, PGD, 
EEF1A1 and RPL6 have all been reported as binding to p53. The novel partners identified 
were, MTHFD1, DYNC1H1, GRHPR, LOC92755, MYO18A, MYH11, and SRM.  
Lastly among the p53 interaction partners that were common in both control and 2-FaraA-
treated cells, GAPDH, TUMF, HSPD1, UBC, HYRC, PARP1, HNRNPU and SUPT16H 
have all been reported to bind to p53, whereas C1QBP, PHB2, TUBA4A, LDHA, MYH9, 
DARS, LMNB1, and LCP1 are novel p53 binding proteins. 
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Figure 4.4 Venn diagram showing p53 interaction partners found in Control (Blue), 2-FaraA-treated (Red, 
3µM, 24 h) in both Raji and IM9 cells. Proteins are represented by Gene names. Identifications that were found 
in both cell lines and in all replicates (n=3) with greater 2 or more unique peptides from MS/MS analysis are 
reported (Supplementary Table ST4.2, Appendix II). 
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4.3.2.2 p53 and HSP90 interactions 
The interaction of p53 with HSP90 potentially represents a very important mechanism 
controlling p53 protein expression and function. To investigate the interaction of HSP90 with 
p53 further, HSP90 was immuno-precipitated in Raji, IM9 and MEC1 cells with and without 
2-FaraA treatment (Figure 4.5). It is clear that HSP90 binds to p53 in all 3 cell lines before 
drug treatment and that 2-FaraA disrupts this interaction in Raji and IM9 but not MEC1 cells.  
Flow cytometry analysis showed that inhibition of HSP90 with AUY-922 (Novartis) induced 
expression of p21 and p27 in Raji, IM9 and MEC1 cells, indicated by a right shift in the 
histogram peak (Figure 4.6). Figure 4.7 suggests that combining 2-FaraA and AUY922 has a 
greater effect on the distribution of cells within the cell cycle than either drug alone. The M1 
region on each plot indicates the sub-G1 region that is indicative of apoptotic cells with 
fragmented DNA. 
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Figure 4.5 Western blots of HSP90 immuno-precipitates (ppt) and flow through (FT) from Raji, IM9 and 
MEC1 cells. Extracts (5 µg protein) were analysed by 1D SDS-PAGE in 12% gels, blotted and probed for  p53 
(clones DO1) and HSP90 (clone C45G5). 
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Figure 4.6 Flow cytometry analysis of p21 and p27 in Raji, IM9 and MEC1 cells in control (black outline) and 
treated (grey outline) with the HSP90 inhibitor AUY922 (Novartis, 20 nM, 48 h). 
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Figure 4.7 Cell cycle analysis of MEC1 cells with 2-FaraA, AUY992 or 2-FaraA+AUY992. The M1 region on 
each plot indicates the sub-G1 region that is indicative of the apoptotic cells with fragmented DNA. 
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4.3.3 Effect of 2-FaraA on the p53 interactome in Wild-type (IM9) cells 
Treatment with 2-FaraA induced significant differences in the proteins bound to p53 in IM9 
cells. Analysis with the online meta-search tool BioMyn categorised the interaction partners 
into a map of biological functions (Supplementary Figure SF4.1). The functional areas where 
2-FaraA had the greatest effect are represented in Table 4.1  
Table 4.1: Biomyn categorised functional groups of p53 interactome in IM9 cells 
Number Protein name Entrez ID Accession number Control Test 
Other 
categories 
Protein folding 
1 Heat shock protein HSP 90-beta HS90B_HUMAN P08238 YES NO  
Nucleo-cytoplasmic transport/ protein targeting 
2 Stress-70 protein, mitochondrial GRP75_HUMAN P38646 NO YES  
3 Importin subunit alpha-2 IMA2_HUMAN P52292 NO YES  
4 Spectrin beta chain SPTB2_HUMAN Q01082 NO YES Protein modification 
5 Importin subunit beta-1 IMB1_HUMAN Q14974 NO YES Cell death 
Protein modification 
6 
Interferon-induced, 
double-stranded 
RNA-activated 
protein kinase 
(PKR) 
E2AK2_HUMAN P19525 NO YES Cell death  
7 
Tyrosine-protein 
phosphatase non-
receptor type 6 
(SHPTP1) 
PTN6_HUMAN P29350 NO YES Cell death 
8 
Serine/threonine 
protein phosphatase 
2A 65 kDa 
regulatory subunit A 
alpha isoform 
(PP2A) 
2AAA_HUMAN P30153 NO YES  
9 
Serine/threonine-
protein phosphatase 
(PP-1A) 
Q07161_HUMA
N Q07161 NO YES  
10 Protein-tyrosine kinase 2-beta FAK2_HUMAN Q14289 NO YES Cell death 
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(PYK2) 
11 
Serine/threonine-
protein kinase 
VRK1(VRK1) 
VRK1_HUMAN Q99986 NO YES  
12 
Ubiquitin carboxyl-
terminal hydrolase 
isozyme L1 
UCHL1_HUMA
N P09936 YES NO Cell death 
13 
Eukaryotic 
translation initiation 
factor 5A-1-like 
IF5AL_HUMAN Q6IS14 YES NO  
14 
Cullin-associated 
NEDD8-dissociated 
protein 1 
CAND1_HUMA
N Q86VP6 YES NO  
15 Protein-arginine deiminase type-1 PADI1_HUMAN Q9ULC6 YES NO  
16 
26S proteasome 
non-ATPase 
regulatory subunit 
13 
PSD13_HUMAN Q9UNM6 YES NO Cell death 
Cell death 
17 
Programmed cell 
death 6-interacting 
protein 
PDC6I_HUMAN Q8WUM4 YES NO  
18 Cytoplasmic FMR1-interacting protein 2 CYFP2_HUMAN Q96F07 YES NO  
19 Pyruvate kinase isozymes M1/M2 KPYM_HUMAN P14618 YES NO  
20 Spectrin alpha chain SPTA2_HUMAN Q13813 NO YES  
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4.4 DISCUSSION 
4.4.1 p53 interactome in cell lines with various p53 mutations 
The comparison of the p53 interactome in the cell lines with their p53 mutational status 
showed striking trends. p53 is found in all sub-cellular compartments, this study was 
conducted using whole cell p53 precipitates, thus the HPRD assigned primary localisation of 
the interactome (Figure4.3A) was used to indicate the sub-cellular compartments from which 
the p53 binding partners originates. Interestingly, in IM9 and Raji the protein localisation is 
similar with ~50-60% cytosolic and ~20-30% nuclear but in MEC1, 81% of the interactome 
were cytosolic proteins while only 12% were nuclear. This observation is consistent with the 
results in Chapter 3 (Figure 3.3) where sub-cellular fractionation demonstrated that p53 
mutation (truncation) prevented its translocation to the nucleus and therefore its association 
with nuclear proteins including certain transcription factors.  
For Raji and IM9, 10-15% of the proteins identified in the p53 interactome have known 
functions in cell growth and maintenance, while in MEC1, proteins with these functions 
represent 32% of the interactome. Unlike Raji and IM9, MEC1 cells have a truncation 
mutation of p53 that confers growth and survival advantages, such as increased proliferation, 
evasion of apoptosis, and chemo-resistance [151, 152]. In the MEC1 but not Raji or IM9 
lines,  we identified DNA topoisomerase 2 beta as a p53 binding partner (Supplementary 
Table ST4.1, Appendix II). Topoisomerase 2 beta is the main target of topoisomerase 2-
binding protein 1 (TOPBP1), and p53 and TOPBP1interactions are a hallmark of gain of 
function (GOF) mutations [153]. MEC1 mutant p53 may have a GOF that affects DNA repair 
through an interaction with TOPBP1 and may contribute toward the survival advantage and 
chemo-resistance of CLL cells harbouring this mutation of p53.  
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Comparison of the p53 interactomes showed a predominance of proteins with functions in 
cellular energy production and metabolism in the Raji and IM9 cell lines compared to MEC1. 
Many cancers have the Warburg effect that involves consumption of high amounts of glucose 
with less efficient production of ATP produced by the glycolytic pathway, even in the 
presence of oxygen. By contrast, normal cells preferentially use glycolysis and the 
mitochondrial tricarboxylic acid (TCA) cycle for the oxidative degradation of glucose and 
generation of ATP, resorting to glycolysis only under conditions of oxygen deprivation. 
Several studies show that by promoting oxidative phosphorylation, functional p53 might 
oppose the Warburg affect [154, 155]. It is interesting to note that in our study the two cell 
lines with normal p53, interactions of the p53 protein with proteins involved with energy 
pathways and metabolism were identified whereas in the p53 mutated MEC1 cell line no such 
interactions were observed.  
4.4.2 Fludarabine induced effects on the p53 interactome in Raji and IM9 cells  
In control cells, the p53 interactome included the ribosomal protein L13. Previous studies 
report that L13 plays an essential role in the progression of gastro-intestinal malignancies by 
suppressing activity of the p53 pathway, thus allowing tumorigenic growth in the presence of 
wild-type p53 [156]. We also identified the tri-functional protein CAD as binding to p53 in 
control cells; amplification of the CAD gene and over-expression of the CAD protein confers 
resistance to pyrimidine nucleotide biosynthesis inhibitor PALA. The process of gene 
amplification is facilitated by DNA strand breaks promoted by a deficiency in p53 [157, 158]. 
 
In response to 2-FaraA treatment, we observed dissociation of HSP90 from p53. HSP90 
interactions with p53 have been reported previously; Walerych et al., showed that in human 
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fibroblasts HSP90 forms a complex with wild-type p53 partially unfolding it and preventing 
p53 regulation of p21 gene expression. Treatment with the HSP90 inhibitors geldanamycin or 
radicicol, promoted the transcriptional activities of p53 [159]. Our study shows for the first 
time that in the human B-cell lines Raji and IM9, treatment with 2-FaraA dissociates HSP90 
from p53. This does not occur in p53-mutated MEC1, however treatment of MEC1 with the 
HSP90 inhibitor AUY922, results in increases of p21 and p27, known p53 targets. In 
addition, MEC1 cells do not respond to 2-FaraA or AUY922 individually but in combination 
of these two drugs causes cells to undergo apoptosis indicated by the higher proportion of 
cells with sub-G1 DNA content (Figure 4.7). Taken together, these data suggest HSP90 may 
negatively regulate the function of p53 in cells that respond to 2-FaraA (Raji and IM9) and in 
cells unresponsive to 2-FaraA (MEC1), HSP90 inhibition may restore sensitivity to DNA 
damaging agents in tumour cells with truncated forms of p53 releasing p53 from a mis-folded 
state.  
4.4.3 Effects of 2-FaraA on the interactions of p53 in the IM9 cell line 
Treatment with 2-FaraA induced significant changes in the proteins bound to p53 in IM9 
cells. In response to 2-FaraA, several proteins involved in nucleo-cytoplasmic transport were 
found in the p53 interactome. These include Stress-70 protein (GRP75), Importin subunit 
alpha-2 (IMA2), Importin subunit beta-1 (IMB1) and Spectrin beta (SPTB2). 
The Stress-70 protein (GRP75) is a known binding partner of p53. It binds to the cytoplasmic 
sequestering domain of p53. Studies by Wadhwa et al. show that GRP75 binds and retains 
p53 in the cytoplasm, suggesting that the binding inhibits p53 function by nuclear exclusion 
[160]. However recent studies demonstrate that p53 plays a different role in the cytoplasm, 
thus p53 cytoplasmic sequestering may aid cytoplasmic/mitochondrial apoptosis. The binding 
of GRP75 to p53 has not been reported in response to a DNA damaging agent such as 2-
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FaraA and may play an important role in regulating apoptosis induced in the cytoplasm. 
Importin alpha is also implicated in p53 transport. Kim et al. show that importin alpha 
functions as a component of the nuclear localization signals receptor for p53 and mediates 
nuclear import of p53 [161]. The binding of importin alpha to p53 after 2-FaraA treatment 
and subsequent nuclear translocation of p53 may represent an important step in the induction 
of p53-dependent apoptosis in the nucleus.  
It is interesting to note the interaction of spectrin/fodrin with p53 after 2-FaraA treatment. 
Studies have shown that during radiation and tumour necrosis factor-induced apoptosis, 
spectrin is cleaved by calpains and caspases to 150 kDa and 120 kDa fragments, respectively 
[162, 163]. However no reports to date have an interaction between full length spectrin, or its 
breakdown products, with p53.  
Protein modification: Protein modification is an essential biological function crucial in many 
cellular pathways, including apoptosis. Proteins that interact with p53 after 2-FaraA treatment 
include kinases and phosphatases. Kinases include PKR, VRK1 and PYK2 and phosphatases 
include SHPTP1, PP-1A and PP2A.  
All of the kinases have been reported to have interactions with p53. For example, interferon 
enhanced complex formation of PKR with wild-type p53 has been reported. In addition, 
phosphorylation of human p53 on serine392 is induced by activated PKR, stabilizing the p53 
tetramer required for the action of p53 as a transcription factor [164]. This observation is 
consistent with previous findings showing that apoptosis induced by 2-FaraA increases p53 
phosphorylation on serine 392 [165]. VRK1 is a nuclear kinase that has been reported to 
phosphorylate p53 at Thr18. This phosphorylation disrupts the p53-MDM2 interaction and 
stabilizes p53. In the absence of MDM2, VRK1 also stabilizes p53 through phosphorylation 
of MDMX and p300 [166].  
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The PYK2 kinase has a functional role that opposes VRK1. PYK2 is responsible for 
recruiting the ubiquitin ligase MDM2 to the nucleus, thereby regulating p53 activity by 
ubiquitination and proteosomal degradation [167]. This seemingly contradictory mechanism 
is typical as both pro- and anti- apoptotic mechanisms are induced by DNA damaging agents. 
Additionally, this may explain the presence of the lower molecular weight p53 derivatives 
observed in Chapter 3 when levels of p53 increase after 2-FaraA treatment.  
Among the phosphatases, SHPTP1 does not directly interact with p53 but is a substrate of c-
ab1; interaction of c-abl with p53 has been reported to play a role in the induction of JNK 
activity following DNA damage [168]. p53 and c-ab1 form a complex in response to DNA 
damage which induces cell cycle arrest [169]. Therefore, the observation in the current study 
that SHPTP1 interacts with p53 after 2-FaraA treatment may contribute to the 2-FaraA-
induced cell cycle arrest observed in IM9 cells.  
PP2A has been shown to mediate the dephosphorylation of p53 at Thr55 in response to DNA 
damage, thus reducing p53 stability, Bax expression and cell apoptosis [170]. Our 
observation that p53 interacts with PP2A following 2-FaraA treatment may be a pro-
proliferative response. Lastly, PP1A has not been reported as interacting directly with p53, 
however it binds to BRCA1 [171] which interacts with p53 [172]. The BRCA1/2 pathway 
arbitrates DNA damage response pathways that mediate the repair of DNA double strand 
breaks. While this pathway has primarily been described in breast and ovarian cancers, it is 
also known to be suppressive of hematologic cancers [173].  
 
Cell death: The previously discussed enzymes PKR, PYK2 and SHPTP1 that we have shown 
to interact with p53 after 2-FaraA treatment have described roles in cell death. Spectrin alpha 
(SPTA2) an isoform of the previously discussed SPTB2 also interacts with p53 after 
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treatment. Similar to the beta isoform, spectrin alpha is broken down by caspase-3 and 
calpains during apoptosis [174]. Its binding to p53 has not been reported.  
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4.5 CONCLUSION 
Taken together, our analysis of the p53 interactome provides a snapshot of the cellular 
processes involving p53 and the effects of 2-FaraA on these interactions in B-lymphoid 
malignancies. Comparison of the p53 interactions in Raji, IM9 and MEC1 cells suggests that 
p53 in the MEC1 line interacts more closely with proteins involved in cell growth and 
cellular maintenance than in the Raji and IM9 lines. This could be attributed to a gain-of-
function of the mutated p53 in this line, which may contribute to a survival advantage and the 
chemoresistance observed in Chapter 3 (Figure 3.2). We also observe that in p53 cell lines 
(Raji and IM9) the p53 interactome include several proteins involved in energy production 
and metabolism. Similar interactions were not identified in the MEC1 cells, suggesting that 
the functions of normal p53 may in the Raji and IM9 cells may include energy generation by 
the glycolytic pathway, described as the Warburg effect.  
In the Raji and IM9 cell lines, HSP90 was identified as being bound to p53 in the untreated 
control samples but was shown to dissociate from p53 following 2-FaraA treatment. In 
contrast in MEC1, HSP90 remained bound to p53 even after 2-FaraA treatment. This 
suggests that HSP90 binding to p53 may play a role in regulating p53 activity and sensitivity 
to 2-FaraA treatment. This hypothesis is supported by evidence (Figure 4.6 and 4.7; Best et 
al., 2012) that suggests that inhibition of HSP90 restores sensitivity to 2-FaraA even in cell 
lines and CLL patient samples that are resistant to 2-FaraA as a single agent [175].  
Further investigation of the effects of 2-FaraA on the p53 interactome in the p53 wild-type 
IM9 cell line, identified several proteins that bound to p53 following 2-FaraA treatment. 
These proteins (GRP75, IMA2, PKR, VRK1, PYK2, PP2A, SHPTP1 and SPTA2) have roles 
in biological functions such as nucleocytoplasmic transport, protein modification and cell 
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death. Several of these proteins include kinases and phosphatases that are known to function 
in regulating p53 phosphorylation and have crucial roles in the regulation of apoptosis.  
In conclusion, the data presented within this chapter provide further insight into the effects of 
fludarabine on p53, extending the observations described in (Chapter 3 Figure 3.1). The 
identification of several previously undescribed p53 interactions indicates novel roles and 
mechanisms of p53 yet to be elucidated that may involve the sensitivity of B-lymphoid cells 
to 2-FaraA. 
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CHAPTER FIVE 
Phosphorylation of the p53 interactome in B-lymphoid 
cancers treated with 2-FaraA 
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5.1 INTRODUCTION 
Protein phosphorylation is a common post-translational modification (PTM) in living cells. 
Regulatory functions such as cell cycle control, receptor-mediated signal transduction, 
differentiation, proliferation, apoptosis, transformation, and metabolism [176] are all 
controlled by phosphorylation. Phosphopeptide enrichment increases sensitivity for low 
abundance proteins such as transcription factors that cannot otherwise be detected by mass 
spectrometers. Quantitative phospho-proteomics detects increases or decreases of 
phosphopeptides that are indicative of change in the protein abundance or a change in the 
phosphorylation status of particular amino acid residues. Parallel analysis by mass 
spectrometry of flow through of enrichment columns (unmodified peptides) often aids in 
distinguishing which of the aforementioned changes is occurring.  
This chapter focuses on differentially abundant phosphopeptides in the p53 interactome with 
2-FaraA treatment of the drug responsive B-lymphoid cell lines Raji and IM9.  
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5.2 METHODS 
Cells lines were grown and treated with 2-FaraA (3 µM, 24 h) as described earlier (Chapter 
2). Cells (5 x 108) were harvested, washed in phosphate buffered saline (PBS) and lysed in 
RIPA buffer (Chapter 2). p53 was precipitated from cell lysates using monoclonal antibody 
(clone DO1) coupled to protein G coated Dynabeads. Four biological replicates were 
prepared for each cell line and treatment condition. Western blotting was used to confirm 
successful precipitation of p53. The p53 interactome was digested from the beads and 
labelled using dimethyl labelling with sodium cyanoborohydride (NaBH3CN) for light and 
sodium cyanoborodeuteride (NaBD3CN) for heavy, followed by titanium dioxide enrichment 
and analysis by mass spectrometry (Orbitrap Velos). Max Quant software was used for 
protein identification, quantification. Statistical significance assigned by Microsoft Excel 
using student t-test (n=4) for each cell line and a fold change of ±1.5. This was determined by 
a screen of the phosphoproteome based literature where they deem a change of 1.5 to be a 
significant [177-180]. Up-stream and down-stream pathway analysis was conducted using 
Ingenuity Pathway Analysis.  
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5.3 RESULTS 
5.3.1 Assessment of successful workflow 
Prior to mass spectrometry, complete digestion of the p53 interactome was assessed by SDS-
PAGE. Bands corresponding to proteins of the p53 interactome and the monoclonal antibody 
(DO1) (lane 2) were removed from the Dynabeads by tryptic digestion (lane 3) and appeared 
as a dark smear below 10 kDa in the digest supernatant in lane 4 (Figure 5.1). The efficiency 
of stable isotopic dimethyl labelling was assessed by inspection of the mass shifts (8 Da m/z) 
of the light (L) and heavy (H) peptide pair in the MS spectra (Figure 5.2).  
Figure 5.2 shows phosphorylation of Histone H2A.x at serine 139 in the Raji p53 
interactome. Unmodified peptide TSATVGPK had no change in relative abundance when 
comparing control (L) and treated (H) peaks, but phosphorylated peptide KATQAS*QEY 
increased in relative abundance after 2-FaraA. Phosphorylation at this residue was validated 
by flow cytometry using an antibody against γ-H2A.x conjugated to Alexa 488 fluorochrome. 
The formation of γ-H2A.x (H2A.x with phosphorylated serine 139) was quantified in Raji 
and IM9 cells after 24 h and 48 h with 2-FaraA (Figure 5.3). Results show the increase of γ-
H2A.x in Raji cells after 24 h which persists at 48 h. In IM9 cells, there is no increase in γ-
H2A.x until 48 h. These results were consistent with the data obtained by MS where 2-FaraA 
treatment for 24 h induced phosphorylation of H2a.x at serine 139 in Raji cells, but not in 
IM9 cells (Supplementary Tables 5.1 and 5.2). 
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Figure 5.1 Sypro Ruby staining of p53 immuno-precipitated from Raji cells run on 15% SDS-PAGE, (1), 
molecular weight markers; (2), Dynabeads with p53 precipitate; (3), Dynabeads after on-bead-digestion with 
trypsin; (4), Supernatant from the beads after digestion.  
Figure 5.2 Quantitation of phosphorylation of Histone H2A.x in the p53 interactome of Raji cells. Spectra of 2 
peptides of (A) unmodified and (B) phosphorylated (Ser139) following isotopic dimethyl labelling are shown. 
Peptides from vehicle control cells are indicated with (L), 2-FaraA treated cells (H).  
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Figure 5.3 Phosphorylation of H2A.x to produce γ-H2A.x validated by flow cytometry using monoclonal 
antibody conjugated to Alexa 488 in Raji and IM9 cells treated with 2-FaraA (3 µM, 24 h, 48 h). The violet area 
represents untreated cells and the green outline 2-FaraA-treated cells. A shift in median fluorescence intensity 
(MFI) indicates an increase in γ-H2A.x. Graphs of relative amounts of γ-H2A.x in each cell line are shown on 
the right. Significant changes (p <0.05) are indicated by (*) relative to the control (n=3). 
116 | P a g e  
 
5.3.2 Differential phosphorylation of p53 interactome after 24 h 2-FaraA treatment 
In the IM9 p53 interactome a total of 301 phosphopeptides were detected, with 24 of these 
peptides showing increased phosphorylation and 75 peptides showed decreased 
phosphorylation after 2-FaraA treatment. In the Raji p53 interactome a total of 294 
phosphopeptides were detected, with 15 peptides showing increased phosphorylation and 23 
peptides showing decreased phosphorylation. Ingenuity Pathway Analysis (IPA) software 
was used to assign biological significance to differentially phosphorylated proteins in Raji 
and IM9 cell lines. The most significant biological pathways regulated were, RNA post 
transcriptional modifications, gene expression, cell cycle, cellular movement and 
haematological disease (Figure 5.4). Figure 5.5 shows the IPA of the differential phospho-
proteome in Raji (A) and IM9 (B) cells. Consistent for both cell lines were pathways 
involved with the inhibition of Rnr (5.8S) ribosomal RNA. 
 
Figure 5.4 Biological pathway comparison for p53 interactome proteins that are differentially phosphorylated in 
Raji and IM9 cells after 2-FaraA. The significance threshold was set at –log (0.05). Pathways regulated by 
phosphorylation after 2-FaraA are shown as –log (p-value) > 1.3 (bars). The number of proteins detected that 
are involved in the pathway, are indicated in brackets.  
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Figure 5.5 Ingenuity Pathway networks for the phospho-proteins common between (A) Raji (B) IM9. Proteins in red showed increased phosphopeptides and those in green 
decreased phosphopeptides in the p53 interactome. Proteins in orange are predicted to be activated and those in blue inhibited in function, based on the differential expression of 
proteins in the dataset.  
B A 
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5.3.3 Kinases and motif analysis  
Table 5.1 summarises all the amino acid residues of proteins phosphorylated after 2-FaraA treatment 
of Raji and IM9 cells. The main predicted kinase families that contribute to the response to 2-FaraA 
include the CMGC kinases (ERK1, ERK2, CDK), AGC kinases (PKA, PKC, GRK1) and the Casein 
kinases (CK1, CK2). Analysis using Motif-x software revealed two phosphorylation motifs in 
common for the Raji and IM9 cell lines (Figure 5.6 A, B). The xxSPxx motif was from serine 
phosphorylated residues of CHD4, NCL, HIST1H1E, SRRM2, TCOF1 and TP53. The second motif 
SxxE was from serine phosphorylated residues of HSP90AB1, MCM2, TOP2A and NLC. A search 
using the online database PhosphoNetworks (http://www.phosphonetworks.org) revealed 3 kinases 
that have binding motifs analogous to those identified by Motif-x, in our study including MAPK8 
(NCL), CDK7 (TP53) and CSNK2A1 (HSP90AB1) (Figure 5.6C). 
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Table 5.1 Proteins phosphorylated in the p53 interactome in Raji and IM9 cells after 2-FaraA (p-
values and abundance ratios are in Supplementary Table 5.1 and 5.2).  
Accession 
number Protein name 
Gene 
names Sequence Residues
Kinase 
substrate 
motif 
Cell line  
Q14839 
Chromodomai
n-helicase-
DNA-binding 
protein 4 
CHD4 MSQPGSPSPK S1535 ERK1, ERK2 Raji and IM9 
P16104 Histone H2A.x H2AFX KATQASQEY S140  ATM Raji  
P10412 Histone H1.4 HIST1H1E 
KAPKSPAK S187 ERK1, ERK2 Raji and IM9 
KASGPPVSELI
TK S36 PKA,PKC Raji  
P17096 
High mobility 
group protein 
HMG-I/HMG-
Y 
HMGA
1 SSQPLASK S8 GRK Raji  
P08238 
Heat shock 
protein HSP 
90-beta 
HSP90
AB1 
IEDVGSDEED
DSGKDK S254  CK2 Raji  
P49736 
DNA 
replication 
licensing 
factor MCM2 
MCM2 GLLYDSDEEDEERPAR S139 CK2 Raji  
P19338 Nucleolin NCL VVVSPTKK S67 MAPK8  Raji  
P05388 
60S acidic 
ribosomal 
protein P0 
RPLP0 KEESEESDDDMGFGLFD S304 CK2 Raji  
Q9UQ35 
Serine/arginine 
repetitive 
matrix protein 
2 
SRRM
2 SATRPSPSPER 
S351, 
S353 CK2 Raji  
E9PHK9 Treacle protein TCOF1 
LGAGEGGEAS
VSPEKTSTTS
K 
S1376 ERK1, ERK2 Raji  
P11388-4 
DNA 
topoisomerase 
2-alpha 
TOP2A KPSTSDDSDSNFEK 
S1471, 
S1474 CK1, CK2 Raji  
P04637 Cellular tumour antigen TP53 
ALPNNTSSSP
QPK S315  Aurora A 
Raji and 
IM9 
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p53 
Q9BVJ6 
U3 small 
nucleolar 
RNA-
associated 
protein 14 
homolog A 
UTP14
A 
SELSQDAEPA
GSQETK S445 
DNA-PK, 
ATM 
Raji and 
IM9 
Q9UIG0 
Tyrosine-
protein kinase 
BAZ1B 
BAZ1B LAEDEGDSEPEAVGQSR S1468 CK2 IM9 
Q14137 
Ribosome 
biogenesis 
protein BOP1 
BOP1 IGDEYAEDSSDEEDIR 
S126, 
S127 CK2 IM9 
Q13112 
Chromatin 
assembly 
factor 1 
subunit B 
CHAF1
B 
TQDPSSPGTT
PPQAR S429 GRK1 IM9 
P07814 Glutamate-tRNA ligase EPRS 
EYIPGQPPLSQ
SSDSSPTR S886 
CDK1, 2, 4, 
6 IM9 
Q9NQS7 
Inner 
centromere 
protein 
INCEN
P IAQVSPGPR S263 ERK1, ERK2 IM9 
P20700 Lamin-B1 LMNB1 
TTIPEEEEEEE
EAAGVVVEEE
LFHQQGTPR 
T575 PKA,PKC IM9 
A8MXP9 Matrin-3 MATR3 
RDSFDDRGPS
LNPVLDYDH
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Figure 5.6 Motifs found in (A) Raji and (B) IM9 cells phosphorylated after 2-FaraA treatment identified using Motif-x 
software. (C) Binding motifs for kinases that are analogous to the motifs discovered by Motif-x. 
 
5.3.4 Upstream molecule analysis of p53 interactome phosphorylation using IPA  
In upstream molecule analysis significant proteins were determined by comparing Fisher's exact p-
value and the number of associated proteins found in our study. The top 2 upstream molecules found 
to be regulated were a synthetic retinoic acid (CD437, 7.68x10-7, 8) and the MYC protein (2.04x10-6, 
9). Figure 5.7 shows the p53 network incorporating these two upstream molecules and the 
differential proteins involved. Western blots of retinoic acid receptor alpha (RARα) were conducted 
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to determine whether RARs play a role in 2-FaraA-induced apoptosis. In Raji (2-FaraA responsive) 
RARα was up-regulated (2-fold) but not in MEC1 (2-FaraA resistant) cells (Supplementary Figure 
S5.2). Figure 5.8 shows histograms of Annexin V binding to externalised phosphatidyl serine (PS, 
apoptosis marker) in MEC1 and Raji cells treated with 2-FaraA (3 µM) and -trans retinoic acid 
(ATRA, 1 µM) alone and  in combination. For MEC1 cells, the combination of ATRA and 2-FaraA 
induces apoptosis, in Raji ATRA does not alter the effect of 2-FaraA.  
 
Figure 5.7 MYC and CD437 are the top 2 upstream molecules activated by changes in the p53 interactome induced by 2-
FaraA. Proteins in red represent increase in phosphopeptides and green decrease in phosphopeptides in the p53 
interactome.  
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Figure 5.8 Apoptosis was determined by measuring the expression of Annexin V by MEC1 and Raji cells after treatment with 2-FaraA (3 µM) alone and combined with 
ATRA (1 µM). The grey area represents cells incubated with vehicle control; the black line represents cells incubated with 2-FaraA and/or ATRA. A shift in the median 
fluorescence intensity indicates an increase or decrease in Annexin V binding to PS. 
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5.4 DISCUSSION 
5.4.1 DNA damage induces a protein phosphorylation signature  
Identification of phosphopeptides in the p53 interactome high-lighted some interesting 
cellular functional nodes, including proteins involved in RNA modification and gene 
expression (Figure 5.4). This correlates well with transcriptional regulation by of p53 and the 
ability to bind to other transcription factors, as well as DNA and RNA. A comparison of our 
data with the literature showed several DNA damage phosphorylation signatures. 
Phosphorylation of H2AX at Serine 139 produces γH2AX that plays a key role in the DNA 
damage response (DDR) [181] and is required for the assembly of DNA repair proteins at 
sites containing damaged chromatin and activation of checkpoint proteins that arrest the cell 
cycle [182]. We observe the formation of γH2AX by mass spectrometry and flow cytometry 
(Figures 5.2, Figure 5.3 and Supplementary Table ST5.1).  Bennetzen et al. identified 
proteins that were specifically phosphorylated in response to DNA damage in the nucleus. 
Several of the proteins listed overlap with our study. These include phosphorylation at NCL 
(S67), UTP14A (S445), CHAF1B (S429), MATR3 (S188), PPAN (S238) and 
dephosphorylation at BCLAF1 (S285), DDX21 (S71, S121), CCDC86 (S47), CTTN (T401, 
S405) and MATR3 (S9) [183]. Other protein identified, but with opposite responses were 
PDS5B (S1166), SCAF1 (S498, S500), and BCLAF1 (S496). Our study focused the on p53 
interactome in multiple sub-cellular compartments, not exclusively nuclear p53.  
Bracken et al. describes a novel SNARP complex composed of the proteins SNIP1, SNW1, 
THRAP3, BCLAF1 and PNN, required for production of mature cyclin D1 mRNA [184]. We 
found decreases in the phospho-proteins SNW1, THRAP3, BCLAF1 and PNN 
(Supplementary Table ST5.2) with decreases in cyclin D1 (Supplementary Figure SF5.4) 
after 2-FaraA. This indicates that dissociation and/or dephosphorylation of these proteins in 
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the p53 interactome could down-regulate the SNARP complex resulting in down-regulation 
of oncogenic Cyclin D1.  
 
5.4.2 HSP90 phosphorylation and specific kinases  
As discussed in Chapter 4, the dissociation of HSP90 from the p53 interactome after 2-FaraA 
treatment may play a crucial role in p53-induced apoptosis. However, the mechanism of the 
dissociation was unknown. In this chapter, we found phosphorylation of HSP90 at serine 254 
(Table 5.1 and Supplementary Figure SF5.1). This phosphorylation of HSP90 has been 
shown to regulate apoptosome formation by modulating the affinity of HSP90 for apoptotic 
peptidase activating factor 1 (APAF1). In leukaemias, reduced phosphorylation of serine 254 
strengthens the HSP90–APAF1 complex, abrogates cytochrome c-induced apoptosome 
assembly, and confers chemoresistance [185]. Accordingly, phosphorylation of HSP90 at 
Serine 254 here may reduce the affinity of HSP90-p53 binding resulting in release of p53 to 
induce apoptosis. Motif analysis programs indicate that casein kinase 2 alpha 1 (CSNK2a1) is 
primarily responsible for the HSP90 phosphorylation at Serine 254 (Table 5.1, Figure 5.6 C), 
activation of CSNK2a1 may enhance chemotherapeutic efficacy through by HSP90 
phosphorylation and subsequent dissociation of p53 from HSP90. Site-specific mutagenesis 
studies of HSP90 may also be useful in determining the importance of this particular 
phosphorylation in 2-FaraA response.  
 
5.4.3 Ribosome biogenesis and p53  
Ribosome biogenesis is essential for cell survival. Defects in ribosome production cause p53 
stabilization and induce p53-dependent inhibition of cell proliferation. A review by Donati et 
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al. describes the role of ribosomal proteins in this mechanism. Dysregulation of ribosome 
biogenesis results in release of RPL5, RPL11 and RPL23 as they are no longer required for 
ribosome construction. The ribosomal proteins bind to MDM2 and it dissociates from p53, 
with activation of p53 [186, 187]. Consistent with this theory, we show that after 2-FaraA 
treatment, RPL11 (Supplementary Table ST5.2) and RPL23 (Chapter 4, Figure 4.4) decrease 
in the p53 interactome, indicating their binding to MDM2 and disassociation from the 
interactome.  
Secondly, we observe increases in the differential abundance of proteins involved with the 
production of rRNA such as DDX21, BOP1 and TP53 (Figure 5.5). The production of 5.8S 
rRNA is an essential step in ribosomal biogenesis [187] and is predicted to be inhibited by 
changes induced by 2-FaraA. Lastly, we observe the phosphorylation of Histone H1.4 at 
serine 187 that likely regulates transcription of ribosomal and steroid hormone-responsive 
genes [188] which may also regulate rRNA.  
 
5.4.4 Retinoic acid  
IPA upstream protein analysis indicates activation of the retinoic acid receptor (RAR) agonist 
CD437 (Figure 5.7). Sun et al. have shown that this synthetic retinoid induces apoptosis in a 
variety of cancer cells including human head and neck squamous cell carcinoma and lung 
cancer [189, 190]. Further these studies have demonstrated that cancer cells with wild-type 
p53 are more sensitive to CD437 than those with mutant p53, although CD437 can induce 
both p53-dependent and -independent apoptosis. We hypothesise the involvement of retinoic 
acid (RA) and receptors in the 2-FaraA induced apoptosis mechanism. To test this 
hypothesis, Western blotting of RARα was conducted in cells before and after 2-FaraA 
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(Supplementary Figure SF5.2). These results indicate that RARs and naturally occurring RA 
may have roles in 2-FaraA induced apoptosis. Ahmed et al. found that treatment of acute 
myeloid leukemia (AML) cell lines with a combination of 2-FaraA and all-trans RA (ATRA) 
induces greater apoptosis than 2-FaraA alone [191]. Other studies report that 1 µM ATRA 
induces p53–independent apoptosis in AML cells [192].  
To observe the effects of RA in our laboratory the 2-FaraA responsive cell line Raji and the 
resistant cell line MEC1 were treated with increasing concentrations of ATRA (0-50 µM) for 
24 h and 48 h (Supplementary Figure SF5.3). ATRA decreased proliferation of Raji and 
MEC1 cells after 48 h. Further, we found 1 µM ATRA induced apoptosis in MEC1 cells lines 
when treated in combination 2-FaraA after 48 h (Figure 5.8). In light of these findings we 
hypothesise that retinoic acid may increase chemo-sensitivity in p53 mutant cells. Future 
studies with both ATRA as well as the RAR agonist CD437 in combination with 2-FaraA in 
leukemic cell lines with p53 mutations as well as in primary CLL cells with fludarabine 
refractory disease should be conducted. Our study indicates that retinoic acid consumption or 
exposure may lead to better chemotherapeutic outcomes in patients with CLL. 
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5.5 CONCLUSIONS 
Analysis of the p53 phospho-interactome revealed novel cellular responses to 2-FaraA. DNA-
damage induced phosphorylation of H2A.x at serine 139 and residue specific phosphorylation 
of TP53, NCL and DDX21. We found de-phosphorylation of proteins of the SNARP 
complex with decreased cyclin D1; the p53 interactome could regulate this complex. 
Phosphorylation of HSP90 at serine 254 by CSNK2a1 may induce dissociation of the HSP90-
p53 complex occurs after 2-FaraA treatment. Pathway analysis of the phospho-interactome 
indicated that 2-FaraA may dysregulate ribosome biogenesis, essential for cell survival. 
Upstream molecule analysis using IPA indicated retinoic acid receptors may play a role in 2-
FaraA induced apoptosis; treatment with all trans-retinoic acid inhibits proliferation and 
induces apoptosis in 2-FaraA resistant MEC1 cells. The results indicate that ATRA may 
enhance the therapeutic effects of 2-FaraA. 
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CHAPTER SIX 
Effects of siRNA knockdown of p53 on 2-FaraA induced 
apoptosis
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6.1 INTRODUCTION 
Previous chapters have demonstrated the responses of p53 and related proteins in 2-FaraA 
induced apoptosis in B-lymphoid cancers. This chapter will focus on the proteomic effects of 
p53 knockdown in 2-FaraA treated Raji and IM9 cell lines using quantitative iTRAQ 
labelling. Apoptosis in response to 2–FaraA and ATRA in p53 knock-down in Raji and 
MEC1 cells will be measured using the Annexin V-PE/7-AAD kit (BD Bioscience). This 
study could identify p53-independent mechanisms in 2-FaraA responsive cell lines, or 
mechanisms of drug resistance in p53 null cells. 
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6.2 METHODS 
Raji, IM9 and MEC1 cells were grown in RPMI medium minus gentamycin. Cells were transiently 
transfected with p53 siRNA using Lipofectamine RNAiMax and incubated for 24 h. p53 knockdown 
was confirmed using Western blotting. The transfected cells were harvested and re-cultured in RPMI 
with gentamycin and treated with 2-FaraA (1 µM, 24 h). Proteins were extracted and analysed by 8-
plex iTRAQ on a QSTAR Elite mass spectrometer. ProteinPilot 3.0 software (Paragonalgorithm) 
was used to assign protein IDs and determine ratios for differential expression. Data were combined 
using Microsoft Exceland proteins of interest were assignedbiological pathways using Ingenuity 
Pathway Analysis software (IPA; Ingenuity® Systems, USA; www.ingenuity.com). Apoptosis was 
determined by measuring the externalisation of phosphatidyl serine using Annexin V-PE with 
analysis by flow cytometry. 
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6.3 RESULTS 
6.3.1 Proteomic changes in response to 2-FaraA with p53 knockdown  
The 2-FaraA-responsive cells (Raji and IM9) were transfected with small interfering RNA (siRNA) 
made by Life Technologies (Invitrogen) using a lipid-based transfection system. Figure 6.1A shows 
the mRNA sequence of p53, boxed areas are regions where the respective siRNAs bind to silence 
translation of the TP53 gene. After transfection, p53 knockdown was validated by Western blotting 
using p53 antibody (DO1, Figure 6.1B). In Raji and IM9 cells, RNA 2 and RNA 1, respectively, 
gave the most efficient p53 knock-down. These respective RNase were used to conduct transfections 
for the cell lines for subsequent proteomic analysis using ITRAQ. Cells transfected with scrambled 
RNA sequence was used for each cell line and treatment condition as a negative control. Table 6.1 
summarises all the differentially abundant proteins that have opposite expressions (increase and 
decrease in abundance) when comparing p53 knockdown cells and control RNA cells. Proteins with 
increased abundance (fold-change >1.5) in knock-down cells and decreased abundance (fold-change 
<0.66) in control cells after 2-FaraA include PSMD12, ACTR2, BID, CORO7, COX2, HLA-DQB1, 
ICAM1, NGDN, KIAA0020, and YY1. Proteins decreased in knockdown cells but increased in 
control cells include RPS16, RPS9, DCTN2, EIF2A, EIF4E, FDPS, NAP1L1, PLIN3, PSMA2, 
SFPQ, UBE2K and EZR. IPA analysis of these differentially abundant proteins suggests several 
interesting mechanisms (Figure 6.2) such as the activation of the p38 MAPK pathway as well as an 
increase extracellular VEGF.  
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Figure 6.1 siRNA p53 knock-down (A) p53 RNA sequence for open reading frame coding region. The boxed regions 
show respective areas where the three different siRNA bind. (B) Western blots for p53 and actin (n=2), performed using 
p53 antibody (clone DO1). The PVDF membrane was then stripped and blotted with antibody against actin (clone C-2) 
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Table 6.1 Differentially abundant proteins in Raji and IM9 cell lines treated with 2-FaraA with and without p53 knockdown  
Accession Name 
% 
coverage 
Peptides 
(95%) 
Fold-change (± 2-FaraA)    
p53 
knockdown 
Negative 
control  
p-value 
O00232 26S proteasome non-ATPase regulatory subunit 12 (PSMD12) 16.5 4 3.76 0.36 0.167 
P62249 40S ribosomal protein S16  (RPS16) 60.3 12 0.31 1.75 0.041 
P46781 40S ribosomal protein S9 (RPS9) 54.1 14 0.23 2.42 0.012 
F5H6T1 Actin-related protein 2 (ACTR2) 27.5 6 2.32 0.27 0.013 
P55957 BH3-interacting domain death agonist (BID) 36.4 6 2.45 0.64 0.038 
I3L416 Coronin-7 (CORO7) 10 4 2.28 1.45 0.017 
P00403 Cytochrome c oxidase subunit 2 (COX2) 17.6 6 1.80 0.65 0.118 
F8WAG8 Dynactin subunit 2 (DCTN2) 39.3 12 0.41 2.51 0.001 
P05198 Eukaryotic translation initiation factor 2 (EIF2A) 24.8 5 0.24 1.99 0.016 
D6RBW1 Eukaryotic translation initiation factor 4E (EIF4E) 12.2 2 0.28 2.39 0.004 
E9PCI9 Farnesyl pyrophosphate synthase (FDPS) 16.2 3 0.40 5.39 0.001 
Q5Y7D3 HLA class II antigen, DQ (HLA-DQB1) 29.9 8 4.07 0.48 0.011 
P05362 Intercellular adhesion molecule 1 (ICAM1) 7.1 3 3.73 0.58 0.002 
Q8NEJ9 Neuroguidin (NGDN) 29.2 4 8.40 0.41 0.082 
P55209 Nucleosome assembly protein 1-like 1 (NAP1L1) 62.9 51 0.22 7.44 0.040 
O60664 Perilipin-3 (PLIN3) 26.3 7 0.40 4.91 0.001 
P25787 Proteasome subunit alpha type-2 (PSMA2) 31.2 11 0.16 3.30 0.000 
Q15397 Pumilio domain-containing protein (KIAA0020) 4.9 2 2.40 0.49 0.026 
P23246 Splicing factor, proline- and glutamine-rich (SFPQ) 45.8 38 0.39 2.48 0.017 
P25490 Transcriptional repressor protein YY1 (YY1) 10.6 2 2.32 0.74 0.016 
P61086 Ubiquitin-conjugating enzyme E2 K (UBE2K) 42 7 0.19 2.61 0.013 
P15311 Ezrin (EZR) 61.6 40 0.30 1.80 0.006 
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Figure 6.2 Ingenuity Pathway Analysis network of differentially abundant proteins induced after 2-FaraA 
treatment in p53 knock-down cells. Proteins in red represent increased abundance, and green a decrease in 
abundance in the p53 interactome. Molecules in orange are predicted to be activated and blue inhibited based on 
the differential abundance of proteins in the dataset and current knowledge.  
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6.3.2 p53 knockdown inhibits 2-FaraA and ATRA induced apoptosis  
2-FaraA-responsive cells (Raji) and resistant cells (MEC1) were transfected with a negative 
control RNA sequence, or p53 siRNA 1 or 2, and treated with 2-FaraA (3 µM, 24 h) plus 
ATRA (1 µM, 24 h). The staining with Annexin V of cell lines with different drug treatments 
is shown in Figure 6.3. For MEC1, cells treated with control RNA, the combination of 2-
FaraA + ATRA increased the exposure of phosphatidyl serine (PS) similar to Figure 5.8 in 
Chapter 5. In cells transfected with siRNA against p53, 2-FaraA + ATRA no longer induced 
an increase in Annexin V binding. For Raji cells with control RNA 2-FaraA + ATRA 
induced Annexin V binding. In p53 knock-down cells, neither drug had an effect.  
Table 6.2 summarises the percentage of cells viable, apoptotic (Annexin V binding to PS) and 
dead (7-AAD binding to cellular DNA). In MEC1, only treatment with 2-FaraA + ATRA 
induced apoptosis. In cells with control RNA, cells with no treatment had a total of  5% 
apoptotic and 10% dead compared to the 7.3% apoptotic and 17% dead cells in 2-FaraA 
treated. In the p53 knock-down MEC1 cells, there was no increase of apoptosis when 
comparing treated to untreated samples. In Raji cells with control RNA, 2-FaraA treated cells 
were 12% apoptotic and 11% dead and 2-FaraA + ATRA treated cells were 9% apoptotic and 
9.5% dead compared to control cells where only 2.5% were apoptotic and 3.3% were dead. 
After p53 knockdown the treatment was no longer effective.  
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Figure 6.3 Effect of p53 knock-down on apoptosis induced in MEC1 and Raji cells by 2-FaraA ± ATRA. Apoptosis was determined by measuring the externalisation of 
phosphatidyl serine using Annexin V-PE. MEC1 and Raji cells were treated with 2-FaraA (3 µM, 24 h) ±ATRA (1 µM, 24 h). The grey area represents untreated cells; the 
black line represents cells incubated with 2-FaraA ±ATRA. A shift in the median fluorescence intensity indicates an increase in externalised phosphatidyl serine (apoptosis).  
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Table 6.2 Determination of percentage of viable, apoptotic and dead cells using the Annexin V-PE and 7-AAD kit 
    Control RNA  RNA 1  RNA 2 
  (%) Control   2-FaraA 2-FaraA +ATRA Control  2-FaraA 
2-FaraA 
+ATRA Control  2-FaraA 
2-FaraA 
+ATRA 
MEC1 
Viable 85.00 85 75 81 92 95 94 87 93 
Apoptotic 5.00 5.8 7.3 8 3.5 1.5 2 5 3 
Dead 10.00 9 17 11 4.3 3.5 4 8 4 
Raji 
Viable 94.00 77 81 87 87 86 80 86 86 
Apoptotic 2.50 12 9 6.8 6.4 7.7 12 5.7 8.1 
Dead 3.30 11 9.5 6 6 5.6 8 8.1 5.8 
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6.4 DISCUSSION 
 
6.4.1 The role of YY1 in 2-FaraA response in p53 knocked-down Raji and IM9 cells 
Expression of the transcription repressor Ying Yan 1 (YY1) increased 2.3-fold in cells with 
siRNA knock-down of p53. YY1 promotes formation of a p53 MDM2 complex inducing 
ubiquitination of p53 [193]. YY1 siRNA knockdown induces p53 and subsequent apoptosis 
in HeLa cells [194]. Our data show a complementary effect where knock-down of p53 
increases YY1 protein levels and prevents apoptosis of B-cell lymphomas (Figures 6.3 and 
6.4).  
An increase in YY1 would increase in extracellular vascular endothelial growth factor 
(VEGF, Figure 6.2). VEGF mediates angiogenesis in tumours and is a target for cancer 
therapy. YY1 forms an active complex with hypoxia-inducible factor (HIF) 1α to activate 
VEGF gene expression [195]. The role of HIF1α in CLL survival is attributed to induction of 
VEGF [196]. CLL cells constitutively express HIF-1α under normoxia. HIF-1α is able to 
form an active complex with the transcriptional coactivator p300 and phosphorylated-STAT3 
at the VEGF promoter and to recruit RNA polymerase II [197]. High VEGF levels elevate the 
tissue neovascularization in the marrow [198] and lymph nodes [199] of patients with CLL. 
Studies in non-Hodgkin’s lymphoma showed that VEGF serum level is increased in active 
lymphomas [200]. In addition, VEGF increases expression of human ICAM1 mRNA in 
cultured HUVEC cells [201, 202] we have observed an increase of ICAM1 in B-cell 
lymphomas (Figure 6.2). Thus the increase in YY1 and predicted increase in VEGF may 
contribute to the chemo-resistance and cell survival in p53 knock-down cells.  
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6.4.2 Regulation of surface antigens on p53 knock-down cells may increase survival  
ICAM1 (CD54) is up-regulated (3.7-fold, Table 6.1) in p53 knock-down (chemo-resistant) 
Raji and IM9 cells after 2-FaraA treatment. This effect is similar to the observations made in 
Chapter 3 (Table 3.4) where CLL cells grown on a feeder layer become 2-FaraA-resistant and 
up-regulate CD54 (4.2-fold). Thus the mechanism of chemo-resistance in both cases may be 
linked to increases in CD54. ICAM1 modulates cell–cell and cell–matrix adhesion and has 
roles in inflammation [203]. Studies with human endothelial cells show that ICAM-1 and 
VEGF synergise to promote production of each other [204] and metastatic potential [205]. 
For B-cell leukaemias, increased ICAM1 correlates with disease progression [206].  
The observed increases in YY1, ICAM1, HLA-DQB1, KIAA0020 and PSMD12 would 
contribute to inhibition of CD3 activity (Figure 6.2). In T-lymphocytes, CD3 antibody 
increases transcription of the YY1 gene [207], increases ICAM1 [208, 209] and increased 
mRNAs of PSMD12, KIAA0020, HLA-DQB1 [210]. Tsoukas et al. show that in T-
lymphocytes, inhibition of CD3 by binding to CD3 antibody induces proliferation of the cells 
in response to IL-2 [211]. Our study used B-lymphoid cell lines that may aberrantly express 
T-cell markers such as CD3 [212], although little is known about the biological significance. 
For these B-lymphoid cell lines, CD3 is predicted to be down-regulated after p53 knock-
down (Figure 6.2) increasing cell viability in p53 knock-down cells (Figure 6.5). We 
hypothesise that down-regulation of CD3 on B-lymphomas after p53 knock-down would 
stimulate cell proliferation as for T-lymphomas. For the ITRAQ analysis the transfections 
were performed in 3 biological replicates for each cell line and treatment condition, however 
due to the extremely low yield of transfected cells, replicate cells from each condition had to 
be combined for the ITRAQ analysis. Thus there was only one technical replicate. This 
limitation should be considered when assessing the results. In addition, the candidates in this 
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study need to be further validated using techniques such as western blotting or flow 
cytometry, without which this discussion remains speculative in nature.  
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6.5  CONCLUSIONS 
Comparison of the effects of 2-FaraA treatment of siRNA p53 knock-down and control RNA 
in Raji and IM9 cells showed a differentially regulated subset of proteins. We compiled a 
protein list with opposite effects between knockdown and control RNA, i.e. an increase in 
abundance in knock-down but decrease in abundance in control RNA cells. Proteins up-
regulated in p53 knock-down cells included the p53 antagonist, transcription factor YY1 
which may lead to an extracellular increase of VEGF contributing to increases cell survival 
after knock-down. The surface antigen ICAM1 (CD54) is also up-regulated and could 
modulate metastatic potential. The up-regulation of oncogenic transcription factor YY1 and 
the increase of adhesion molecule ICAM1 may change the biochemistry of the cells and 
allow them to become resistant to 2-FaraA-induced apoptosis in p53 knock-down cells. 
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CHAPTER SEVEN 
Summary and Future Directions
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7.1 PURPOSE OF THE STUDY 
The tumour suppressor protein p53, is a transcription factor responsible for regulating the cell 
cycle and/or apoptosis in proliferating cells that may be subjected to a variety of stressful 
events, including DNA damage. Mutations of p53 occur in >50% of human tumours, TP53 is 
the most frequently altered gene in cancers [213, 214]. p53 is not only the ‘master watchman 
of the genome’, but is also important for the response to many chemotherapeutic agents 
[215]. However, proteins rarely act alone and p53 is involved in multiple molecular events in 
various sub-cellular locations. Research into the p53 regulatory network provides a better 
understanding of the ‘p53-centric’ cellular responses to chemotherapy-induced DNA-damage 
in cancer. The overall purpose of this thesis was to contribute to our understanding of the 
treatment of B-lymphoid cancers by 1) looking at the response of p53 and the family proteins 
p63 and p73, after 2-FaraA induced DNA-damage, 2) compare the p53 interactome following 
DNA damage in cells with and without mutations in p53, 3) study the DNA-damage 
phosphorylation cascades in the p53 interactome and 4) analyse the effects of p53 knock-
down on fludarabine-responsive cells. Detailed below are the novel p53-centric mechanisms 
and network events elucidated in this study that may be involved in 2-FaraA-induced DNA-
damage in B-lymphoid cancers. 
 
7.2 P53, P63, P73 RESPONSES TO 2-FARAA 
Henrich and Christopherson (2008) showed that p53 accumulates in the nuclei of Raji cells 
treated with 2-FaraA (3 µM, 24 h), prior to apoptosis. As an extension of these observations, 
we demonstrate here that the 2-FaraA-sensitive cell lines, Raji and IM9, accumulate p53 in 
their nuclei, mitochondria and cytosol. p53 accumulates at the mitochondria of Raji earlier 
than in the nucleus suggesting that initiation of apoptosis in these cells may be dependent on 
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the roles of p53 at mitochondria, prior to effects on gene expression in the nucleus. In Raji 
cells, accumulation of p53 is attributed to increased de novo p53 protein expression with the 
concomitant increase in mRNA levels, and to inhibition of p53 degradation due to 
phosphorylation. 2-FaraA also induces phosphorylation and accumulation of lower molecular 
weight derivatives of p53, p63 and p73 in the nuclei of Raji cells that may have roles in 
inducing apoptosis. Several distinct molecular weight and phosphorylated forms of p63 exist 
in the nuclear, mitochondrial and cytosolic fractions of Raji following 2-FaraA treatment. 1D 
Western blots showed that mitochondrial p63 in the 2-FaraA-sensitive cell lines (Raji and 
IM9), exists as dimers and tetramers, while in the cell lines resistant to 2-FaraA (MEC1 and 
U266), p63 is found as a monomer. These data provide further insight into the effects and 
mechanisms of action of 2-FaraA, and define patterns of response of the p53 family members 
in sub-cellular compartments of B-lymphoid cancers. 
 
7.3 INTERACTION OF HSP90 WITH P53  
We used mass spectrometry and Western blotting to observe dissociation of HSP90 from p53 
in response to 2-FaraA treatment (Figures 4.4 and 4.5). Interaction of HSP90 with p53 has 
been reported. Structural analysis has shown that the DNA-binding domain of p53 interacts 
with the middle and C-terminal domains of HSP90 [216, 217]. Walerych et al. showed that in 
human fibroblasts, HSP90 forms a complex with wild-type p53 partially unfolding it and 
preventing p53 regulation of p21 gene expression. Treatment with HSP90 inhibitors 
promoted the transcriptional activities of p53 [159]. Additionally, Lin et al. showed that 
treatment with the HSP90 inhibitor geldanamycin restored the functionality of mutated p53 
[218]. Our study shows for the first time that in the human B-cell lines Raji and IM9, 
treatment with 2-FaraA dissociates HSP90 from p53. This does not occur in the p53-mutated 
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MEC1 cell line, however, treatment of MEC1 with the HSP90 inhibitor AUY922, did result 
in a significant increase in the expression of p21 and p27, known p53 targets. In addition, in 
MEC1 cells the combination of 2-FaraA with AUY922 was synergistic in inducing apoptosis 
(Figures 4.6 and 4.7). Taken together, these data suggest that HSP90 may negatively regulate 
the function of p53 in both 2-FaraA-responsive and resistant cells. HSP90 inhibition may 
restore sensitivity to DNA damaging agents in tumour cells with truncated forms of p53 
releasing p53 from a misfolded state [218]. HSP90 and p53 undergo post-translational 
modifications that mediate their interactions with other binding partners. HSP90 and p53 are 
both phosphoproteins, containing several phospho-residues. Using a phospho-proteomic 
approach, we found phosphorylation of HSP90 at serine 254 (Table 5.1 and Supplementary 
Figure S5.1). This phosphorylation of HSP90 has been shown to modulate the affinity of 
HSP90 for apoptotic protease activating factor 1 (APAF1). In leukaemias, reduced 
phosphorylation of serine 254 of HSP90 strengthens the HSP90–APAF1 complex [185]. In 
the context of the current study, phosphorylation at HSP90 at serine 254 may reduce the 
availability of HSP90 to bind p53 resulting in release of p53 to induce apoptosis. Motif 
analysis programs indicate that casein kinase 2 alpha 1 (CSNK2a1) is primarily responsible 
for the HSP90 phosphorylation at Serine 254 (Table 5.1, Figure 5.6 C), suggesting that 
activation of CSNK2a1 may enhance chemotherapeutic efficacy.  
 
7.4 RIBOSOME BIOGENESIS  
Ribosome biogenesis is essential for cell survival. Defects in ribosome production result in 
p53 stabilization and induce p53-dependent inhibition of cell proliferation. Dysregulation of 
ribosome biogenesis results in release of RPL5, RPL11 and RPL23. These ribosomal proteins 
bind to MDM2 causing its dissociation from p53 [186, 187]. We show that 2-FaraA treatment 
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reduces the levels of RPL11 (Supplementary Table 5.2) and RPL23 (Chapter 4, Figure 4.4) 
present in the p53 interactome, that in turn is likely to decrease the level of Mdm2. In 
addition, we observed the differential phosphorylation of proteins involved with the 
production of rRNA (Figure 5.5). The production of 5.8S rRNA is an essential step in 
ribosomal biogenesis [187] and is predicted to be inhibited in our study. Lastly we observe 
the phosphorylation of Histone H1.4 at residue serine 187. Studies show that such 
phosphorylation regulates transcription of ribosomal and steroid hormone-responsive genes 
[188] that may also regulate rRNA. This is the first study to document the effects of 2-FaraA 
on ribosomal biogenesis in B-lymphoid cancer cell lines.  
 
7.5 RETINOIC ACID INDUCED APOPTOSIS IN 2-FARAA RESISTANT CELLS 
Upstream molecule analysis of post translational regulation, of a subset of proteins found in 
our phosphoproteomic study indicates the up-regulation of pathways involved in response to 
synthetic retinoic acid (CD473) treatment, after 2-FaraA treatment. As no synthetic retinoic 
acids were added to the cells, natural cellular retinoic acid (RA) and its receptors may 
underlie 2-FaraA-induced apoptosis. To test this hypothesis, Western blots of RARα were 
conducted on extracts from Raji and MEC1 cells before and after 2-FaraA (Supplementary 
Figure S5.2). These results indicate that RARs and naturally occurring RA may indeed have 
roles in 2-FaraA-induced apoptosis. Previously published studies support this hypothesis, 
demonstrating that for acute myeloid leukemia (AML) cells, treatment with 2-FaraA + all-
trans RA (ATRA) induced more apoptosis than fludarabine alone, and suggested that ATRA 
may induce p53–independent apoptosis in AML cells [191, 192]. Co-administration of 
ATRA and 2-FaraA in our study showed that the combination does induce apoptosis in the 
p53 mutant MEC1 cell line while either drug as a single agent does not (Figure5.8).  
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7.6 SUMMARY OF OUTCOMES  
This project revealed some interesting cellular mechanisms by which apoptosis may be 
induced in cells responsive to 2-FaraA (Raji and IM9). Figure 7.1 illustrates the p53-centric 
mechanisms in the cells after treatment. 2-FaraA is incorporated into DNA and induces strand 
breaks. This triggers the accumulation of kinases and phosphatases and other proteins 
involved in the regulation of transcription. Together they result in the accumulation and 
phosphorylation of p53, p63 and p73 in the nucleus that control the transcription of proteins 
required for apoptosis and cell cycle arrest. We demonstrated that kinase activation results in 
the phosphorylation of HSP90 in the cytosol that causes dissociation of HSP90-p53 
complexes. Cytosolic p53 is then free to either translocate to the nucleus or mitochondria to 
induce apoptosis via MOMP or regulate energy metabolism. Kinase activation also 
phosphorylates H2AX, which is an essential step in the DNA repair process. Our data also 
showed de-phosphorylation of the SNARP complex in the cells following 2-FaraA-treatment, 
known to be responsible for cyclin D1 mRNA stability. The resulting decrease in cyclin D1 
levels is likely to result in cell cycle arrest. We have also shown that 2-FaraA induced DNA 
damage induces the post-translational regulation (de/phosphorylation) of proteins involved in 
ribosomal biogenesis, leading to dysregulation of this process. 
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Figure 7.1 Schematic of the p53-centric 
mechanisms of 2-FaraA induced apoptosis. 
2-FaraA is incorporated into DNA and 
induces strand breaks. This triggers the 
accumulation of kinases, phosphatases and 
proteins involved in the regulation of 
transcription. Resulting in accumulation and 
phosphorylation of p53, p63 and p73 in the 
nucleus of the cell and transcription of 
proteins required for apoptosis and cell 
cycle arrest. Phosphorylation of HSP90 in 
the cytosol causes dissociation of HSP90-
p53 complexes. Cytosolic p53 may 
translocate to the nucleus or the 
mitochondria to induce apoptosis via 
MOMP or regulate energy metabolism. 
Phosphorylated H2AX, aids in the DNA 
repair process. 
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7.7 FUTURE DIRECTIONS 
This thesis proposes novel p53-centric mechanisms that underlie 2-FaraA-induced apoptosis 
in B-lymphoid cancers. Protein phosphorylation plays a major role in this model. One 
approach to further validate the outcomes would be to inhibit the kinases identified using 
commercially available inhibitors or siRNA knockdown. Then using proteomic approaches, it 
might be possible to identify the impact of these kinases on the sensitivity of cells to 2-FaraA.  
One step further would be to determine the roles of specific sites of phosphorylation using 
site-specific mutagenesis to mutate these sites on a protein. For example, our data suggest 
that mutation of serine 254 in HSP90 would likely affect the response of Raji cells to 2-
FaraA, as HSP90 could not be phosphorylated resulting in an inability to dissociate from p53.  
 
ICAM1 (CD54), a plasma membrane protein, was significantly higher in 2-FaraA-resistant 
cells, following either p53 knockdown or co-culture of primary CLL cells with a CD40L 
feeder layer. Expression of this antigen may be a key marker for therapeutic outcome with 2-
FaraA as it increases in cells that acquire 2-FaraA resistance. It would be interesting to 
investigate whether CD54 levels on B-CLL of patients correlated with resistance to 2-FaraA 
using a high-throughput flow cytometry assay. Further studies might determine whether 
blocking signalling through CD54, using a CD54 monoclonal antibody, enhances sensitivity 
to 2-FaraA.  
 
Similarly, in p53 knockdown cells, there is an increase in the transcription factor YY1, a 
known proto-oncogene. In p53 mutant cells, it would be interesting to explore combination 
treatments that target the YY1 pathway such as the proteasome inhibitor NPI-0052 
(salinosporamide A) [219], plus 2-FaraA.  
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p53 has been heavily researched in cancer studies since its discovery by Sir David Lane in 
1979 [44] with over 67,000 published studies. In this thesis, we have contributed further 
novel data to add to p53 mechanisms with B-lymphoid cancers and 2-FaraA treatment. 
Further research may lead to advanced treatment strategies for patients suffering from B-
lymphoid cancers. 
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MATERIALS COMPANIES 
2-Fluoroadenine-9-β-D-arabinofuranoside Sigma-Aldrich (St. Louis, MO, USA) 
2-Mercaptoethanol Bio-Rad (Hercules, CA, USA) 
3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) 
Sigma-Aldrich (St. Louis, MO, USA) 
3-[N-Morpholine]propanesulfonic acid (MOPS) Sigma-Aldrich (St. Louis, MO, USA) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES buffer) 
Sigma-Aldrich (St. Louis, MO, USA) 
Acrylamide/Bis solution, 40%, 37.5 1 (2.6% C) Bio-Rad (Hercules, CA, USA) 
Agarose biotech grade Sigma-Aldrich (St. Louis, MO, USA) 
all trans-RETINOIC ACID Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium chloride (NH4Cl) Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium hydroxide solution (NH4OH) Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium persulfate (APS) Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium sulfate [(NH4)2SO4] Sigma-Aldrich (St. Louis, MO, USA) 
Benzonase Sigma-Aldrich (St. Louis, MO, USA) 
Bio-Lyte 3–10 carrier ampholytes Bio-Rad (Hercules, CA, USA) 
Bis[sulfosuccinimidyl] suberate (BS3) Thermo Scientific (Rockford, IL USA) 
Bovine serum albumin (BSA) Sigma-Aldrich (St. Louis, MO, USA) 
Bromophenol blue Sigma-Aldrich (St. Louis, MO, USA) 
Calcium chloride (CaCl2) 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Calf intestinal alkaline phosphatase (CIP) Kit 
New England Biolabs (Ipswich, MA, 
USA) 
Caspase Inhibitor Z-VAD-FMK Promega (Sydney, NSW, Australia) 
Coomassie G-250 Sigma-Aldrich (St. Louis, MO, USA) 
Countess TM automated cell counter system 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Criterion XT Bis-Tris Gel Bio-Rad (Hercules, CA, USA) 
Diethyl pyrocarbonate (DEPC) Sigma-Aldrich (St. Louis, MO, USA) 
Dimethyl sulfoxide (DMSO) Merck Pty Ltd (Kilsyth, VIC, Australia) 
Diploma Instant Skim Milk Powder Fonterra Foodservice (North Ryde, 
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NSW, Australia) 
Dithiothreitol (DTT) Sigma-Aldrich (St. Louis, MO, USA) 
Dithiothreitol (DTT) Sigma-Aldrich (St. Louis, MO, USA) 
DNAse, RNAse free cell culture flasks (25 cm2, 
75 cm2 and 175 cm2) 
Greiner (Frickenhausen, Germany) 
Dynabeads Protein G 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Ethanol 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Ethidium Bromide (EtBr)  10mg/ml 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (St. Louis, MO, USA) 
Fast SYBER Green Master Mix 
Applied Biosystems (Carlsbad, CA, 
USA) 
Foetal Calf Serum (FCS) 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
JRH Biosciences inc.(Lenexa, USA) 
Formaldehyde Sigma-Aldrich (St. Louis, MO, USA) 
Formamide Sigma-Aldrich (St. Louis, MO, USA) 
Forward and reverse primers Sigma-Aldrich (St. Louis, MO, USA) 
Gentamycin (50 mg/mL) 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Glycerol Sigma-Aldrich (St. Louis, MO, USA) 
Glycine Sigma-Aldrich (St. Louis, MO, USA) 
Glycolic acid Sigma-Aldrich (St. Louis, MO, USA) 
Halt Phosphatase Inhibitor Cocktail Thermo Scientific (Rockford, IL USA) 
Hydrochloric acid 32% (HCl) 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Immobilon-P PVDF membrane Millipore (Temecula, CA, USA) 
Lipofectamine RNAiMAX 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Magnesium dichloride (MgCl2) Ajax Finechem Pty Ltd (Auburn, NSW, 
156 | P a g e  
 
Australia) 
Methanol 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Mineral oil (biotechnology grade) Sigma-Aldrich (St. Louis, MO, USA) 
MMTS Thermo Scientific (Rockford, IL USA) 
N,N,N’,N’-tetramethylethyl-ethylenediamine 
(TEMED) 
Sigma-Aldrich (St. Louis, MO, USA) 
Okadaic acid Calbiochem (Darmstadt, Germany) 
Opti-MEM® Reduced Serum Medium 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Pan-caspase inhibitor Z-VAD-FMK BD Bioscience (San Jose, CA, USA) 
Paraformaldehyde powder, 95% Sigma-Aldrich (St. Louis, MO, USA) 
Phenylmethylsufonyl fluoride (PMSF) Sigma-Aldrich (St. Louis, MO, USA) 
Phosphoric acid Sigma-Aldrich (St. Louis, MO, USA) 
Pierce Trypsin Protease, MS Grade Thermo Scientific (Rockford, IL USA) 
Potassium chloride (KCl) 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Potassium hydrogen carbonate (KHCO3) 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Precision Plus Protein™ Dual Color molecular 
weight standards 
Bio-Rad (Hercules, CA, USA) 
Precission Plus Protein™ unstained molecular 
weight standards 
Bio-Rad (Hercules, CA, USA) 
Propidium iodide Sigma-Aldrich (St. Louis, MO, USA) 
Protease inhibitor cocktail Sigma-Aldrich (St. Louis, MO, USA) 
ReadyStrip™ IPG Strips Bio-Rad (Hercules, CA, USA) 
RNase A 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
RPMI-1640 medium HEPES modification Sigma-Aldrich (St. Louis, MO, USA) 
Saponin Sigma-Aldrich (St. Louis, MO, USA) 
Sodium cyanoborodeuteride (NaBD3CN) Sigma-Aldrich (St. Louis, MO, USA) 
Sodium cyanoborohydride (NaBH3CN) Sigma-Aldrich (St. Louis, MO, USA) 
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Sodium dodecyl sulfate (SDS) Sigma-Aldrich (St. Louis, MO, USA) 
Sodium fluoride (NaF) Sigma-Aldrich (St. Louis, MO, USA) 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich (St. Louis, MO, USA) 
Sucrose 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
Sulfobetaine 3–10 Sigma-Aldrich (St. Louis, MO, USA) 
Surfact-Amps® NP-40 Sigma-Aldrich (St. Louis, MO, USA) 
SYPRO®Ruby Protein Gel Stain 
Invitrogen Life Technologies 
(Mulgrave, NSW, Australia) 
Thiourea Sigma-Aldrich (St. Louis, MO, USA) 
Titansphere Titanium dioxide (TiO2) beads, (5μm) GL Science Inc, Japan 
Tributyl phosphine (TBP) Sigma-Aldrich (St. Louis, MO, USA) 
Triethyl Ammonium Bicarbonate (TEAB) Sigma-Aldrich (St. Louis, MO, USA) 
Tris (2-carboxyethyl) phosphine HCl (TCEP) Sigma-Aldrich (St. Louis, MO, USA) 
Tris-hydroxymethyl-methylamine (TRIS) 
Ajax Finechem Pty Ltd (Auburn, NSW, 
Australia) 
TRITM Reagent Solution Sigma-Aldrich (St. Louis, MO, USA) 
Triton-X-100 Sigma-Aldrich (St. Louis, MO, USA) 
Trypan Blue Solution (0.4%) Sigma-Aldrich (St. Louis, MO, USA) 
TWEEN® 20 Sigma-Aldrich (St. Louis, MO, USA) 
Urea Sigma-Aldrich (St. Louis, MO, USA) 
XT MES Running Buffer Bio-Rad (Hercules, CA, USA) 
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SUPPLEMENTARY DATA 
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Supplementary Figure SF3.1 1D Western blots for p53 family members in whole lysates of different cell lines 
treated with 2-FaraA (3 µM). Cells were harvested and lysed in Laemmli buffer. Changes in protein levels can 
be compared with changes in mRNA levels in Figure 3.6. 
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Supplementary Figure SF3.2 Differentially expressed antigens with p-value of < 0.05 in (A) media vs feeder 
co-culture, (B) media with 2-FaraA (C) feeder co-culture with 2-FaraA, after 24 h incubation. Standard error of 
mean (SEM) was used for error bars using 4 CLL samples and 2 technical replicates (n=8). 
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Supplementary Table ST4.1: List of p53 binding proteins identified in MEC1 (p53 
truncated) cells 
Uniprot ID Name Peptides (95%) 
Sequence 
coverage 
(%) 
Primary 
localisation Biological processes
IPI:IPI00337
387.3 
 Isoform 3 of Pre-
mRNA-processing 
factor 40 homolog A 
2 8.3 Nucleus  Nucleic acid metabolism 
IPI:IPI00607
818.2 
 MYH14 variant 
protein 28 31.1 Cytosol  
Cell 
growth/maintenance
IPI:IPI00844
172.1  Myosin 9 17.5 Cytosol  
Cell 
growth/maintenance
IPI:IPI00873
982.2 
 Myosin heavy chain 
11  41 44.4 Cytosol  
Cell 
growth/maintenance
HCD2 3-hydroxyacyl-CoA dehydrogenase type-2 2 18 
Mitochondri
a 
Metabolism ; Energy 
pathways 
RS10 40S ribosomal protein S10  2 14.6 Ribosome  Protein metabolism
RS15A 40S ribosomal protein S15a  5 46.2 Ribosome  Protein metabolism
RLA1 60S acidic ribosomal protein P1  5 63.2 Ribosome  Protein metabolism
RL26 60S ribosomal protein L26 3 35.9 Ribosome  Protein metabolism
RL28 60S ribosomal protein L28  2 15.3 Ribosome  Protein metabolism
RL31 60S ribosomal protein L31  2 25.6 Ribosome  Protein metabolism
IPI:IPI00790
339.1 
ACTG1 22 kDa 
protein 99 61.6 Cytosol  
Cell 
growth/maintenance
ACTC Actin, alpha cardiac muscle 1  27 57.8 Cytosol  
Cell 
growth/maintenance
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ACTH Actin, gamma-enteric 85 94.4 Cytosol  Cell growth/maintenance
IPI:IPI00470
573.1 
Actin-related protein 2 
isoform a 6 22.6 Cytosol  
Cell motility ; Cell 
growth/maintenance
ARF3 ADP-ribosylation factor 3  10 59.1 Cytosol  Cell signalling 
ARF5 ADP-ribosylation factor 5  5 45.6 Cytosol  Cell signalling 
A2MG Alpha-2-macroglobulin  2 6.2 Cytosol  Protein Metabolism
APOA1 Apolipoprotein A-I  8 33.3 Cytosol  Transport 
SYRC 
Arginyl-tRNA 
synthetase, 
cytoplasmic  
4 7.9 Cytosol  Protein metabolism
AKNA AT-hook-containing transcription factor  2 10.4 Nucleus  
Nucleic acid 
metabolism 
A8K2X8 Chaperonin containing TCP1, subunit 5  4 17.4 Cytosol  Protein metabolism
CCD61 Coiled-coil domain-containing protein 61 2 11.2 Unknown Unknown 
COR1A Coronin-1A  6 23.4 Cytosol  Cell growth/maintenance
MCM3 
DNA replication 
licensing factor 
MCM3  
2 7.9 Mitochondria unknown 
MCM5 
DNA replication 
licensing factor 
MCM5  
4 11.6 Nucleus   Nucleic acid metabolism 
DREB Drebrin  7 21 Cytosol  Cell growth/maintenance
EHD4 EH domain-containing protein 4  3 20.3 Cytosol  Cell signalling  
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FSCN1 Fascin  2 5.7 Cytosol  Cell growth/maintenance
GNAI2 
Guanine nucleotide-
binding protein G(i), 
alpha-2 subunit  
2 6.2 Cytosol  Cell signalling 
HSP71 Heat shock 70 kDa protein 1  4 31.5 Cytosol  Protein metabolism
Q86YQ1 Hemoglobin alpha-2  10 78 Cytosol  Transport 
Q5T6W5 Heterogeneous nuclear ribonucleoprotein K  6 25.2 Nucleus 
Nucleic acid 
metabolism 
H2AZ Histone H2A.Z  9 66.4 Nucleus Nucleic acid metabolism 
H2B1M Histone H2B type 1-M 2 19.1 Nucleus Nucleic acid metabolism 
H31 Histone H3.1  2 43.4 Nucleus Nucleic acid metabolism 
MX1 
Interferon-induced 
GTP-binding protein 
Mx1  
4 15.1 Cytosol  Cell signalling 
IPI:IPI00376
005.2 
Isoform 2 of 
Eukaryotic translation 
initiation factor 5A-1 
2 25.5 Cytosol  Protein metabolism
IPI:IPI00220
154.1 
Isoform 3 of Myosin-
Va 4 9.9 Cytosol  
Cell 
growth/maintenance
IPI:IPI00828
082.1 
Isoform 4 of Myosin-
XVIIIa 55 38.9 
Endoplasmic 
recticulum  
Cell 
growth/maintenance
KINH Kinesin-1 heavy chain 2 8 Mitochondria 
Cell 
growth/maintenance
IPI:IPI00425
404.2 
Kinesin-like protein 
KIF21A 8 15.9 Cytosol  
Cell 
growth/maintenance
KIF2C Kinesin-like protein KIF2C  2 5.5 Cytosol  
Cell 
growth/maintenance
Q549N7 Mutant beta-globin  12 74.2 Cytosol  Transport 
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MYL6B Myosin light chain 6B 9 66.4 Cytosol  Cell growth/maintenance
MRLC2 Myosin regulatory light chain MRLC2  37 79.7 Cytosol  
Cell 
growth/maintenance
MRLC3 Myosin regulatory light chain MRLC3  41 80.1 Cytosol  Cell signalling 
MYH11 Myosin-11  16 22.5 Cytosol  Cell growth/maintenance
MYO1C Myosin-Ic  6 13.1 Cytosol  Cell growth/maintenance
MYO1D Myosin-Id 16 21.6 Cytosol  Cell growth/maintenance
MYO1G Myosin-Ig  12 18.6 Cytosol  Cell growth/maintenance
OFD1 Oral-facial-digital syndrome 1 protein  3 18.6 Nucleus 
biological process 
unknown 
PCM1 Pericentriolar material 1 protein  7 13.4 Centrosome  
Cell 
growth/maintenance
PDIA1 Protein disulfide-isomerase  2 7.1 Cytosol  Protein metabolism 
RB11B Ras-related protein Rab-11B  2 17.9 Cytosol  Cell signalling 
RAB14 Ras-related protein Rab-14  2 26.1 Cytosol  Cell signalling 
RAB6A Ras-related protein Rab-6A  2 29.8 Cytosol  Cell signalling 
Q53G20 Ribosomal protein L14 variant  6 28 Ribosome  protein metabolism
Q59GK9 Ribosomal protein L21 variant  6 34.4 Ribosome  protein metabolism
Q6IPX5 Ribosomal protein S2 3 28.7 Ribosome  protein metabolism
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IPI:IPI00793
696.1 RPL24 19 kDa protein 4 45.2 Ribosome  Protein metabolism
IPI:IPI00872
430.1 RPS8 25 kDa protein 5 33.6 Cytosol  Protein metabolism
A4QN19 SEC16A protein  26 26.2 Endoplasmic recticulum  
Cell motility ; ER 
organization and 
biogenesis ; Protein 
transport 
STAT1 
Signal transducer and 
activator of 
transcription 1-
alpha/beta  
8 19.2 Cytosol  Nucleic acid metabolism 
SON SON protein 12 12.5 Cytosol  Nucleic acid metabolism 
SMC2 
Structural maintenance 
of chromosomes 
protein 2  
2 11.5 Mitochondria 
Biological processes 
unknown 
IPI:IPI00414
101.4 
TOP2A Isoform 2 of 
DNA topoisomerase 2-
alpha 
6 12.3 Nucleus Nucleic acid metabolism 
IPI:IPI00217
709.1 
TOP2B Isoform Beta-
1 of DNA 
topoisomerase 2-beta 
5 18.9 Cytosol  Nucleic acid metabolism 
SSRD Translocon-associated protein subunit delta  2 13.9 
Endoplasmic 
recticulum  Transport 
TMOD1 Tropomodulin-1  6 35.7 Cytosol  Cell growth/maintenance
PTN6 
Tyrosine-protein 
phosphatase non-
receptor type 6  
7 27.1 Cytosol  Cell signalling 
Q3MIH3 
Ubiquitin A-52 residue 
ribosomal protein 
fusion product 1 
2 60.2 Ribosome  protein metabolism
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Supplementary Table ST4.2: List of p53 binding proteins identified in Raji and IM9 cells 
following vehicle Control or 2-FaraA (3 µM, 24 h) and binding proteins unchanged following 
treatment.  
Uniprot 
ID Name 
Peptides 
(95%) 
Sequence 
coverage 
(%) 
Primary 
localisation 
Biological 
processes 
Control (Raji and IM9) 
A8K3Q9 Ribosomal protein L14 (RPL14) 4 22.7 Ribosomes 
Protein 
metabolism 
ATPB ATP synthase subunit beta, mitochondrial 6 30.4 Mitochondria 
 Energy 
pathways 
HS90B Heat shock protein HSP 90-beta 4 18.2 Cytosol Cell signalling 
IPI:IPI003
82470.3 
HSP90AA1 heat 
shock protein 90kDa 
alpha (cytosolic), class 
A member 1 isoform 1 
20 33.6 Cytosol Protein metabolism 
IPI:IPI007
93523.1 
RPL23A Putative 
uncharacterized 
protein RPL23A 
2 24.1 Cytosol Nucleic acid metabolism 
KPYM Pyruvate kinase isozymes M1/M2 12 34.8 Cytosol 
Energy 
pathways 
PO210 
Nuclear pore 
membrane 
glycoprotein 210 
2 4.9 Nucleus Transport 
ROA1L 
Heterogeneous 
nuclear 
ribonucleoprotein A1-
like protein 
3 21.3 Unknown Nucleic acid metabolism 
TAGL2 Transgelin-2 3 26.1 Unknown Unknown 
CLH1 Clathrin heavy chain 1 9 14.8 Cytosol 
Cell 
growth/mainten
ance 
DDX21 Nucleolar RNA helicase 2 4 19.2 Nucleolus 
 Energy 
pathways 
LPPRC 
Leucine-rich PPR 
motif-containing 
protein, mitochondrial 
2 12 Nucleus Nucleic acid metabolism 
NOL5 Nucleolar protein 5 2 4.5 Nucleolus Nucleic acid metabolism 
PYR1 CAD protein 5 8.4 Cytosol  Energy pathways 
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RL13 60S ribosomal protein L13 2 19 Ribosomes 
Protein 
metabolism 
RL26L 60S ribosomal protein L26-like 1 2 29.7 Ribosomes Unknown 
SYEP 
Bifunctional 
aminoacyl-tRNA 
synthetase 
2 7.8 Cytosol Protein metabolism 
2-FaraA (Raji and IM9) 
6PGD 
6-phosphogluconate 
dehydrogenase, 
decarboxylating 
2 12.8 Cytosol Energy pathways 
C1TC C-1-tetrahydrofolate synthase, Cytosolic 3 7.6 Cytosol 
Energy 
pathways 
DDX39 ATP-dependent RNA helicase DDX39 5 17.3 Nucleus 
Nucleic acid 
metabolism 
DYHC1 Cytosolic dynein 1 heavy chain 1 3 8.8 Cytosol 
Energy 
pathways 
GRHPR 
Glyoxylate 
reductase/hydroxypyr
uvate reductase 
2 11.6 Cytosol Energy pathways 
HNRH1 
Heterogeneous 
nuclear 
ribonucleoprotein H 
5 18.9 Nucleus Nucleic acid metabolism 
IPI:IPI001
76692.7 32 kDa protein 2 19.9 Unknown Unknown 
IPI:IPI008
48150.1 Tubulin beta1 10 57.6 Cytosol 
Cell 
growth/mainten
ance 
MY18A Myosin-XVIIIa 2 16.5 Cytosol 
Cell 
growth/mainten
ance 
MYH11 Myosin-11 18 45.3 Cytosol 
Cell 
growth/mainten
ance 
Q53HR5 Elongation factor 1-alpha (Fragment) 6 28.8 Cytosol 
Regulation of 
cell cycle 
Q5T6W5 
Heterogeneous 
nuclear 
ribonucleoprotein K 
3 10.1 Nucleus Nucleic acid metabolism 
RL6 60S ribosomal protein L6 6 33.3 Nucleolus 
Protein 
metabolism 
SPEE Spermidine synthase 2 10.6 Cytosol Energy pathways 
HNRPM 
Heterogeneous 
nuclear 
ribonucleoprotein M 
7 22.7 Nucleus Nucleic acid metabolism 
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MCM5 
DNA replication 
licensing factor 
MCM5 
2 8.2 Nucleus Nucleic acid metabolism 
In BOTH Control and Treated (Raji and IM9) 
C1QBP 
Complement 
component 1 Q 
subcomponent-
binding protein, 
mitochondrial 
2 11 Mitochondria Immune response 
CH60 60 kDa heat shock protein, mitochondrial 3 18.3 Cytosol 
Protein folding, 
Apoptosis and 
Signal 
transduction 
EFTU Elongation factor Tu, mitochondrial 6 23.2 Mitochondria 
Protein 
metabolism 
G3P 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
11 55.5 Cytosol Energy pathways 
HNRPU 
Heterogeneous 
nuclear 
ribonucleoprotein U 
7 18 Nucleus Nucleic acid metabolism 
LDHA 
L-lactate 
dehydrogenase A 
chain 
4 23.8 Cytosol Energy pathways 
LMNB1 Lamin-B1 OS=Homo sapiens 2 3.9 Nucleus 
Cell 
growth/mainten
ance 
MYH9 Myosin-9 OS=Homo sapiens 86 54.1 Cytosol 
Cell 
growth/mainten
ance 
PARP1 Poly [ADP-ribose] polymerase 1 12 24.7 Nucleus 
Protein 
metabolism 
PHB2 Prohibitin-2 5 33.1 Nucleus Nucleic acid metabolism 
PLSL Plastin-2 8 31.3 Cytosol Cell signalling 
PRKDC 
DNA-dependent 
protein kinase 
catalytic subunit 
23 17.3 Nucleus Cell signalling 
Q5UGI3 
Ubiquitin C splice 
variant - Homo 
sapiens 
4 71.9 Cytosol Protein metabolism 
SP16H FACT complex subunit SPT16 8 24.5 Nucleus 
Nucleic acid 
metabolism 
SYDC Aspartyl-tRNA synthetase, Cytosolic 2 21.4 Cytosol 
Protein 
metabolism 
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TBA1C Tubulin alpha-1C chain 12 40.1 Cytosol 
Cell 
growth/mainten
ance 
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Supplementary Figure SF4.1 BioMyn generated map of biological functions in the p53 interactomes of IM9 in Control and 2-FaraA treated cells. The size of the boxes is an 
indication of the number of proteins in each category 
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Supplementary Figure SF5.1 Spectra of 2 peptides of HSP90 (A) unmodified and (B) phosphorylated (ser254) 
using stable isotopic dimethyl labelling. Indicated are the light-labeled (L) peptides from vehicle control cells 
and the heavy-labeled (H) peptides from 2-FaraA treatment. (C) MS/MS ion spectra of phosphopeptide 
IEDVGSDEEDDSGK (D) western blots using antibody against phospho S254 of HSP90 and loading control 
actin after 2-FaraA treatment (24 h, 3 µM).  
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Supplementary Figure SF5.2 Western blots of RARα with loading control actin in MEC1 and Raji cells 
after 2-FaraA, 24 h. 
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Supplementary Figure SF5.3 Sulforhodamine B Assay for Raji and MEC1 cells after (A) 24 h and (B) 48 h of 
treatment with all trans-retinoic acid. At 100% indicated by the dotted red line the number of cells in control 
and treated wells are equivalent indicating no effect.  
 
174 | P a g e  
 
 
Supplementary Figure SF5.4 Western blots of Cyclin D1 after 2-FaraA treatment of MEC1, Raji and IM9 
cells (24 h). 
 
Supplementary Table ST5.1 2-FaraA induced differential phosphorylation of peptides in 
Raji cells after 24 h treatment  
Accession Protein Names  
Gene 
Names Sequence Modification 
Ratio H/L 
normalized P-value
Q9NYF
8 
Bcl-2-associated 
transcription factor 1 BCLAF1 YSPSQNSPIHHIPSR 
Phospho 
(STY) 0.53 0.0249 
Q14137 Ribosome biogenesis protein BOP1 BOP1 
IGDEYAEDSSDEEDI
R 
2 Phospho 
(STY) 0.57 0.0278 
Q14137 Ribosome biogenesis protein BOP1 BOP1 SFIPSLVEK Unmodified 1.03 0.6148 
Q13185 Chromobox protein homolog 3 CBX3 RKSLSDSESDDSK 
2 Phospho 
(STY) 0.64 0.0003 
Q13185 Chromobox protein homolog 3 CBX3 KVEEAEPEEFVVEK Unmodified 1.05 0.8329 
Q9H6F
5 
Coiled-coil domain-
containing protein 
86 
CCDC86 ALVEFESNPEETREPGSPPSVQR 
Phospho 
(STY) 0.75 0.0235 
Q9H6F
5 
Coiled-coil domain-
containing protein 
86 
CCDC86 LQQGAGLESPQGQPEPGAASPQR 
Phospho 
(STY) 0.55 0.0093 
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Q14839 
Chromodomain-
helicase-DNA-
binding protein 4 
CHD4 MSQPGSPSPK Phospho (STY) 1.85 0.0259 
Q14247 Src substrate cortactin CTTN 
TQTPPVSPAPQPTEE
R 
2 Phospho 
(STY) 0.55 0.0230 
       
Q9NR3
0 
Nucleolar RNA 
helicase 2 DDX21 AEPSEVDMNSPK 
Phospho 
(STY) 0.71 0.0188 
Q9NR3
0 
Nucleolar RNA 
helicase 2 DDX21 GVTFLFPIQAK Unmodified 1.15 0.8663 
Q9NR3
0 
Nucleolar RNA 
helicase 2 DDX21 IGVPSATEIIK Unmodified 1.09 0.8591 
Q9NR3
0 
Nucleolar RNA 
helicase 2 DDX21 EGAFSNFPISEETIK Unmodified 1.09 0.5990 
P16104 Histone H2A.x H2AFX KATQASQEY Phospho (STY) 3.78 0.0420 
P16104 Histone H2A.x H2AFX TSATVGPK Unmodified 1.04 0.7849 
P16401 Histone H1.5 HIST1H1B ALAAGGYDVEK Unmodified 2.81 0.0187 
P16401 Histone H1.5 HIST1H1B ALAAGGYDVEK Unmodified 0.88 0.8353 
P16401 Histone H1.5 HIST1H1B ATGPPVSELITK Unmodified 0.77 0.2516 
P16401 Histone H1.5 HIST1H1B KALAAGGYDVEK Unmodified 1.25 0.9820 
P16401 Histone H1.5 HIST1H1B KATGPPVSELITK Unmodified 0.88 0.8174 
P16401 Histone H1.5 HIST1H1B 
SETAPAETATPAPVE
K Unmodified 1.04 0.0341 
P10412 Histone H1.4 HIST1H1E KAPKSPAK 
Phospho 
(STY) NaN 0.0026 
P10412 Histone H1.4 HIST1H1E KASGPPVSELITK 
Phospho 
(STY) 1.72 0.0398 
P10412 Histone H1.4 HIST1H1E SGVSLAALK Unmodified 1.36 0.5363 
P10412 Histone H1.4 HIST1H1E 
SETAPAAPAAPAPAE
K Unmodified 0.99 0.5267 
P10412 Histone H1.4 HIST1H1E GTGASGSFK Unmodified 2.45 0.8751 
P68431 Histone H3.1 HIST1H3A KSAPATGGVK 
Phospho 
(STY) 0.27 0.0216 
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P68431 Histone H3.1 HIST1H3A EIAQDFKTDLR Unmodified 0.10 0.0213 
P68431 Histone H3.1 HIST1H3A EIAQDFK Unmodified 0.82 0.4665 
P68431 Histone H3.1 HIST1H3A SAPATGGVK Unmodified 0.57 0.2753 
P68431 Histone H3.1 HIST1H3A RVTIMPK Unmodified 0.74 0.4548 
P68431 Histone H3.1 HIST1H3A STELLIR Unmodified 0.97 0.7265 
P68431 Histone H3.1 HIST1H3A YRPGTVALR Unmodified 0.83 0.6305 
P62805 Histone H4 HIST1H4A DAVTYTEHAK Unmodified 3.30 0.0279 
P62805 Histone H4 HIST1H4A DNIQGITK Unmodified 0.55 0.0097 
P62805 Histone H4 HIST1H4A TVTAMDVVYALKR 
Oxidation 
(M) 0.67 0.0395 
P62805 Histone H4 HIST1H4A DNIQGITKPAIR Unmodified 1.15 0.1936 
P62805 Histone H4 HIST1H4A VFLENVIR Unmodified 2.83 0.7431 
B4DR5
2 Histone H2B 
HIST2H
2BF HAVSEGTK Unmodified 6.51 0.0072 
B4DR5
2 Histone H2B 
HIST2H
2BF EIQTAVR Unmodified 3.65 0.6028 
B4DR5
2 Histone H2B 
HIST2H
2BF LLLPGELAK Unmodified 4.84 0.0951 
B4DR5
2 Histone H2B 
HIST2H
2BF IAGEASR Unmodified 2.00 0.7612 
P17096 
High mobility group 
protein HMG-
I/HMG-Y 
HMGA1 SSQPLASK Phospho (STY) 19.26 0.0066 
P17096 
High mobility group 
protein HMG-
I/HMG-Y 
HMGA1 EPSEVPTPK Unmodified 0.84 0.2241 
P17096 
High mobility group 
protein HMG-
I/HMG-Y 
HMGA1 KQPPVSPGTALVGSQK Unmodified 0.75 0.4337 
A6NEL
0 
Non-histone 
chromosomal protein 
HMG-14 
HMGN1 TEESPASDEAGEK 2 Phospho (STY) 0.58 0.0212 
A6NEL
0 
Non-histone 
chromosomal protein HMGN1 TEESPASDEAGEK Unmodified 0.96 0.7263 
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HMG-14 
Q1KM
D3 
Heterogeneous 
nuclear 
ribonucleoprotein U-
like protein 2 
HNRNP
UL2 SKPAGSDGER 
Phospho 
(STY) 0.60 0.0015 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 
IEDVGSDEEDDSGK
DK 
Phospho 
(STY) 2.02 0.0442 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 ADLINNLGTIAK Unmodified 1.29 0.9058 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 YIDQEELNK Unmodified 1.26 0.5478 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 EGLELPEDEEEK Unmodified 1.23 0.9829 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 GVVDSEDLPLNISR Unmodified 1.33 0.7723 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 IDIIPNPQER Unmodified 1.58 0.2931 
P08238 Heat shock protein HSP 90-beta 
HSP90A
B1 SLVSVTK Unmodified 1.93 0.3194 
Q96ST
2 
Protein IWS1 
homolog IWS1 EAEDSDSDDNIKR 
Phospho 
(STY) 0.62 0.0358 
P49736 
DNA replication 
licensing factor 
MCM2 
MCM2 GLLYDSDEEDEERPAR 
Phospho 
(STY) 1.76 0.0478 
J3QRS
3 
Myosin regulatory 
light chain 
12B;Myosin 
regulatory light 
polypeptide 
9;Myosin regulatory 
light chain 12A 
MYL12
B 
ATSNVFAMFDQSQI
QEFK 
Oxidation 
(M),Phospho 
(STY) 
0.56 0.0079 
J3QRS
3 
Myosin regulatory 
light chain 
12B;Myosin 
regulatory light 
polypeptide 
9;Myosin regulatory 
light chain 12A 
MYL12
B EAFNMIDQNR 
Oxidation 
(M) 0.74736 0.2912 
P19338 Nucleolin NCL TLVLSNLSYSATEETLQEVFEK Unmodified 2.04 0.0295 
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P19338 Nucleolin NCL VVVSPTKK Phospho (STY) 1.71 0.0353 
P19338 Nucleolin NCL ALELTGLK Unmodified 1.13 0.7806 
P19338 Nucleolin NCL ALVATPGK Unmodified 1.18 0.9394 
P19338 Nucleolin NCL GLSEDTTEETLK Unmodified 1.31 0.6919 
Q14978
-2 
Nucleolar and 
coiled-body 
phosphoprotein 1 
NOLC1 GSPRPQAPK Phospho (STY) 0.72 0.0056 
Q14978
-2 
Nucleolar and 
coiled-body 
phosphoprotein 1 
NOLC1 SPAVKPAAAPK Unmodified 1.12 0.839097468 
Q14978
-2 
Nucleolar and 
coiled-body 
phosphoprotein 1 
NOLC1 VVPSDLYPLVLGFLR Unmodified 0.90 0.1536 
Q9H1E
3 
Nuclear ubiquitous 
casein and cyclin-
dependent kinase 
substrate 1 
NUCKS
1 
NSQEDSEDSEDKDV
K 
2 Phospho 
(STY) 0.54 0.0354 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX GLPPSMER 
Oxidation 
(M),Phospho 
(STY) 
0.72 0.0452 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX DVYLSPR Phospho (STY) 0.67 0.0196 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX LFIGGLNTETNEK Unmodified 0.49 0.0245 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
RBMX ALEAVFGK Unmodified 0.55 0.2984 
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protein, X 
chromosome, N-
terminally processed 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX RGPPPPPR Unmodified 0.40 0.0696 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX SAPSGPVR Unmodified 1.12 0.9287 
P38159 
RNA-binding motif 
protein, X 
chromosome;RNA-
binding motif 
protein, X 
chromosome, N-
terminally processed 
RBMX VEQATKPSFESGR Unmodified 0.93 0.9367 
P05388 60S acidic ribosomal protein P0 RPLP0 
KEESEESDDDMGFG
LFD 
Oxidation 
(M),Phospho 
(STY) 
1.96 0.0478 
Q9NW
H9 
SAFB-like 
transcription 
modulator 
SLTM DGQDAIAQSPEKESK Phospho (STY) 0.71 0.0043 
E9PCT
1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM1 HRPSPPATPPPK 2 Phospho (STY) 0.51 0.0086 
E9PCT
1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM1 KAASPSPQSVR 2 Phospho (STY) 0.73 0.0430 
E9PCT
1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM1 RASPSPPPKR 2 Phospho (STY) 0.75 0.0471 
Q9UQ3
5 
Serine/arginine 
repetitive matrix 
protein 2 
SRRM2 SATRPSPSPER 2 Phospho (STY) 1.31 0.0403 
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E9PHK
9 Treacle protein TCOF1 
LGAGEGGEASVSPE
KTSTTSK 
Phospho 
(STY) 2.13 0.0150 
B0QYS
7 
Transcription factor 
EB TFEB 
VHGLPTTSPSGMNM
AELAQQVVK 
2 Oxidation 
(M),Phospho 
(STY) 
0.71 0.0204 
P11388
-4 
DNA topoisomerase 
2-alpha TOP2A KPSTSDDSDSNFEK 
2 Phospho 
(STY) 1.36 0.0479 
P11388
-4 
DNA topoisomerase 
2-alpha TOP2A TLAVSGLGVVGR Unmodified 1.27 0.9386 
P11388
-4 
DNA topoisomerase 
2-alpha TOP2A IFDEILVNAADNK Unmodified 1.33 0.8989 
P04637 Cellular tumour antigen p53 TP53 ALPNNTSSSPQPK 
Phospho 
(STY) 1.85 0.0460 
Q9BVJ
6 
U3 small nucleolar 
RNA-associated 
protein 14 homolog 
A 
UTP14A SELSQDAEPAGSQETK 
Phospho 
(STY) 3.49 0.0412 
Q8IWA
0 
WD repeat-
containing protein 
75 
WDR75 VQDTSNTGLGEDIIHQLSK 
Phospho 
(STY) 0.25 0.0053 
H0Y44
9 
Nuclease-sensitive 
element-binding 
protein 1 
YBX1 RPQYSNPPVQGEVMEGADNQGAGEQGR 
Oxidation 
(M) 0.52 0.0012 
 
Supplementary Table ST5.2 2-FaraA induced differential phosphorylation of peptides in 
IM9 cells after 24 h treatment  
Accession Protein Names Gene Names Sequence 
Modification
s 
Ratio H/L 
normalized
P-
value 
Q9NY61 Protein AATF AATF YLVDGTKPNAGSEEISSEDDELVEEK 
3 Phospho 
(STY) 0.53 0.0008 
Q9UKV3 
Apoptotic 
chromatin 
condensation 
inducer in the 
nucleus 
ACIN1 SKSPSPPR 2 Phospho (STY) 0.56 0.0089 
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Q02040 A-kinase anchor protein 17A 
AKAP1
7A VVPEDGSPEKR 
Phospho 
(STY) 0.61 0.0320 
Q9UIG0 Tyrosine-protein kinase BAZ1B BAZ1B 
LAEDEGDSEPEAVGQS
R 
Phospho 
(STY) 1.39 0.0187 
Q9NYF8 
Bcl-2-associated 
transcription 
factor 1 
BCLAF
1 ETQSPEQVK 
Phospho 
(STY) 0.66 0.0021 
Q9NYF8 
Bcl-2-associated 
transcription 
factor 1 
BCLAF
1 IDISPSTLR 
Phospho 
(STY) 0.70 0.0002 
Q9NYF8 
Bcl-2-associated 
transcription 
factor 1 
BCLAF
1 YSPSQNSPIHHIPSR 
2 Phospho 
(STY) 0.56 0.0013 
Q14137 
Ribosome 
biogenesis 
protein BOP1 
BOP1 IGDEYAEDSSDEEDIR 2 Phospho (STY) 1.40 0.0266 
Q9BX63 Fanconi anemia group J protein BRIP1 PADEGVSEK Unmodified 0.20 0.0034 
Q13185 
Chromobox 
protein homolog 
3 
CBX3 KSLSDSESDDSK Phospho (STY) 0.54 0.0276 
Q13112 
Chromatin 
assembly factor 1 
subunit B 
CHAF1
B TQDPSSPGTTPPQAR 
Phospho 
(STY) 1.42 0.0168 
Q14839-2 
Chromodomain-
helicase-DNA-
binding protein 4 
CHD4 MSQPGSPSPK 
Oxidation 
(M),Phospho 
(STY) 
1.31 0.0484 
Q9NR30 Nucleolar RNA helicase 2 DDX21 NEEPSEEEIDAPKPK 
Phospho 
(STY) 0.60 0.0250 
Q9NR30 Nucleolar RNA helicase 2 DDX21 NEEPSEEEIDAPKPK Unmodified 0.61 0.0163 
Q9NR30 Nucleolar RNA helicase 2 DDX21 EGAFSNFPISEETIK Unmodified 0.89 0.0183 
Q9NR30 Nucleolar RNA helicase 2 DDX21 APQVLVLAPTR Unmodified 0.94 0.2255 
Q9NR30 Nucleolar RNA helicase 2 DDX21 ELANQVSK Unmodified 0.91 0.0563 
Q9GZR7 ATP-dependent DDX24 AQAVSEEEEEEEGKSSS Phospho 0.49 0.0004 
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RNA helicase 
DDX24 
PK (STY) 
Q5QJE6 
Deoxynucleotidyl
transferase 
terminal-
interacting 
protein 2 
DNTTI
P2 
VTPTKESYTEEIVSEAE
SHVSGISR 
Phospho 
(STY) 0.68 0.0438 
Q5QJE6 
Deoxynucleotidyl
transferase 
terminal-
interacting 
protein 2 
DNTTI
P2 ASIQAASAESSGQK Unmodified 0.81 0.2325 
P07814 
Bifunctional 
glutamate/proline
--tRNA 
ligase;Glutamate-
-tRNA 
ligase;Proline--
tRNA ligase 
EPRS EYIPGQPPLSQSSDSSPTR 
Phospho 
(STY) 1.39 0.0352 
Q92522 Histone H1x H1FX AGGSAALSPSK Phospho (STY) 0.56 0.0277 
Q6FI13 Histone H2A.x H2AFX HLQLAIR Unmodified 0.48 0.0117 
Q6FI13 Histone H2A.x H2AFX AGLQFPVGR Unmodified 0.51 0.0002 
Q6FI13 Histone H2A.x H2AFX TSATVGPK Unmodified 1.07 0.2249 
P0C0S5 Histone H2A.Z H2AFZ GDEELDSLIK Unmodified 0.51 0.0002 
P0C0S5 Histone H2A.Z H2AFZ ATIAGGGVIPHIHK Unmodified 0.97 0.6709 
P0C0S5 Histone H2A.Z H2AFZ GDEELDSLIK Unmodified 0.88 0.2670 
P14317 
Hematopoietic 
lineage cell-
specific protein 
HCLS1 RSPEAPQPVIAMEEPAVPAPLPK 
Oxidation 
(M),Phospho 
(STY) 
0.65 0.0008 
P14317 
Hematopoietic 
lineage cell-
specific protein 
HCLS1 SAVGFNEMEAPTTAYK Oxidation (M) 0.68 0.0004 
P16401 Histone H1.5 HIST1H1B ALAAGGYDVEK Unmodified 0.34 0.0002 
P16401 Histone H1.5 HIST1H1B GTGASGSFK Unmodified 0.50 0.0044 
P16401 Histone H1.5 HIST1H1B ALAAGGYDVEK Unmodified 0.58 0.1595 
P16401 Histone H1.5 HIST1H1B KATGPPVSELITK Unmodified 0.72 0.0637 
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P16401 Histone H1.5 HIST1H1B SETAPAETATPAPVEK Unmodified 0.73 0.0259 
P10412 HIST1H1C Histone H1.2 KAPKSPAK 
Phospho 
(STY) NaN 0.0253 
P10412 HIST1H1C Histone H1.2 SGVSLAALK Unmodified 0.52 0.0071 
P10412 HIST1H1C Histone H1.2 GTLVQTK Unmodified 0.79 0.3350 
P10412 HIST1H1C Histone H1.2 ALAAAGYDVEK Unmodified 0.81 0.0734 
P10412 HIST1H1C Histone H1.2 KALAAAGYDVEK Unmodified 0.83 0.3271 
P10412 HIST1H1C Histone H1.2 GTGASGSFK Unmodified 0.72 0.0827 
P10412 HIST1H1C Histone H1.2 ASGPPVSELITK Unmodified 0.76 0.3217 
P68431 HIST1H3A Histone H3.1 KSAPATGGVK 
Phospho 
(STY) 0.31 0.0080 
P68431 HIST1H3A Histone H3.1 STELLIR Unmodified 0.59 0.0049 
P68431 HIST1H3A Histone H3.1 YRPGTVALREIR Unmodified 0.83 0.0367 
P68431 HIST1H3A Histone H3.1 EIAQDFK Unmodified 1.02 0.3093 
P68431 HIST1H3A Histone H3.1 KSAPATGGVK Unmodified 0.43 0.0092 
A6NEL0 
Non-histone 
chromosomal 
protein HMG-14 
HMGN
1 TEESPASDEAGEK 
2 Phospho 
(STY) 0.69 0.0066 
P09651 
Heterogeneous 
nuclear 
ribonucleoprotein 
A1 
HNRN
PA1 SESPKEPEQLR 
Phospho 
(STY) 0.70 0.0177 
P09651 
Heterogeneous 
nuclear 
ribonucleoprotein 
A1 
HNRN
PA1 EDSQRPGAHLTVK Unmodified 0.64 0.1939 
P10809 
60 kDa heat 
shock protein, 
mitochondrial 
HSPD1 ALMLQGVDLLADAVAVTMGPK 
2 Oxidation 
(M) 0.65 0.0078 
Q9NZI8 Insulin-like growth factor 2 
IGF2B
P1 QGSPVAAGAPAK 
Phospho 
(STY) 0.50 0.0428 
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mRNA-binding 
protein 1 
Q9NQS7 Inner centromere protein 
INCEN
P IAQVSPGPR 
Phospho 
(STY) 1.61 0.0391 
Q8N9T8 Protein KRI1 homolog KRI1 
QLPALDGSLMGPESPPA
QEEEAPVSPHK 
Oxidation 
(M),Phospho 
(STY) 
0.63 0.0000 
Q8N9T8 Protein KRI1 homolog KRI1 YVDEENSDGETSNHR 
Phospho 
(STY) 0.69 0.0003 
Q9UHB6-
4 
LIM domain and 
actin-binding 
protein 1 
LIMA1 ETPHSPGVEDAPIAK Phospho (STY) 0.57 0.0086 
Q9UHB6-
4 
LIM domain and 
actin-binding 
protein 1 
LIMA1 SEVQQPVHPKPLSPDSR Phospho (STY) 0.60 0.0023 
P20700 Lamin-B1 LMNB1 
TTIPEEEEEEEEAAGVV
VEEELFHQQGTPR 
Phospho 
(STY) 1.34 0.0405 
P20700 Lamin-B1 LMNB1 ALYETELADAR Unmodified 1.01 0.3870 
P20700 Lamin-B1 LMNB1 DAALATALGDKK Unmodified 1.16 0.1579 
P20700 Lamin-B1 LMNB1 IQELEDLLAK Unmodified 0.97 0.2752 
P20700 Lamin-B1 LMNB1 LLEGEEER Unmodified 1.29 0.2029 
Q9Y608 
Leucine-rich 
repeat flightless-
interacting 
protein 2 
LRRFI
P2 
RGSGDTSSLIDPDTSLSE
LR 
Phospho 
(STY) 0.72 0.0004 
E9PFP3 Lymphocyte-specific protein 1 LSP1 QASIELPSMAVASTK 
Oxidation 
(M),Phospho 
(STY) 
0.54 0.0072 
E9PFP3 Lymphocyte-specific protein 1 LSP1 DIVAGDMSK Unmodified 0.57 0.0160 
E9PFP3 Lymphocyte-specific protein 1 LSP1 
EGPGPEDTVQDNLGAA
GAEEEQEEHQK Unmodified 0.58 0.0018 
E9PFP3 Lymphocyte-specific protein 1 LSP1 WETGEVQAQSAAK Unmodified 0.73 0.0117 
Q9BXY0 Protein MAK16 homolog 
MAK1
6 
ALEQQEAESDSSDTEEK
DDDDDDEEDVGKR 
2 Phospho 
(STY) 0.32 0.0000 
Q9BXY0 Protein MAK16 MAK1 ALIAAQLDNAIEK Unmodified 0.77 n/a 
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homolog 6 
A8MXP9 Matrin-3 MATR3 
RDSFDDRGPSLNPVLD
YDHGSR 
Phospho 
(STY) 1.68 0.0252 
A8MXP9 Matrin-3 MATR3 SYSPDGKESPSDKK 
2 Phospho 
(STY) 0.33 0.0020 
P55081 
Microfibrillar-
associated protein 
1 
MFAP1 RPDYAPMESSDEEDEEFQFIK 
Oxidation 
(M),2 
Phospho 
(STY) 
0.65 0.0003 
P46013 Antigen KI-67 MKI67 AQSLVISPPAPSPR Phospho (STY) 1.40 0.0014 
P46013 Antigen KI-67 MKI67 AQALEDLAGFK Unmodified 1.24 0.0095 
O00566 
U3 small 
nucleolar 
ribonucleoprotein 
protein MPP10 
MPHO
SPH10 
SDLRKSPVFSDEDSDLD
FDISK 
3 Phospho 
(STY) 0.71 0.0034 
O00566 
U3 small 
nucleolar 
ribonucleoprotein 
protein MPP10 
MPHO
SPH10 TAEEENPEHVEIQK Unmodified 1.10 0.2023 
A5PL00 
Myosin-binding 
protein C, 
cardiac-type 
MYBP
C3 VETTKDRSIFTVEGAEK 
4 Phospho 
(STY) 0.59 0.0424 
F8VTL3 Myosin-10 MYH10 
QLHLEGASLELSDDDT
ESK 
Phospho 
(STY) 0.55 0.0001 
P35579 Myosin-9 MYH9 KGAGDGSDEEVDGKADGAEAK 
Phospho 
(STY) 0.41 0.0250 
P35579 Myosin-9 MYH9 DFSALESQLQDTQELLQEENR Unmodified 0.81 0.0154 
P35579 Myosin-9 MYH9 ELESQISELQEDLESER Unmodified 0.59 0.0223 
P35579 Myosin-9 MYH9 IAQLEEELEEEQGNTELINDR Unmodified 0.75 0.0062 
P35579 Myosin-9 MYH9 IMGIPEEEQMGLLR Unmodified 0.46 0.0233 
P35579 Myosin-9 MYH9 LQVELDNVTGLLSQSDSK Unmodified 0.64 0.0390 
Q3KQS4 
Putative 
ribosomal RNA 
methyltransferase 
NOP2 
NOP2 EAAAGIQWSEEETEDEEEEKEVTPESGPPK 
2 Phospho 
(STY) 0.73 0.0120 
Q3KQS4 Putative NOP2 GTDTQTPAVLSPSK Phospho 0.72 0.0105 
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ribosomal RNA 
methyltransferase 
NOP2 
(STY) 
Q3KQS4 
Putative 
ribosomal RNA 
methyltransferase 
NOP2 
NOP2 DLAQALINR Unmodified 0.96 0.1978 
Q3KQS4 
Putative 
ribosomal RNA 
methyltransferase 
NOP2 
NOP2 LVPTGLDFGQEGFTR Unmodified 1.04 0.4784 
P06748 Nucleophosmin NPM1 DELHIVEAEAMNYEGSPIKVTLATLK 
Oxidation 
(M),Phospho 
(STY) 
0.46 0.0241 
P06748 Nucleophosmin NPM1 GPSSVEDIK Unmodified 0.38 0.0493 
P06748 Nucleophosmin NPM1 
LAADEDDDDDDEEDD
DEDDDDDDFDDEEAEE
KAPVKK 
Unmodified 0.40 0.0017 
P06748 Nucleophosmin NPM1 LLSISGK Unmodified 0.36 0.0006 
P06748 Nucleophosmin NPM1 MQASIEK Unmodified 0.37 0.0263 
P06748 Nucleophosmin NPM1 MSVQPTVSLGGFEITPPVVLR Unmodified 0.43 0.0049 
P06748 Nucleophosmin NPM1 TVSLGAGAK Unmodified 0.40 0.0029 
P06748 Nucleophosmin NPM1 VDNDENEHQLSLR Unmodified 0.41 0.2028 
Q15154 Pericentriolar material 1 protein PCM1 
KDEETEESEYDSEHENS
EPVTNIR 
3 Phospho 
(STY) 0.56 0.0012 
Q15154 Pericentriolar material 1 protein PCM1 YMSQMSVPEQAELEK 
2 Oxidation 
(M),Phospho 
(STY) 
0.61 0.0012 
Q15154 Pericentriolar material 1 protein PCM1 VTNDISPESSPGVGR 
Phospho 
(STY) 2.91 0.0048 
Q9NTI5 
Sister chromatid 
cohesion protein 
PDS5 homolog B 
PDS5B METVSNASSSSNPSSPGR 
Oxidation 
(M),Phospho 
(STY) 
1.41 0.0325 
Q9P1Y6 
PHD and RING 
finger domain-
containing 
protein 1 
PHRF1 VLSDSEDEEKDADVPGTSTR 
2 Phospho 
(STY) 0.72 0.0006 
P29590 Protein PML PML AVSPPHLDGPPSPR 2 Phospho (STY) 1.45 0.0179 
P29590 Protein PML PML SSPEQPRPSTSK Phospho (STY) 1.75 0.0490 
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Q9H307 Pinin PNN SLSPGKENVSALDMEK 
Oxidation 
(M),Phospho 
(STY) 
0.59 0.0010 
Q9H307 Pinin PNN TLQEQLEK Unmodified 0.73 0.2420 
C9J3F9 Suppressor of SWI4 1 homolog 
PPAN-
P2RY1
1 
LQDISELLATGAGLSES
EAEPDGDHNITELPQAV
AGR 
2 Phospho 
(STY) 1.32 0.0472 
O75475 
PC4 and SFRS1-
interacting 
protein 
PSIP1 TGVTSTSDSEEEGDDQEGEK 
2 Phospho 
(STY) 0.63 0.0009 
Q13610 
Periodic 
tryptophan 
protein 1 
homolog 
PWP1 EKLQEEGGGSDEEETGSPSEDGMQSAR 
Oxidation 
(M),Phospho 
(STY) 
0.75 0.0106 
Q96I25 Splicing factor 45 RBM17 RPDPDSDEDEDYER Phospho (STY) 0.62 0.0000 
Q5VTR2 
E3 ubiquitin-
protein ligase 
BRE1A 
RNF20 VYGAGSSLYGGTITINARK 
4 Phospho 
(STY) 12.82 0.0437 
Q15287 
RNA-binding 
protein with 
serine-rich 
domain 1 
RNPS1 RSPSPKPTK 2 Phospho (STY) 0.54 0.0166 
P62913 60S ribosomal protein L11 RPL11 VLEQLTGQTPVFSKAR Unmodified 0.53 0.0464 
P62913 60S ribosomal protein L11 RPL11 YDGIILPGK Unmodified 0.61 0.0016 
P05387 
60S acidic 
ribosomal protein 
P2;60S acidic 
ribosomal protein 
P1 
RPLP2 KEESEESDDDMGFGLFD 
Phospho 
(STY) 0.19 0.0053 
O76021 
Ribosomal L1 
domain-
containing 
protein 1 
RSL1D
1 AAESETPGKSPEK 
Phospho 
(STY) 0.60 0.0050 
O76021 
Ribosomal L1 
domain-
containing 
RSL1D
1 EKSPSLGK 
Phospho 
(STY) 0.56 0.0286 
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protein 1 
O76021 
Ribosomal L1 
domain-
containing 
protein 1 
RSL1D
1 DDVAPESGDTTVK Unmodified 0.71 0.0277 
O76021 
Ribosomal L1 
domain-
containing 
protein 1 
RSL1D
1 LLPSLIGR Unmodified 1.03 0.0165 
Q5T802 
Runt-related 
transcription 
factor 2 
RUNX
2 
GGTMASNSLFSTVTPC
QQNFFWDPSTSRR 
Oxidation 
(M),4 
Phospho 
(STY) 
0.28 0.0022 
Q9H7N4 
Splicing factor, 
arginine/serine-
rich 19 
SCAF1 QRSPSPAPAPAPAAAAGPPTR 
2 Phospho 
(STY) 1.70 0.0385 
Q9NWH9 
SAFB-like 
transcription 
modulator 
SLTM DGQDAIAQSPEKESK Phospho (STY) 0.63 0.0028 
Q9NWH9 
SAFB-like 
transcription 
modulator 
SLTM ISSKSPGHMVILDQTK 
Oxidation 
(M),Phospho 
(STY) 
0.68 0.0040 
G3V3A4 
SNW domain-
containing 
protein 1 
SNW1 GPPSPPAPVMHSPSR 
Oxidation 
(M),2 
Phospho 
(STY) 
0.69 0.0078 
P18583-9 Protein SON SON SAASPVVSSMPER 
Oxidation 
(M),Phospho 
(STY) 
1.32 0.0231 
Q01082 Spectrin beta chain, brain 1 
SPTBN
1 RPPSPEPSTK 
Phospho 
(STY) 0.53 0.0010 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 AASPSPQSVR 
2 Phospho 
(STY) 0.57 0.0000 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 ASPSPPPKR 
2 Phospho 
(STY) 0.60 0.0000 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 EARSPQPNK 
Phospho 
(STY) 0.55 0.0002 
E9PCT1 Serine/arginine SRRM EKTPELPEPSVK Phospho 0.50 0.0393 
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repetitive matrix 
protein 1 
1 (STY) 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 HRPSPPATPPPK 
2 Phospho 
(STY) 0.58 0.0092 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RASPSPPPKR 
2Phospho 
(STY) 0.61 0.0000 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RLSPSASPPR 
2 Phospho 
(STY) 0.53 0.0115 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RRSPSPAPPPR 
2 Phospho 
(STY) 0.65 0.0004 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RRSPSPPPTR 
2 Phospho 
(STY) 0.72 0.0051 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RRTASPPPPPK 
2 Phospho 
(STY) 0.48 0.0129 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RSPSPPPTR 
2 Phospho 
(STY) 0.66 0.0021 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RVSHSPPPK 
2 Phospho 
(STY) 0.50 0.0016 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RVSRTPEPK 
2 Phospho 
(STY) 0.58 0.0012 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RYSPPIQR 
Phospho 
(STY) 0.61 0.0188 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 RYSPSPPPK 
2 Phospho 
(STY) 0.53 0.0118 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 SVSGSPEPAAK 
Phospho 
(STY) 0.49 0.0004 
E9PCT1 
Serine/arginine 
repetitive matrix 
protein 1 
SRRM
1 VSVSPGR 
Phospho 
(STY) 0.56 0.0023 
Q9UQ35 
Serine/arginine 
repetitive matrix 
protein 2 
SRRM
2 SATRPSPSPER 
Phospho 
(STY) 0.57 0.0141 
J3KTL2 
Serine/arginine-
rich splicing 
factor 1 
SRSF1 VDGPRSPSYGR 2 Phospho (STY) 0.33 0.0004 
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P84103 
Serine/arginine-
rich splicing 
factor 3 
SRSF3 ERSLSRER 2 Phospho (STY) 0.62 0.0087 
Q16629 
Serine/arginine-
rich splicing 
factor 7 
SRSF7 YFQSPSRSR 2 Phospho (STY) 0.40 0.0044 
E9PHK9 Treacle protein TCOF1 AALAPAKESPR Phospho (STY) 1.80 0.0483 
E9PHK9 Treacle protein TCOF1 EAASGTTPQK Phospho (STY) 1.49 0.0350 
E9PHK9 Treacle protein TCOF1 TSQVGAASAPAKESPR Phospho (STY) 2.20 0.0293 
E9PHK9 Treacle protein TCOF1 TNVVTMPTAHPR Unmodified 1.28 0.3602 
E9PHK9 Treacle protein TCOF1 VVTAAAQAK Unmodified 0.75 0.5060 
Q9Y2W1 
Thyroid hormone 
receptor-
associated protein 
3 
THRA
P3 IDISPSTFR 
Phospho 
(STY) 0.69 0.0003 
P04637 Cellular tumour antigen p53 TP53 ALPNNTSSSPQPK 
Phospho 
(STY) 1.87 0.0364 
P62995 
Transformer-2 
protein homolog 
beta;Transformer-
2 protein 
homolog alpha 
TRA2B
;TRA2
A 
RSPSPYYSR 2 Phospho (STY) 0.44 0.0113 
Q9BVJ6 
U3 small 
nucleolar RNA-
associated protein 
14 homolog A 
UTP14
A 
DYLLSESEDEGDNDGE
R 
2 Phospho 
(STY) 1.48 0.0128 
Q9BVJ6 
U3 small 
nucleolar RNA-
associated protein 
14 homolog A 
UTP14
A SELSQDAEPAGSQETK 
Phospho 
(STY) 3.18 0.0199 
Q9Y5J1 
U3 small 
nucleolar RNA-
associated protein 
18 homolog 
UTP18 KTSSDDESEEDEDDLLQR 
2 Phospho 
(STY) 0.58 0.0107 
Q9Y5J1 
U3 small 
nucleolar RNA-
associated protein 
UTP18 AGAGPGGPPQKPAPSSQR Unmodified 0.93 0.3662 
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18 homolog 
Q8IWA0 
WD repeat-
containing 
protein 75 
WDR7
5 
VQDTSNTGLGEDIIHQL
SK 
Phospho 
(STY) 0.74 0.0215 
Q9H0D6 5-3 exoribonuclease 2 XRN2 KAEDSDSEPEPEDNVR 
2 Phospho 
(STY) 0.58 0.0006 
H0Y449 
Nuclease-
sensitive element-
binding protein 1 
YBX1 RPQYSNPPVQGEVMEGADNQGAGEQGR 
Oxidation 
(M) 0.49 0.0104 
J3QR07 
YTH domain-
containing 
protein 1 
YTHD
C1 AKSPTPDGSER 
2 Phospho 
(STY) 0.59 0.0210 
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